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ABSTRACT 
 
Insulin action is associated with the release of the Hepatic Insulin Sensitizing Substance (HISS), 
which enhances peripheral glucose uptake. In the fed state, HISS release is maximal, decreasing with 
the duration of fasting. The prandial control of HISS action is mediated through hepatic 
parasympathetic - derived nitric oxide (NO), and hepatic glutathione (GSH). The current methods used 
to evaluate insulin sensitivity are only performed in the fasted state. The present thesis focus on the 
hypothesis that HISS-dependent mechanism exists in humans and can be manipulated. 
In humans, a new powerful tool to characterize HISS-dependent insulin action not only in the 
fasted, but also in the fed state, the Rapid Insulin Sensitivity Test (RIST), was developed. The RIST 
can be performed with reproducible results, having no intra and inter-variability.  
The decreased insulin sensitivity observed in the fasted state is potentiated following a meal, and 
intravenous atropine administration suppresses this effect. The partial blockade of meal-induced insulin 
sensitization (MIS), is consistent with the hypothesis that a hepatic parasympathetic “feeding signal” is 
necessary for hepatic HISS release.  
When lean and overweight subjects were submitted to a 24h fasting period, the insulin action per 
se, was similar in both groups studied. However, when one performed the insulin sensitivity in the fed 
state, the results present within this thesis have shown that, the lower MIS observed in the overweight 
subjects is associated with an impairment of the HISS-dependent component. These results indicate 
the importance of postprandial insulin sensitivity evaluation, and also suggested that the prediabetic 
state can only be detected in the fed state. 
Hyperglucagonemia is associated with type 2 diabetes. It is already known that glucagon leads to a 
decrease in GSH synthesis and hepatic GSH is crucial for HISS release, therefore the effect of glucagon 
on HISS-pathway was evaluated.  In animals, both a cAMP analog, and glucagon produce a decrease 
of insulin sensitivity in a dose-dependent manner. The HISS-dependent insulin resistance produced by 
a NO synthase inhibitor was not aggravated by glucagons. These results suggest that glucagon, leads 
to reduced insulin sensitivity through a decrease of HISS action, and not via some other action. The 
two observations together are in support that glucagon acts via cAMP pathway to decrease hepatic 
GSH levels, leading to an impairment of HISS release. This decrease might be responsible for an 
earlier stage of insulin release. 
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RESUMO 
 
A acção da insulina está associada à libertação da substância hepática sensibilizadora da insulina 
(HISS), que aumenta o aporte de glucose periférico. No estado pós-prandial, a libertação da HISS é 
máxima, diminuindo com o período de jejum. O controlo prandial da acção da HISS é mediado pelo 
sistema parassimpático hepático/óxido nítrico (NO) e pelo glutationo (GSH) hepático. Os actuais 
métodos utilizados para avaliar a sensibilidade à insulina são realizados no estado de jejum. A 
presente dissertação destaca a hipótese de que o mecanismo dependente da HISS existe em 
humanos, e pode ser manipulado. 
Em humanos, uma robusta ferramenta para caracterizar a acção da insulina dependente da HISS, 
não só no estado de jejum, mas também após uma refeição, o teste rápido de sensibilidade à insulina 
(RIST), foi desenvolvido. O RIST pode ser realizado com reproductibilidade, e  sem intra e inter-
variabilidade.  
A diminuição da sensibilidade à insulina observada no jejum é potenciada após uma refeição, e a 
administração de atropina, suprime este efeito. A inibição parcial da sensibilidade à insulina induzida 
pela refeição, é consistente com a hipótese de que um “sinal prandial” dependente do sistema 
parassimpático hepático é necessário para a libertação hepática da HISS. 
Quando voluntários magros e com excesso de peso foram submetidos a um período de 24h de 
jejum, a acção da insulina per se, foi similar em ambos os grupos estudados. Contudo, quando 
avaliados no estado pós-prandial, os resultados apresentados nesta dissertação mostraram que, a 
potenciação induzida pela refeição era inferior nos voluntários com excesso de peso, estando esta 
associada a uma alteração da componente da acção da insulina dependente da HISS. Estes resultados 
indicam a importância da avaliação da sensibilidade à insulina no estado pós-prandial, e sugerem 
também que este estado de pré-diabetes apenas pode ser detectado após a ingestão de uma refeição. 
Níveis elevados de glucagina estão associados à diabetes tipo 2. Sabendo que a glucagina leva a 
uma diminuição da síntese de GSH, e que o GSH é fundamental para a libertação da HISS, foi avaliado 
o efeito da glucagina na via da HISS. Em animais, tanto a administração de um análogo do cAMP, 
como de glucagina, produziram um decréscimo da sensibilidade à insulina, sendo este efeito 
dependente da dose. A resistência à insulina dependente da HISS observada aquando da 
administração de um inibidor do sintetase do NO, não se agravou com a posterior administração de 
glucagina. Estes resultados sugerem então que a glucagina induz um decréscimo da sensibilidade à 
insulina, sendo este dependente da via da HISS, e não por acção de outra via. Estas duas observações 
indicam que a glucagina, através da via de sinalização do cAMP, leva à diminuição dos níveis hepáticos 
de GSH e, consequentemente, a uma alteração da via da HISS. Esta alteração poderá ser a 
responsável por um estado precoce de resistência à insulina. 
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PREFACE 
 
Diabetes is reaching pandemic proportions across the globe. Estimates from 2006 indicate 
that 5.9% of the world‟s population (246 million) have diabetes, and 7.1% (380 million) will 
have the condition by 2025, with type 2 diabetes responsible for nine in every 10 diabetes 
patients (Ceriello et al., 2008a).  
The majority of studies and diagnosis of type 2 diabetes depend almost entirely upon 
determinations of fasting plasma levels of glucose and, less frequently, insulin. This 
approach also leads to a severe underestimation of the metabolic dysfunction that is typical 
of the type 2 diabetic.  
It is known that well before the deterioration of fasting glucose, as glucose intolerance 
progresses, also the control of postprandial glucose control is lost.  
A distinction has been created, to describe an intermediate stage between completely 
normal glucose homeostasis and the clinical entity of type 2 diabetes, which has become 
known as prediabetes. The prediabetic state encompasses both impaired fasting glucose and 
impaired glucose tolerance. The prediabetic state of insulin resistance can be diagnosed by 
determining the response to a test meal. Early identification and treatment of subjects with 
prediabetes has the potential to reduce or delay the progression to the disease, and the 
related complications (Woerle et al., 2004). 
Some studies developed by Lautt and Macedo groups, has shown that postprandial 
regulation of acute metabolic response to insulin is mediated by the hepatic parasympathetic 
nerves (Lautt et al., 2001). Activation of this mechanism leads to the release of an hormone 
from the liver, referred to as hepatic insulin sensitizing substance (HISS), which acts to 
stimulate glucose uptake in skeletal muscle, heart and kidney (Fernandes et al., 2009; 
Lautt, 1999).  
In the absence of the ability to release HISS in response to a meal, the metabolic effect of 
insulin is reduced, which leads to an increase of postprandial glucose excursions. Hence, the 
absence of HISS in the postprandial state might be the first metabolic defect that occurs in 
the prediabetic state. In this setting HISS dysfunction may contribute decisively to the 
progression of metabolic defects towards type 2 diabetes. 
 
If the HISS quantification will be evaluated in an earlier stage, one can avert the 
development from prediabetes to diabetes, and taking this in account, HISS quantification 
could be a very important tool to diagnose diabetes. 
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Unfortunately, the information available about the acute effect of feeding on insulin 
sensitivity is scarce. 
The basis of this PhD thesis is associated to the implementation, in human subjects, of a 
new insulin sensitivity method, to evaluate insulin sensitivity, in both fasted and fed states, 
trying to fill the gap over postprandial insulin sensitivity measurements; and with the 
involvement of HISS pathway in humans on the increased insulin sensitization induced by a 
meal.  
 
In insulin resistant animal models, the HISS pathway showed a different behavior from 
the physiological situation. This dissertation also regards studies that will allow us to 
understand what ensues in the absence of HISS release, in response to a meal, which takes 
place when the HISS pathway is pharmacologically blocked or in any state of insulin 
resistance. 
 
The insulin antagonist hormone, glucagon, have been shown to be altered by a 
dysfunction of the autonomic nervous system. As the HISS pathway can also be influenced 
by the autonomic nervous system, it will be very interesting to evaluate the role of glucagon 
in prediabetes, and on the HISS pathway. 
Additionally, other studies revealed the increased levels of cAMP (through the activation 
of adenylate cyclase, by glucagon) are vigorously related to the decreased hepatic GSH 
content. Since hepatic GSH is fundamental to HISS synthesis/release, it is relevant to 
approach the relationship between glucagon and HISS pathway. 
 
This dissertation also considers studies related to the axis prediabetes, glucagon, HISS 
secretion/action and insulin resistance, in healthy animals. 
It is expected that this dissertation will lead to a progression of the knowledge of 
prediabetes, and will give novel approaches to better understand and reverse the prediabetic 
state. Also, if the HISS-resistant population are identified, one can prevent and delay the 
progression from prediabetes towards diabetes, and reverse the insulin resistant state 
observed in these subjects. 
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1. GENERAL INTRODUCTION 
 
1.1. GLUCOSE HOMEOSTASIS 
 
Plasma glucose concentration is a function of the rate of glucose entering the 
circulation (glucose appearance) balanced by the rate of glucose removal from the 
circulation (glucose disappearance).  
 
1.1.1. Physiological glucose metabolism 
 
Circulating glucose levels are derived from three sources: intestinal absorption during 
the fed state, glycogenolysis, and gluconeogenesis. The major determinant of how 
quickly glucose appears in the circulation during the fed state is the rate of gastric 
emptying. Other sources of circulating glucose are derived chiefly from hepatic 
processes: glycogenolysis, the breakdown of glycogen, the polymerized storage form of 
glucose; and gluconeogenesis, the formation of glucose primarily from lactate and amino 
acids during the fasting state (Gerich, 1993). 
The main tissues that regulate blood glucose levels are the liver (by glucose 
production and uptake) and skeletal muscle (glucose uptake). 
 
As hepatic glycogen decreases, blood glucose levels fall, as does insulin secretion. A 
decrease in plasma insulin leads to an increase in glucagon secretion, mobilization of 
gluconeogenic precursors and alternative fuels, such as, free fatty acids (FFA), and an 
increase in hepatic gluconeogenesis. The first of these reactions includes conversion of 
pyruvate to oxaloacetate to phosphoenolpyruvate. The second of these reactions, is the 
conversion of fructose-1,6-bisphosphate to fructose-6-phosphate, which represents the 
rate-limiting reaction for gluconeogenesis. The final reaction is the conversion of glucose-
6-phosphate to free glucose, which is necessary for glucose to enter the plasma, and to 
the hepatocytes (Figure 1.1). 
The rate-limiting step of glycolysis is the conversion of fructose-6-phosphate to 
fructose-1,6-bisphosphate, requiring an ATP and the enzyme phosphofructokinase-1. This 
step is considered irreversible. The other two irreversible steps are the conversion of 
glucose to glucose-6-phosphate by hexokinase/glucokinase and the conversion of 
phosphoenolpyruvate to pyruvate by pyruvate kinase (Figure 1.1). These three reactions 
are significant because they are the major obstacles that must be overcome in the 
formation of glucose during gluconeogenic reactions.  
When there is an adequate supply of oxygen to tissues, the overall reaction for the 
glycolytic pathway ends in pyruvate, which is then converted to acetyl-CoA, which enters  
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the tricarboxylic acid (TCA) cycle. Under anaerobic conditions the cells rely on glycolysis 
for ATP, and pyruvate is converted to lactate. Conversion of pyruvate to lactate 
regenerates cofactors needed for glycolysis (Pickup et al., 2003). 
 
 
 
 
 
Figure 1.1 - Overview of glycolysis and gluconeogenesis. The level of fructose-2,6-bisphosphate (F2,6P2) 
is the most important allosteric effector for controlling the rates of gluconeogenesis and glycolysis. CoA: 
coenzyme A; TCA: tricarboxylic acid; ATP: adenosine triphosphate; cAMP: 3‟,5‟-cyclic adenosine 5‟-
monophosphate; : increase; : decrease; : activation; : inhibition. 
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1.1.2. Hormonal regulation of glucose metabolism 
 
The glucoregulatory hormones of the body are designed to maintain circulating 
glucose concentrations in a relatively narrow range.  
In the fasting state, glucose leaves the circulation at a constant rate, which indicates 
that rates of glucose production and utilization are equal. After a meal, glucose 
absorption results in rates of exogenous glucose delivery into the circulation that can be 
more than twice the rate of postabsorptive endogenous glucose production, depending on 
the carbohydrate content of the meal and the rate and degree of glucose absorption. As 
glucose is absorbed, endogenous glucose production is suppressed, and glucose 
utilization by liver, muscle, and fat accelerates (Radziuk et al., 2001). With fasting, as 
plasma glucose decreases, endogenous glucose production increases. The main source of 
endogenous glucose production is the liver. Renal gluconeogenesis contributes 
substantially to the systemic glucose pool, only during periods of extreme starvation. 
Although most tissues have the ability to hydrolyze glycogen, only the liver and kidneys 
contain glucose-6-phosphatase, the enzyme necessary for the release of glucose into the 
circulation. 
 
In the following paragraphs, the main key players in the regulation of glucose 
homeostasis will be approached. Glucoregulatory hormones include insulin, glucagon, 
somatostatin, amylin, cholecystokinin (CCK), pancreatic polypeptide, glucagon-like 
peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), ghrelin, 
catecholamines (epinephrine and norepinephrine), cortisol, and growth hormone. Of 
these, insulin and amylin are derived from the pancreatic -cells, glucagon from the 
pancreatic -cells, somatostatin from the pancreatic -cells and pancreatic polypeptide 
from the PP cells of the pancreas; GLP-1 from the L-cells, GIP from the K-cells and CCK 
from the I-cells of the intestine. 
 
1.1.2.1. Pancreatic hormones 
 
Insulin 
 
Insulin is the dominant glucoregulatory hormone. Insulin is a key anabolic hormone 
that is secreted in response to increased blood glucose levels. While glucose is the most 
potent stimulus of insulin, other factors stimulate insulin secretion. These additional 
stimuli include increased plasma concentrations of some aminoacids, especially arginine, 
leucine, and lysine; GLP-1 and GIP released from the gut following a meal; and 
parasympathetic stimulation via the vagus nerve (Balks et al., 1997; Drucker, 1998). 
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Like many hormones, insulin exerts its actions through binding to specific receptors 
present on many cells of the body, including fat, liver, and muscle cells. The primary 
action of insulin is to stimulate glucose disappearance. Insulin helps control postprandial 
glucose in three ways. Initially, insulin signals the cells of insulin-sensitive peripheral 
tissues, mainly skeletal muscle, to increase plasma glucose uptake (Gerich et al., 1976). 
Secondly, insulin acts on the liver to promote glycogenesis. Finally, insulin 
simultaneously inhibits glucagon secretion from pancreatic -cells, thus signalling the 
liver to stop producing glucose via glycogenolysis and gluconeogenesis (Figure 1.1). All of 
these actions reduce blood glucose. Other actions of insulin include the stimulation of fat 
synthesis, promotion of triglyceride storage in fat cells, promotion of protein synthesis in 
the liver and muscle, and proliferation of cell growth (Pickup et al., 2003). 
Insulin action is carefully regulated in response to circulating glucose concentrations. 
Insulin is not secreted if the blood glucose concentration is ≤60mg/dl, but is secreted in 
increasing amounts, as glucose concentrations increase beyond this threshold (Gerich, 
1993). 
Insulin decreases gluconeogenesis by decreasing intracellular 3‟,5‟-cyclic adenosine 5‟-
monophosphate (cAMP) levels, which inhibits phosphorylation of enzymes. Insulin also 
inhibits hepatic glucose production indirectly by restraining lipolysis and proteolysis 
systemically, which reduces delivery of glucose precursors to the liver (DeFronzo, 1988; 
DeFronzo, 2004).  
Since the peripheral action of insulin is a central aspect of this thesis, it will be 
therefore discussed in more detail in the following sections (Section 1.2). 
 
Glucagon 
 
Glucagon is a key catabolic hormone secreted from pancreatic -cells. Described by 
Unger in the 1950‟s, glucagon was characterized as opposing the effects of insulin 
(Unger, 1971). Glucagon plays a major role in sustaining plasma glucose during fasting 
conditions by stimulating hepatic glucose production. Hepatic glucose production, which 
is primarily regulated by glucagon, maintains basal blood glucose concentrations within a 
normal range during the fasting state. When plasma glucose falls below the normal 
range, glucagon secretion increases, resulting in hepatic glucose production and return of 
plasma glucose to the normal range (Jiang et al., 2003). This endogenous source of 
glucose is not needed during and immediately following a meal and glucagon secretion is 
suppressed (Unger, 1985). When coupled with insulin‟s direct effect on the liver, 
glucagon suppression results in a near-total suppression of hepatic glucose output 
(Unger, 1971). 
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Glucagon has a potent effect on hepatic glucose production by stimulating both 
glycogenolysis and gluconeogenesis, and it increases glucose output within minutes 
(Figure 1.1). Glucagon‟s effects on gluconeogenesis are persistent, whereas its effects on 
glycogenolysis are short-lived (Gerich et al., 1988). Glucagon stimulates gluconeogenesis 
by increasing intracellular cAMP levels. Increased hepatic glucose production, in turn, 
results in suppression of glucagon secretion (Gerich et al., 1976).  
Since one of the chapters of this thesis is related with the glucagon‟s effect on insulin 
action, it will be therefore discussed in more detail in the following sections (Section 1.3). 
 
Somatostatin  
 
Somatostatin (somatotropin release-inhibiting factor or SRIF) is expressed by neurons 
in the hypothalamus and other central nervous system sites, and in numerous other 
tissues, including the pancreatic -cells and D-cells of the gastrointestinal tract. 
Somatostatin secretion is regulated by a combination of nutrients (glucose, aminoacids, 
fatty acids, ketone bodies), endocrine factors (insulin, glucagon, GIP, GLP-1, CCK) and 
neural factors (ACh, vasoactive intestinal polypeptide, gastrin-releasing polypeptide) 
(Pickup et al., 2003). Within the pancreatic islets, somatostatin released from -cells is a 
potencially important paracrine inhibitor of insulin and glucagon secretion from adjacent 
- and -cells (Samols et al., 1988). 
 
Amylin 
 
Amylin (islet amyloid polypeptide or IAPP), a 37 aminoacid peptide, is a 
neuroendocrine hormone co-expressed and co-secreted with insulin by pancreatic -cells 
in response to nutrient stimuli (Koda et al., 1992). Studies in humans have demonstrated 
that the secretory and plasma concentration profiles of insulin and amylin are similar with 
low fasting concentrations and increases in response to nutrient intake (Young, 2005). 
Preclinical findings indicate that amylin works with insulin to help coordinate the rate of 
glucose appearance and disappearance in the circulation, thereby preventing an 
abnormal rise in glucose concentrations.  
Amylin complements the effects of insulin on circulating glucose concentrations via 
two main mechanisms. Amylin suppresses postprandial glucagon secretion, thereby 
decreasing glucagon-stimulated hepatic glucose output following nutrient ingestion 
(Gedulin et al., 1997). This amylin-dependent suppression of postprandial glucagon 
secretion is postulated to be centrally mediated via efferent vagal signals. Importantly, 
amylin does not suppress glucagon secretion during insulin-induced hypoglycemia (Heise 
et al., 2004; Weyer et al., 2001). Amylin also slows the rate of gastric emptying and, 
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thus, the rate at which nutrients are delivered from the stomach to the small intestine for 
absorption (Samsom et al., 2000). In addition to its effects on glucagon secretion and 
the rate of gastric emptying, amylin dose-dependently reduces food intake and body 
weight in animal models (Geary, 1999; Rushing et al., 2001). 
In summary, amylin works to regulate the rate of glucose appearance from both 
endogenous (liver-derived) and exogenous (meal-derived) sources, and insulin regulates 
the rate of glucose disappearance (Buse et al., 2002; Young, 2005). 
 
Pancreatic polypeptide 
 
The pancreatic polypeptide is a 36 aminoacid peptide produced by the PP cells that lie 
peripherally in islets from the head of the pancreas, and are also sparsely scattered 
throughout the exocrine parenchyma. Secretion of pancreatic polypeptide is mainly under 
autonomic control; it is released following feeding or during hypoglycemia, mainly via 
cholinergic parasympathetic stimulation (Pickup et al., 2003). 
The only physiological effects that are recognized in humans are the inhibition of gall 
bladder contraction, and pancreatic enzyme secretion. Its effect is biphasic in that 
pancreatic polypeptide initially enhances secretion, and then inhibits secretion. It 
increases gastric emptying and gut motility, and also relaxes pyloric and ileocecocolic 
sphincters, colon, and gallbladder. PP levels increase after ingestion of food and remain 
elevated from 4–8h (Batterham et al., 2003). 
 
1.1.2.2. Gastrointestinal hormones 
 
Cholecystokinin (CCK) 
 
Cholecystokinin (CCK) is a member of the “gut–brain” family of peptide hormones. It 
is secreted by enteroendocrine cells (I-cells) located in the mucosa of the duodenum, 
jejunum, and proximal ileum, as well as by specialized neurons in the myenteric plexus 
and brain. CCK performs numerous regulatory functions in the gut and the brain.  
In the gastrointestinal system, CCK inhibits gastric motility and emptying via a 
capsaicin sensitive vagal pathway. The effects on emptying are via its action on the 
proximal stomach and pylorus. CCK is also involved in the regulation of food intake. It is 
released in the gut in response to a meal and acts via vagal afferents to induce satiety. 
CCK has been implicated in gallbladder contraction, pancreatic secretion, and intestinal 
motility (Chua et al., 2006). 
In the central nervous system, CCK plays a role in learning and memory, 
anxiogenesis, nociception and satiation. The physiological significance of CCK as a neural 
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or hormonal regulator of enteroinsular activity remains uncertain, although high 
concentrations of the peptide clearly stimulate insulin secretion (Liddle, 1995). 
 
Glucose-dependent insulinotropic peptide (GIP)  
 
The intricacies of glucose homeostasis become clearer when considering the role of 
gut peptides. By the late 1960s, some authors demonstrated that ingested food caused a 
more potent release of insulin than glucose infused intravenously (Perley et al., 1967). 
This effect, termed the “incretin effect,” suggested that signals from the gut are 
important in the hormonal regulation of glucose disappearance. 
Several incretin hormones have been characterized, and the dominant ones for 
glucose homeostasis are glucose-dependent insulinotropic peptide (GIP) and glucagon-
like peptide 1 (GLP-1). 
GIP is a 42 aminoacid peptide produced predominantly in duodenal K-cells in the 
proximal small intestine. GIP has also been localized in the central nervous system, 
where it may play a role in the control of cell survival. The predominant stimulus for GIP 
secretion is nutrient intake; circulating levels of GIP are low in the fasted state, and rise 
within minutes of food ingestion. GIP stimulates insulin secretion and regulates fat 
metabolism, but does not inhibit glucagon secretion or gastric emptying (Drucker, 2007). 
 
Glucagon-like peptide 1 (GLP-1) 
 
GLP-1 is produced in enteroendocrine cells in the distal small bowel and colon. Plasma 
levels of GLP-1 also rise rapidly within minutes of food intake; hence it seems likely that 
both neural and/or endocrine factors promote GLP-1 secretion from distal L-cells, well 
before digested nutrients cross the small bowel to make direct contact with 
enteroendocrine L-cells. GLP-1 stimulates glucose-dependent insulin secretion, but is 
significantly reduced postprandially in people with type 2 diabetes or impaired glucose 
tolerance (Vilsboll et al., 2004). GLP-1 stimulates insulin secretion when plasma glucose 
concentrations are high, but not when plasma glucose concentrations approach or fall. 
Circulating GLP-1 concentrations are low in the fasting state. However, both GIP and 
GLP-1 are effectively stimulated by ingestion of a mixed meal or meals enriched with fats 
and carbohydrates (Herrmann et al., 1995). In contrast to GIP, GLP-1 inhibits glucagon 
secretion and slows gastric emptying (Drucker, 1998). In the pancreas, GLP-1 stimulates 
insulin secretion in a glucose-dependent manner while inhibiting glucagon secretion. The 
postprandial effect of GLP-1 is partly due to inhibition of glucagon secretion. Yet while 
GLP-1 inhibits glucagon secretion in the fed state, it does not appear to blunt glucagon‟s 
response to hypoglycemia (Drucker, 2007). GLP-1 helps to regulate gastric emptying and 
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gastric acid secretion, perhaps by signaling GLP-1 receptors in the brain, and thereby 
stimulating efferent tracts of the vagus nerve (Nauck et al., 2002). As gastric emptying 
slows, the postprandial glucose excursion is reduced (Nauck et al., 1997). 
 
Ghrelin 
 
Ghrelin is a 28 aminoacid peptide secreted mainly by neuroendocrine cells in the 
stomach mucosa, and it is a powerful stimulator of growth hormone release (Kojima et 
al., 2005). The secretion of ghrelin increases under conditions of negative energy 
balance, such as starvation, whereas its expression decreases under conditions of 
positive energy balance, such as feeding, hyperglycemia, and obesity (Hosoda et al., 
2006). In addition, ghrelin has been reported to affect both insulin and glucagon 
secretion in vitro and in vivo (Dezaki et al., 2008; Salehi et al., 2004). 
 
1.1.2.3. Adipocyte-derived hormones 
 
Leptin 
 
The ob gene was identified in genetically obese insulin resistant mice (Zhang et al., 
1994), with a human homologue gene also being described. ob/ob mice were shown to 
have a mutation in the ob gene which resulted in absence of a functional protein-leptin. 
Later db/db mice were described which had the protein, but were resistant to its actions. 
The protein produced was named leptin. In these genetically obese ob(-/-) mice, 
mutations in the ob gene results in a total lack of leptin production leading to severe 
obesity. When leptin is administered to these mice, they decrease their food intake, their 
metabolic rate increases, and they lose significant amounts of weight suggesting that 
leptin may facilitate negative energy balance.  
Leptin is an hormone predominantly produced, and secreted from the adipose tissue, 
but it is also expressed in low levels in the gastric epithelium, muscle placenta and CNS 
(Margetic et al., 2002). 20% of circulating leptin is bound to plasma proteins 
(Houseknecht et al., 1996), with lean humans having higher levels of the free form 
(Sinha et al., 1996). Bound leptin does not seem to be bioactive, although immunoassays 
detect both bound and free forms. 
Leptin receptors are widely distributed in peripheral organs ensuring that leptin‟s 
actions are more widespread than merely on the central nervous system. Leptin 
receptors have been demonstrated on pancreatic - and -cells, but do not seem to be 
present on -cells (Kieffer et al., 1997). 
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Adiponectin 
 
Adiponectin expression occurs from an intermediate stage of adipogenesis onwards 
(Hu et al., 1996), and represents the most abundant protein secreted by adipose tissue. 
Unlike most other adipokines, plasma adiponectin levels were reduced in animal models 
of obesity and insulin resistance (Hotta et al., 2001; Hu et al., 1996). Administration of 
recombinant adiponectin to rodents resulted in increased glucose uptake and fat 
oxidation in muscle, reduced hepatic glucose production, and improved whole-body 
insulin sensitivity (Yamauchi et al., 2001). 
Adiponectin transgenic mice showed partial amelioration of insulin resistance and 
diabetes and suppression of endogenous glucose production (Combs et al., 2004). In 
contrast, adiponectin-deficient mice exhibited insulin resistance and glucose intolerance 
(Maeda et al., 2002; Nawrocki et al., 2006). In addition to its insulin-sensitizing effects, 
adiponectin may alter glucose metabolism through stimulation of pancreatic insulin 
secretion in vivo (Okamoto et al., 2008). 
Apart from its peripheral actions, adiponectin was shown to modulate food intake and 
energy expenditure during fasting (increased food intake and reduced energy 
expenditure) and re-feeding (opposite effects), through its effects in the central nervous 
system (Kubota et al., 2007). In humans, plasma adiponectin levels were correlated 
negatively with adiposity (Gavrila et al., 2003), insulin resistance (Abbasi et al., 2004; 
Yang et al., 2004), type 2 diabetes (Heidemann et al., 2008), and metabolic syndrome 
(Arner, 2005a; Gavrila et al., 2003). 
 
Resistin 
 
Resistin is an adipocyte hormone expressed in visceral and subcutaneous adipose 
tissue. Resistin causes insulin resistance and glucose intolerance in mice.  Serum resistin 
levels are elevated in obese rodents (Steppan et al., 2001),  although studies have 
reported variable results (Banerjee et al., 2003). 
Administration of resistin to normal mice impairs glucose tolerance and insulin action. 
Resistin impairs insulin stimulated glucose uptake in culture adipocytes, while 
administration of anti-resistin antibodies to animals prevents development of insulin 
resistance and hyperglycemia associated with high fat intake (Steppan et al., 2001). 
Infusion of resistin under euglycemic hyperinsulinemic conditions produces hepatic insulin 
resistance. Mice lacking resistin did not show any difference in body weight compared 
with wild type mice when challenged with a high fat diet, but demonstrated improved 
glucose tolerance even on high fat diet with preserved insulin sensitivity (Banerjee et al., 
2004). 
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Resistin is expressed at very low levels in human adipocytes (Arner, 2005b; Banerjee 
et al., 2003). Insulin and TNF- have been shown to inhibit resistin expression, which 
might explain the low resistin expression in the obese state (Rabe et al., 2008). 
 
Retinol-binding protein 4 (RBP-4) 
 
Retinol Binding Protein-4 (RBP-4) is elevated in insulin resistant adipose specific 
GLUT4 knockout mice, and humans with obesity and type 2 diabetes. Transgenic 
overexpression of human RBP-4 in wildtype mice or administration of recombinant RBP-4 
to wildtype mice, was shown to cause insulin resistance through induction of hepatic 
expression of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase, and 
impairment of skeletal muscle insulin signaling. In contrast, genetic deletion of RBP4 
enhanced insulin sensitivity (Yang et al., 2005).  
Serum RBP-4 concentrations were elevated in insulin resistant humans with obesity, 
impaired glucose tolerance and type 2 diabetes, and even in lean normoglycemic 
subjects with a strong family history of type 2 diabetes (Graham et al., 2006; Yang et 
al., 2005). Previous studies shown that serum RBP4 levels are increased in many insulin-
resistant states induced by genetic and dietary factors (Graham et al., 2006; Yang et al., 
2005).  
 
Visfatin 
 
Visfatin is a newly discovered adipocyte hormone with a direct relationship between 
plasma visfatin levels and type 2 diabetes mellitus. Visfatin binds to the insulin receptor 
at a site distinct from that of insulin, and causes hypoglycemia by reducing glucose 
release from liver cells, and stimulating glucose utilization in adipocytes and myocytes 
(Beltowski, 2006; Rasouli et al., 2008). 
Visfatin is upregulated by hypoxia, inflammation and hyperglycemia and 
downregulated by insulin, somatostatin and statins. This hormone is found in the 
cytoplasm, as well as, the nucleus of cells, and has been identified in many tissues and 
organs including the brain, kidney, lung, spleen and testis but, preferentially expressed in 
visceral adipose tissue (from which the name visfatin was derived), and upregulated in 
some animal models of obesity. Visfatin is an endocrine, autocrine, as well as, paracrine 
peptide with many functions, including enhancement of cell proliferation and 
hypoglycemic effect (Adeghate, 2008; Rabe et al., 2008). Injection of visfatin in mice 
lowered blood glucose, and mice with a mutation in visfatin had higher glucose levels 
(Rasouli et al., 2008). 
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Chemerin 
 
Chemerin is a recently discovered chemokine highly expressed in liver and white 
adipose tissue (Bozaoglu et al., 2007; Goralski et al., 2007). It exerts potent anti-
inflammatory effects on activated macrophages expressing the chemerin receptor 
CMKLR1 (chemokine-like receptor-1), in a cysteine protease-dependent manner. 
Furthermore, chemerin is crucial for normal adipocyte differentiation, and modulates the 
expression of adipocyte genes involved in glucose and lipid homeostasis, such as GLUT4, 
fatty acid synthase, and adiponectin via its own receptor (Bozaoglu et al., 2007; Goralski 
et al., 2007; Roh et al., 2007). 
In 3T3-L1 adipocytes, chemerin was reported to enhance insulin-stimulated glucose 
uptake and insulin receptor substrate-1 tyrosine phosphorylation, suggesting that, 
chemerin may increase insulin sensitivity in adipose tissue (Takahashi et al., 2008). In 
humans, chemerin levels did not differ significantly between subjects with type 2 
diabetes and normal controls. However, in normal glucose tolerant subjects, chemerin 
levels were associated significantly with BMI, triglycerides, and blood pressure (Bozaoglu 
et al., 2007).  
 
Vaspin 
 
Vaspin (Visceral Adipose tissue-derived Serine Protease Inhibitor) was identified in 
visceral adipose tissue of fatty rats, at an age when body weight and hyperinsulinemia 
peaked (Hida et al., 2005). Vaspin expression was shown to decrease with worsening of 
diabetes and body weight loss. It was shown to be regulated in a fat-depot specific 
manner, and to be associated with obesity and parameters of insulin resistance (Kloting 
et al., 2006). Likewise, elevated vaspin serum concentrations were correlated with 
obesity and impaired insulin sensitivity, whereas type 2 diabetes seemed to abrogate this 
correlation (Youn et al., 2008). 
 
Apelin 
 
Apelin is the endogenous ligand for the G-protein-coupled receptor; is expressed in 
the gastrointestinal tract, predominantly in the stomach with lower levels in the intestine, 
and none in the pancreas (Higuchi et al., 2007; Tatemoto et al., 1998; Wang et al., 
2004). 
Apelin has recently been identified to be secreted by rodent and human adipocytes, 
suggesting its potential role as an adipokine (Boucher et al., 2005; Dray et al., 2008). 
Fasting decreases and re-feeding increases apelin levels in fat cells, and initial data seem 
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to suggest that insulin may control adipocyte apelin gene expression (Boucher et al., 
2005). 
Apelin levels in fat and plasma seem to correlate with the hyperinsulinism of obesity 
with higher expression in adipocytes during the stage of differentiation; and stimulates 
glucose utilization in lean and obese insulin-resistant mice  (Beltowski, 2006; Dray et al., 
2008). Obesity thus seems to up-regulate apelin expression in adipose tissue. Initial 
studies do not suggest an appetite modifying action for apelin with central administration 
(Taheri et al., 2002). 
 
Omentin 
 
Omentin is a recognized gene highly localized to the omental tissue (visceral adipose 
tissue). Omentin is present in the stromal vascular cells in the adipose tissue, rather than 
in the adipocytes; and is predominantly expressed in the visceral adipose tissue than the 
subcutaneous tissue, with the omentin mRNA being 150 times higher in the visceral 
adipose tissue. Omentin seems to increase Akt phosphorylation independently of insulin 
presence (Yang et al., 2006). Its role in glucose metabolism and obesity remains to be 
described; however, an insulin-sensitizing action is possible. Lean subjects have higher 
plasma omentin than do obese and overweight subjects (de Souza Batista et al., 2007). 
Plasma omentin is inversely correlated with body mass index, waist circumference, leptin 
levels and insulin resistance (measured by HOMA), and positively correlated with 
adiponectin and HDL-cholesterol levels. Accordingly, omentin gene expression is 
decreased with obesity (de Souza Batista et al., 2007; Wurm et al., 2007). 
 
1.1.2.4. Counterregulatory hormones 
 
Counterregulatory hormones such as cortisol, growth hormone, and catecholamines 
prevent hypoglycemia by stimulating hepatic glucose production. Epinephrine and 
norepinephrine promotes glycogenolysis, whereas cortisol promotes gluconeogenesis. 
The actions of norepinephrine are mediated by the intracellular signals of 
phosphatidylinositol and Ca2+ to promote glycogenolysis (Pickup et al., 2003). Cortisol 
and epinephrine also limit pyruvate use, allowing it to be converted to free glucose, in 
the liver and kidneys. Epinephrine rises before growth hormone and cortisol; its increase 
coincides with the increase in hepatic glucose production (Pickup et al., 2003). 
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1.2. INSULIN AND GLUCOSE METABOLISM 
 
Insulin plays a central role in the control of the body‟s metabolism. One of its primary 
functions is the stimulation of glucose uptake from the systemic circulation, as well as, 
the suppression of hepatic gluconeogenesis, thereby serving a primary role in glucose 
homeostasis and preventing any metabolic disorder. 
 
1.2.1. The insulin molecule  
 
The insulin molecule (5.5kDa) is a 51 aminoacid anabolic peptide-hormone that is 
secreted by the -cells in the pancreatic islets of Langerhans. Insulin is a two chain 
heterodimer consisting of a 21 aminoacid A-chain linked to a 30 residue B-chain by two 
disulfide bonds derived from cysteine residues (A7-B7 and A20-B19). An intrachain 
disulfide bond also exists in the A-chain (A6-A11) (Figure 1.2). 
 
 
Figure 1.2 - Structure of human insulin. Insulin and C-peptide molecules are connected at two sites by 
dipeptide links. An initial cleavage by a trypsin-like enzyme (open arrows) followed by several cleavages by a 
carboxypeptidase-like enzyme (solid arrows) results in the production of the heterodimeric (AB) insulin 
molecule (light blue) and the C-peptide (white). Adapted from (Pickup et al., 2003). 
 
1.2.2. Insulin biosynthesis 
 
Although the primary structure provided valuable information on the aminoacid 
composition and size of the insulin molecule, questions concerning the processes of 
insulin synthesis and secretion were not resolved until the late 1960's with the discovery 
of proinsulin - the precursor of insulin. Proinsulin, a 9kDa protein, contains both the A- 
and B-chain of insulin in a continuous single chain joined through an intervening region 
called, C-peptide. C-peptide is a variable length peptide segment, consisting of 26-31 
residues, which links the carboxy terminus of the B-chain to the amino terminus of the A-
chain via two dibasic residue links (Arg-Arg and Lys-Arg) (Figure 1.2). 
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C-peptide is stored together with insulin in the mature granules within the -cell. It is 
secreted intraportally with insulin, on an equimolar basis, and shows the characteristic 
biphasic shape in response to iv challenges (Caumo et al., 2004). All of the released C-
peptide reaches the peripheral circulation without appreciable extraction by the liver. For 
this reason, C-peptide has proven to be a fundamental tool for accurate quantification of 
-cell secretion. In fact, with the aid of kinetic modelling and deconvolution, C-peptide 
levels can be used to provide a reliable measure of the insulin secretory rate (Eaton et 
al., 1980; Polonsky et al., 1986).  
The half-life of C-peptide has been shown to be relatively slow (35min), and 
glomerular filtration is the major route of its removal. The slow metabolism of C-peptide 
is consistent with the hypothesis that, C-peptide diffuses into the extracellular space, but 
is not integrated into cell membranes. In contrast, insulin is rapidly removed from the 
circulation (half-life, 5min) via insulin receptor-mediated uptake followed by lysosomal 
degradation. C-peptide acts through the activation of G proteins (Maestroni et al., 2005; 
Rigler et al., 1999), but the C-peptide-specific G-coupled receptor has not yet been 
localized. C-peptide has an insulinomimetic effect and, that its action would be mediated 
through the modulation of the (tyrosine kinase-coupled) receptor of insulin (Grunberger 
et al., 2001). 
Proinsulin is cleaved at those dibasic links by a trypsin-like enzyme to release two 
chain insulin and free C-peptide. Chan et al. subsequently discovered that there was an 
additional precursor of insulin, preproinsulin. Preproinsulin is a 12kDa single chain 
polypeptide, which consists of proinsulin extended at the amino terminus by a 24 
aminoacid signal peptide region of hydrophobic residues. This signal sequence is 
characteristic of proteins that enter the secretory pathway (Chan et al., 1976). 
Insulin exists primarily as a monomer at low concentrations (~10-6M), and forms 
dimers at higher concentrations at neutral pH. At high concentrations and in the presence 
of zinc ions, insulin aggregates further to form hexameric complexes (Goldman et al., 
1974). 
 
1.2.3. Insulin secretion 
 
Insulin is stored in large dense core vesicles and is released via exocytosis. This is a 
multistep process that consists on the transport of the secretory vesicles to the plasma 
membrane, then docking, priming, and finally fusion of the vesicle with the plasma 
membrane. It is well known that this process is regulated cooperatively by nutrients, 
other hormones, and neurotransmitters to cause the electrical depolarization of the -cell 
and the release of insulin. However, only a small portion of the insulin stored in vesicles 
in the -cell is released even under maximum stimulation. This suggests that the 
Chapter 1  General Introduction 
  PhD Thesis, Rita S. Patarrão 
 17 
systemic insulin levels are therefore regulated by secretion instead of synthesis or 
storage pools (Eliasson et al., 2008). 
The best characterized mechanism of coupling glucose metabolism to insulin secretion 
resides in the electrical excitability of the -cell (Ashcroft et al., 1989).  
Glucose-stimulated insulin secretion in vivo typically follows a biphasic time course 
(Rorsman et al., 2000). After elevation of the glucose concentration, a transient 
stimulation of insulin secretion is observed, referred to as first phase secretion (short 
duration, 5-10min), which at later times is followed by a gradually developing secondary 
stimulation, second phase secretion. Only fuel secretagogues are capable of eliciting the 
second phase, and, when insulin secretion is evoked by non-metabolizable stimuli, only 
the first phase is observed. This suggests that second phase insulin secretion is an 
energy-dependent process (Porksen, 2002; Porksen et al., 2002; Rorsman et al., 2003). 
The numerous islets composing the endocrine pancreas could be functionally 
heterogeneous, some of them being responsible for the first phase and others for the 
second phase (Henquin et al., 2002). 
During the biphasic time course of insulin secretion, insulin, like many other 
hormones, is secreted in a pulsatile fashion, resulting in oscillatory concentrations in 
peripheral blood. Oscillations include rapid pulses (recurring every 5-15min) 
superimposed on slower, ultradian oscillations (recurring every 80-150min) that are 
closely related to fluctuations in glucose concentration (Caumo et al., 2004; Porksen, 
2002). 
It is important to make a clear distinction between the insulin response following an iv 
glucose challenge and that following oral glucose or food ingestion. The iv administration 
of glucose triggers a biphasic insulin response (featuring a rapid increase with a peak, an 
interpeak nadir, and a subsequent slower increasing phase), only when glucose 
concentration increases rapidly, as after a glucose bolus or a glucose infusion 
determining a square wave of hyperglycemia. A “slow-ramp” iv glucose input induces 
gradually larger secretion without a well-defined first phase. More importantly, a well-
defined first phase is lacking under physiological conditions, i.e., when glucose is given 
orally (Caumo et al., 2004). 
As mentioned before, endogenous insulin release is pulsatile in both humans (Lang et 
al., 1979) and animals (Chou et al., 1991; Goodner et al., 1977). Additionally, studies 
that compared pulsatile and continuous insulin delivery, showed that exogenous insulin 
was more effective when administered in a pulsatile manner, particularly with regard to 
the inhibition of glucagon secretion (Ward et al., 1989), blockade of hepatic glucose 
production (Paolisso et al., 1991) and its hypoglycemic action, both in the fasting and fed 
states (Grubert et al., 2005; Matthews et al., 1983; Matveyenko et al., 2008; Meier et 
al., 2005; Reid et al., 2004; Ward et al., 1989). 
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Regulation of insulin secretion 
 
Several hormones and neurotransmitters regulate insulin secretion in addition to the 
voltage sensitive pathways. Molecules such as epinephrine, somatostatin, ACh, and GLP-
1 all help regulate insulin secretion, by binding to their own receptors. CCK and Ach 
potentiate insulin secretion via phosphoinositide catabolism with the subsequent 
mobilization of intracellular Ca2+ (Barg et al., 2004; Lang, 1999). These ligands bind to 
G-protein coupled receptors that can activate phospholipase C (PLC). PLC hydrolysis of 
phosphatidylinositol 4,5-bisphosphate produces inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). Two families of Ca2+ channels are present on the endoplasmic 
reticulum: IP3 receptors and ryanodine receptors. Both of these are capable of causing 
the release of Ca2+ stored in the endoplasmic reticulum. DAG concomitantly causes the 
activation of protein kinase (PKC) (Barg et al., 2004; Bergsten, 2000). Other potentiators 
of insulin secretion, such as GLP-1, and GIP, bind to their respective heterotrimeric G-
protein coupled receptors to activate adenylate cyclase and increase intracellular cAMP, 
and subsequently cause the activation of protein kinase A (PKA). Stimulation of either 
PKC or PKA alters second messenger systems in the β-cell, and can chemically modify ion 
channels to cause a direct influence on insulin secretion (Lang, 1999). 
 
1.2.4. Insulin signaling and regulation of glucose transport 
 
The concerted regulation of glucose uptake, utilization, and storage by tissues is 
critical to maintaining blood glucose homeostasis. The first step by which insulin 
increases energy storage or utilization, involves the regulated transport of glucose into 
the cell, mediated by the glucose transporters. 
Insulin is essential to regulate carbohydrate, lipid, and protein metabolism (Saltiel, 
2001). Insulin elicits a diverse array of biological responses by binding to its specific 
receptor (Goldfine, 1987; White et al., 1994). Decreased cellular responses to insulin or 
perturbation of the insulin signaling pathways are associated with a number of 
pathological states (Taylor, 1992). 
 
1.2.4.1. Glucose transporters 
 
Glucose derived from the diet is transferred from the lumen of small intestine into the 
blood. Both dietary glucose and glucose synthesized within the body have to be 
transported from the circulation into target cells. These processes involve the transfer of 
glucose across plasma membranes and this occurs via integral transport proteins.  
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Glucose transporters are membrane proteins, which exist on the cell surface and 
incorporate glucose into cells. These transporters comprise two structurally and 
functionally distinct groups, namely: (i) the Na+-dependent glucose co-transporters 
(SGLT, members of a larger family of Na+-dependent transporters) (Wright, 2001); (ii) 
the facilitative Na+-independent sugar transporters (GLUT family) (Asano et al., 2004; 
Joost et al., 2002; Mueckler, 1994), as depicted in Table I. 
 
1.2.4.1.1. Sodium-dependent glucose transporters (STGL) 
 
The SGLT transports glucose (and galactose), with different affinities, via a secondary 
active transport mechanism. The Na+-electrochemical gradient provided by the Na+–K+ 
ATPase pump is utilized to transport glucose into cells against its concentration gradient. 
This form of glucose transport takes place across the lumenal membrane of cells lining 
the small intestine and the proximal tubules of the kidneys (Wood et al., 2007).  
SGLT1 has a limited tissue expression and is found essentially on the apical 
membranes of small-intestinal absorptive cells (enterocytes) and renal proximal straight 
tubules (S3 cells).  
A second Na+-glucose transporter, SGLT2, is of low affinity for glucose and is 
predominantly expressed on the apical membrane of renal convoluted proximal.  
Current studies with the human analogue of SGLT3 suggest that its function may 
require a re-evaluation (Wright, 2001). Signals have been detected for SGLT3 in the 
small intestine of pigs (Wells et al., 1992) and in human subjects (Wood IS, unpublished 
data). These findings conflict with collective data indicating that SGLT1 is the only Na+–
glucose co-transporter expressed in the small intestine. 
 
1.2.4.1.2. Facilitative glucose transporters (GLUT) 
 
The facilitative glucose transporters (GLUT) utilize the diffusion gradient of glucose 
(and other sugars) across plasma membranes and exhibit different substrate specificities, 
kinetic properties and tissue expression profiles. This class of glucose transporters can be 
divided into three subclasses. 
 
 
 
 
 
 
Chapter 1  General Introduction 
  PhD Thesis, Rita S. Patarrão 
 20 
Class I is comprised of the extensively characterized glucose transporters GLUT1 to 
GLUT4, which can be distinguished on the basis of their distinct tissue distributions 
(GLUT11, erythrocytes, brain microvessels; GLUT22, liver, pancreatic β-cells, kidneys, 
intestine; GLUT3, neuronal cells; GLUT43, heart, brain, skeletal muscle, adipose tissue) 
and their hormonal regulation (e.g., insulin sensitivity of GLUT4). 
Class II is comprised of the fructose-specific transporter GLUT5 (GLUT 5, small 
intestine, testis and kidney) and three related proteins, GLUT7, GLUT9, and GLUT114 
(GLUT 7, intestine, testis; GLUT 9, liver, kidneys; GLUT 11, heart, muscle).  
Class III facilitative transporters comprise five members: GLUT6, GLUT8, GLUT10, 
GLUT12 and H+-coupled myo-inositol transporter (HMIT, (Uldry et al., 2001)). This class 
of facilitative transporters is characterized by the lack of a glycosylation site in the first 
extracellular linker domain, and by the presence of such a site in loop 9. Glucose 
transport activity has been demonstrated for GLUT6 and GLUT8 (GLUT 6, spleen, 
leucocytes, brain; GLUT 8, testis, brain, adipose tissue) (Doege et al., 2000; Wood et al., 
2007). GLUT10 is expressed in the insulin-sensitive tissues of skeletal muscle and heart 
and has also been reported as being expressed in the liver and pancreas (Dawson et al., 
2001; McVie-Wylie et al., 2001). HMIT has been shown to be an H+-coupled myo-inositol 
transporter, expressed predominantly in the brain (Uldry et al., 2001). GLUT 12 has not  
the primary substrate identity characterized, but is expressed in heart, small intestine, 
prostate and insulin-sensitive tissues (Rogers et al., 2002). 
It should be emphasized, however, that the designation of the family does not 
necessarily reflect the substrate specificity of its members, which may transport sugars 
or polyols other than glucose (e.g., GLUT5, fructose; HMIT, H+-coupled myo-inositol) 
(Joost et al., 2002). 
                                         
 
1 Moderate levels of GLUT 1 expression are also observed in adipose tissue, muscle and the liver (Mueckler, 
1994). 
2 GLUT2 is thought to play a role in the glucose-sensing mechanism, while in the liver it is expressed on the 
sinusoidal membrane of hepatocytes, and allows for the bi-directional transport of glucose under hormonal 
control. GLUT2 is also found on the basolateral surface of proximal renal tubules, and enterocytes, where it 
forms part of the transcellular pathway for glucose and fructose transport (Asano et al., 2004; Joost et al., 
2002).  
3 Insulin acts by stimulating the translocation of specific GLUT4-containing vesicles from intracellular stores to 
the plasma membrane resulting in an immediate 10–20-fold increase in glucose transport (Shepherd et al., 
1999).  
4 Low-affinity glucose transport is demonstrated by the short form of GLUT11, and is competed for by fructose, 
with the transporter being expressed predominantly in heart and skeletal muscle (Doege et al., 2001). The long 
form of GLUT11, which is not expressed in heart or skeletal muscle but is detected in liver, lung, trachea and 
brain, was shown to increase fructose transport (Wu et al., 2002).  
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Table I - Summary of the properties of facilitative glucose transporter (GLUT) and Na+/Glucose co-transporter 
family members (SGLT). Adapted from (Joost et al., 2002; Wood et al., 2007; Zhao et al., 2007). 
 
Isoform Tissue  
distribution 
 Transported 
molecule 
Proposed function Insulin 
sensitive? 
 
Facilitative glucose transporter (GLUT) 
GLUT 1 Ubiquitous distribution 
in tissues  
Glucose Basal glucose uptake; 
transport across blood 
tissue barriers 
No 
GLUT 2 Liver, pancreas, kidney, 
small intestine 
Glucose (low affinity); 
fructose 
High-capacity low-affinity 
transport 
No 
GLUT 3 Brain, nerves cells Glucose (high affinity) Neuronal transport 
 
No 
GLUT 4 Muscle, WAT, BAT, 
heart, brain 
Glucose (high affinity) Insulin-regulated 
transport in muscle and 
fat 
Yes 
GLUT 5 Intestine, kidney, testis Fructose; glucose (very 
low affinity) 
Transport of fructose 
 
No 
GLUT 6 Spleen, leukocytes, 
brain 
Glucose  No 
GLUT 7 Small intestine, colon, 
testis 
n.d. Transport of fructose 
 
n.d. 
GLUT 8 Testis, blastocyst, brain, 
muscle, adipocytes 
Glucose Fuel supply of mature 
spermatozoa; 
Insulin-responsive 
transport in blastocyst 
No (Yes, in 
blastocytes) 
GLUT 9 Liver, kidney n.d.  n.d. 
GLUT 10 Liver, pancreas Glucose  No 
GLUT 11 Heart, muscle Glucose (low affinity); 
fructose (long form) 
Muscle-specific; fructose 
transporter 
Yes 
GLUT 12 Heart, prostate, muscle, 
small intestine, WAT 
n.d. H+/myo-inositol           
co-transporter 
Yes 
HMIT Brain H+-myo-inositol  n.d. 
 
Na+/Glucose co-transporter (SGLT) 
SGLT1 Kidney, small intestine Glucose (high affinity); 
galactose 
Glucose reabsorption in 
intestine and kidney 
 
SGLT2 Kidney Glucose (low affinity) Low affinity and high 
selectivity for glucose 
 
SGLT3 Small intestine, skeletal 
muscle 
 Glucose activated Na+ 
channel 
 
 
GLUT - Facilitative glucose transporter; SGLT - Sodium glucose co-transporter; HMIT - H+-coupled myo-inositol 
transporter; n.d. – not determined; WAT - White adipose tissue; BAT - Brown adipose tissue. 
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1.2.4.2. The insulin receptor: structure and function 
 
The insulin receptor is a heterotetrameric protein consisting of two extracellular -
subunits (135kDa), and two transmembrane -subunits (95kDa), which are linked 
together by disulphide bonds (Figure 1.3). Insulin binds to -subunits, inducing a 
conformational change which results in autophosphorylation of seven tyrosine residues 
present in the -subunit (Boni-Schnetzler et al., 1986; Schenker et al., 1991; White et 
al., 1994). This tyrosine phosphorylation stimulates the tyrosine kinase activity intrinsic 
to the -subunit of the receptor (Van Obberghen et al., 2001). 
 
 
 
 
Figure 1.3 - Schematic diagram of the insulin receptor tetramer. Insulin binding sites are shown in the 
-subunit, and the autophosphorylation sites are listed in the -subunits. The insulin receptor -subunits are 
linked together and to a -subunit, by disulfide bonds. The relative positions of the insulin binding domain, the 
cysteine-rich region and the transmembrane spanning region are showed. , -subunit; Cys, cysteine residue; -
S-S-, disulfide bond; Tyr, tyrosine residue; Lys, lysine residue. Adapted from (Kido et al., 2001; White, 1997; 
White et al., 1994). 
 
The ability of the receptor to autophosphorylate and phosphorylate intracellular 
substrates is essential for its mediation of the complex cellular responses to insulin (Ellis 
et al., 1987; Kasuga et al., 1982; Rosen et al., 1983; Yu et al., 1984). Structure biology 
studies reveal that the two -subunits jointly participate in insulin binding, and the kinase 
domains in the two -subunits are in a juxtaposition that permits autophosphorylation of 
tyrosine residues, the first step of insulin receptor activation (Luo et al., 1999; 
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Ottensmeyer et al., 2000). The kinase domain undergoes conformational change upon 
autophosphorylation, providing a basis for activation of the kinase, and binding of 
downstream signaling molecules (Hubbard, 1997; Hubbard et al., 1994). 
 
1.2.4.3. Insulin signaling pathway and glucose uptake  
 
Over the last few years, it has been established that two pathways are necessary for 
insulin-stimulated glucose transport; a phosphatidylinositol-3 kinase (PI3K)-dependent 
pathway and a PI3K-independent pathway (Saltiel et al., 2002).  
 
In muscle and adipose tissue, the PI3K-dependent pathway is induced when activation 
of the insulin receptor by insulin, results in tyrosine phosphorylation of several 
substrates, including the insulin receptor substrate 1 (IRS-1), IRS-2 and IRS-3 (in the 
adipose tissue) (Taniguchi et al., 2006). Following tyrosine phosphorylation, IRS proteins 
bind and activate the PI3K enzyme. Once activated, PI3K mediates the increase in serine 
phosphorylation of protein kinase B (Akt/PKB), which, in turn, stimulates glucose 
transport and lipogenesis (Saltiel et al., 2002; Taniguchi et al., 2006)5 (Figure 1.4).  
 
Recently, the proto-oncogene, Casitas b-lineage lymphoma (Cbl), has been suggested 
to play a role in insulin action, independently of the PI3K/Akt pathway, that is localized in 
lipid raft microdomains (Baumann et al., 2000; Saltiel et al., 2003; Saltiel et al., 2002). 
At least some of the insulin receptor has been shown to reside in these microdomains, 
perhaps through its interaction with the raft protein caveolin (Kimura et al., 2002). In 
3T3-L1 adipocytes, Cbl forms a complex with 2 adaptor proteins, adapter protein with 
pleckstrin homology and Src homology 2 domains (APS) and Cbl associated protein 
(CAP). Upon insulin stimulation, this complex binds to the insulin receptor via an 
interaction between an SH2 domain in APS and the tyrosylphosphorylated receptor tail 
(Liu et al., 2002). Cbl then undergoes insulin-dependent tyrosine phosphorylation, 
resulting in the recruitment of the CAP/Cbl complex to lipid rafts, via an interaction 
                                         
 
5 Upon tyrosine phosphorylation, IRS proteins interact with the p85 regulatory subunit and with the p110 
catalytic subunit of PI3K, leading to the activation of the enzyme and, its targeting to the plasma membrane. 
The enzyme generates the lipid product phosphatidylinositol 3,4,5-trisphosphate (PIP3), which regulates the 
localization and activity of numerous proteins (Khan et al., 2002).  Insulin-stimulated increases in PIP3 result in 
the recruitment and/or activation of pleckstrin homology (PH) domain–containing proteins, including various 
enzymes, their substrates, adapter molecules, and cytoskeletal proteins. Among these is the phosphoinositide-
dependent protein kinase-1 (PDK1), which phosphorylates and activates several downstream kinases, including 
Akt/PKB and the atypical protein kinase C (PKC and PKC) (Pessin et al., 2000). The active Akt/PKB 
phosphorylates AS160 protein (Akt substrate of 160 kDa) (Kane et al., 2002; Miinea et al., 2005), which is 
constitutively associated with GLUT4 vesicles (Brozinick et al., 2007) and in particular Rab protein (small G-
proteins involved in vesicle movement and fusion) (Zerial et al., 2001). AS160 phosphorylation by Akt/PKB 
leads to the activation of Rab proteins (Brozinick et al., 2007; Sano et al., 2003), which results in an increased 
rate of GLUT4 translocation (Jordens et al., 2005). 
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between the CAP and the lipid raft protein flotillin (Baumann et al., 2000). Within the 
lipid raft, tyrosyl-phosphorylated Cbl recruits the CrkII/C3G heterodimer via an 
interaction between an SH2 domain in CrkII and a tyrosine phosphorylation site in Cbl 
(Chiang et al., 2001; Ribon et al., 1996). C3G, a guanine nucleotide exchange factor for 
small molecular weight GTPases, activates the small G protein TC10 (Chiang et al., 2001; 
Watson et al., 2001). The activation of TC10 provides a second signal to the GLUT4 
translocation and, may function in parallel with the activation of the PI3K pathway 
(Chiang et al., 2001)6 (Figure 1.4). 
 
 
Figure 1.4 – Simplified representation of molecular mechanism involved in insulin signaling pathway that 
regulates glucose transporter (GLUT4) translocation to cell membrane. Some of the details like, other isoforms 
of insulin receptor substrate and multiphosphorylation of insulin receptor substrate are not shown here. Letter 
'P' indicates phosphorylated species.GLUT4, Glucose transporter isoform 4; IRS-1: Insulin receptor substrate-1; 
tyr, Tyrosine residue; PI3K: Phosphatidylinositol-3-kinase; Akt/PKB: Protein kinase B; p85, regulatory subunit 
of PI3K; p110, catalytic subunit of PI3K; APS, Adaptor protein associated with pleckstrin homology (PH) and 
SH2 domains; AS160, Akt substrate of 160 kDa; Cbl, Casitas b-lineage lymphoma; CAP, Cbl-associated protein; 
CrkII, SH2/SH3 adapter protein; C3G, Crk SH3-binding guanine nucleotide-releasing factor; PDK1, 
Phosphoinositide-dependent kinase 1; PKC (/), Atypical protein kinase C; PLC, Phospholipase C; DAG, 
Diacylglycerol; IP3, Inositol-1,4,5-triphosphate; PIP3, Phosphatidylinositol-3-phosphate.  
                                         
 
6 The TC10 protein promotes the translocation and docking of GLUT4 in the membrane (Saito et al., 2008; 
Watson et al., 2001), possibly through the regulation of actin microfilaments (Brozinick et al., 2007). Although 
the TC10 pathway can be seen as independent of the PI3K pathway, some studies have suggested that atypical 
protein kinase C (PKC and PKC) also promote TC10 activation (Kanzaki et al., 2004; Saito et al., 2008).  
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1.3. GLUCAGON AND GLUCOSE HOMEOSTASIS  
 
Glucagon is critical in regulating hepatic glucose production, and induces about two-
thirds of the glucose released in the post-absorptive and fasted states. Physiological 
increments in glucagon levels stimulate both glycogenolysis and gluconeogenesis (Unger, 
1971). The inappropriate raised plasma glucagon levels found in many patients with 
poorly controlled type 2 diabetes, may play a role in the enhanced gluconeogenesis, and 
excessive glucose release from the liver that contribute to their fasting hyperglycemia 
(Dunning et al., 2007). 
 
1.3.1. The glucagon molecule: structure and synthesis  
 
Glucagon is a single straight-chain peptide hormone of 29 aminoacid (3.5kDa) which 
was discovered as a "contaminant" hyperglycemic factor in pancreatic extracts. Glucagon 
is synthesized in and secreted from -cells of pancreatic islets as a 160 aminoacid 
prohormone (proglucagon)7. Proglucagon ultimately undergoes cleavage into four 
peptides. L-cells of the small intestine synthesize an identical proglucagon molecule, but 
different processing results in the formation of different polypeptides, of which glucagon-
like peptide 1 (GLP-1) and 2 (GLP-2) are probably of most physiologic importance. 
Glucagon is stored in dense granules and is released by exocytosis. This process is 
inhibited if the levels of Ca2+ in the -cell are decreased (Jaspan et al., 1977). 
 
1.3.2. Glucagon secretion  
 
Glucagon, stored within -cells in distinctive granules, is secreted by a process called 
emiocytosis, which involves migration of secretory granules to the periphery of cells, 
fusion of granules with the plasma membrane, and extrusion of granule contents into the 
extracellular space (Gerich et al., 1976). Secretion of glucagon involves -cell substrate 
metabolism, and consequent signals which affect cellular K+ and Ca2+ channels, and 
cAMP levels, as well as, PKA and PKC (Figure 1.5A and Figure 1.5B). 
 
 
 
 
 
 
                                         
 
7 In humans, the circulating half-life of immunoreactive glucagon is estimated to be between 5-6min (Alford et 
al., 1976; Hinke et al., 2000). 
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Figure 1.5 - Schematic representation of stimulators (A) and inhibitors (B) of glucagon of glucagon secretion. 
PKA, Protein kinase A; PKC, Protein kinase C; FFA, Free fatty acids, Ca2+, calcium. 
 
Most substrates (glucose, free fatty acids and ketone bodies), except certain 
aminoacids, suppress glucagon secretion (Gerich et al., 1976). Inhibition of the 
metabolism of these substrates prevents the inhibition of glucagon secretion, suggesting 
that, in contrast to insulin secretion by -cells, production of ATP inhibits glucagon 
secretion. While this is consistent with the reciprocal roles of insulin and glucagon in 
glucose homeostasis, a definitive explanation for this difference remains to be elucidated.  
-cells contain ATP-sensitive K+ channels as well as sulfonylurea, adrenergic, insulin 
and somatostatin receptors (Bokvist et al., 1999). Sulfonylurea receptors and ATP-
sensitive K+ channels are associated with both plasma membranes and secretory granule 
membranes. Sulfonylureas stimulate glucagon release under appropriate conditions 
(Grodsky et al., 1977). This effect is dependent on PKC, mimicked by inhibitors of 
mitochondrial ATP-sensitive K+ channels, and inhibited by K+ channel openers (diazoxide) 
(Hoy et al., 2000) (Figure 1.5A). However, it has been proposed that a decrease in the 
intra -cell ATP/ADP ratio activates adenylate cyclase, and the resultant increase in cAMP 
stimulates PKA, which causes opening of Ca2+ channels, and an increase in intra--cell 
Ca2+, which will trigger glucagon release (Figure 1.5B)8. 
 
                                         
 
8 Plasma glucagon concentration depends on the balance between rates of secretion and degradation, and also 
on the sampling site (e.g. peripheral venous vs portal venous). Basal (non-stimulated) secretion rates of 
glucagon can be estimated from data on portal venous-arterial differences and portal venous plasma flow rates. 
From what is known of the pancreatic content of glucagon and secretory rates of glucagon, it can be estimated 
that at least 25%, and probably more, of the pancreatic content of glucagon is secreted each day (Fisher et al., 
1976). 
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Regulation of glucagon secretion 
 
Glucose is the most important physiologic regular of glucagon secretion. 
Hyperglycemia decreases and hypoglycemia increases glucagon secretion (Gerich et al., 
1976). In vitro studies, indicate that the -cell is as exquisitely sensitive to changes in 
the ambient extracellular glucose concentration as is the -cell (Gerich et al., 1974a). To 
some extent the inhibition of glucagon secretion is dependent on concomitant stimulation 
of insulin release (Mitrakou et al., 1991). Other substrates also influence glucagon 
secretion. Various aminoacids stimulate -cell release of glucagon (Rocha et al., 1972), 
while free fatty acids (Gerich et al., 1974b) and ketone bodies (Goberna et al., 1974) 
suppress glucagon secretion (Quesada et al., 2008). 
The islets of Langerhans are richly innervated. Like insulin release, glucagon secretion 
is influenced by both sympathetic and parasympathetic nervous systems; epinephrine, 
norepinephrine, ACh, electrical stimulation of mixed pancreatic, splanchnic, and vagus 
nerves augment glucagon release. Both - and -cell secretion are influenced in the same 
direction by parasympathetic (i.e. increase), -adrenergic (i.e. increase), and -
adrenergic (i.e. decrease) mechanisms (Gerich et al., 1976; Gromada et al., 1997). The 
observation that glucagon secretion is increased by epinephrine while insulin release is 
simultaneously decreased, can best be explained by postulating that, -cell contains a 
preponderance of -adrenergic receptors, while the -cell contains a preponderance of -
adrenergic receptors. Neural input to the -cell is probably important in modulating the 
increases in plasma glucagon, observed during stress and, perhaps also after mixed 
meals. 
Hypoglycemia stimulates glucagon secretion through both intraislet and central 
nervous system mediated autonomic signals. Within the islets low glucose concentrations 
increase -cell glucagon secretion directly and, by reducing -cell secretion, decrease 
tonic -cell inhibition by insulin. Autonomic adrenergic (i.e. norepinephrine), cholinergic, 
and peptidergic neural and adrenomedullary hormonal (epinephrine) signals, triggered by 
hypoglycemia, may also contribute (Lefebvre, 1995). 
Another important feature to consider, is the pancreatic intraislet communication 
between -, - and -cell, considering the anatomy of the pancreatic islets9 (Samols et 
al., 1988; Stagner et al., 1988). The regulation of pancreatic islet hormone secretion 
may occur by one, or both of two major routes of intraislet communication: the paracrine 
route, utilizing hormone diffusion through interstitial spaces, is thought to operate only 
over short distances, requiring cells to be contiguous or close to one other; and a 
                                         
 
9 -cells are located in the core of the islet, -cells are situated at the periphery of the islet and -cells are 
located between the - and -cells (Unger et al., 1977). 
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vascular route, which may deliver endogenous hormones to islet cells located 
downstream, allows cellular interactions to occur at greater distances, i.e., within the 
confines of the islet (Samols et al., 1988). The vascular cellular perfusion showed that -
cells inhibit -cell secretion and -cells stimulate -cell secretion. -cells appear not to 
significantly stimulate -cells, nor do -cells appear to inhibit -cells in terms of 
microvascular communication (Stagner et al., 1988). Therefore, the intraislet vascular 
compartment is very important in islet regulatory events and, that intraislet interactions 
are dependent upon the direction of flow; and the cellular order of perfusion (    ) 
through the islet microvasculature (Samols et al., 1988; Stagner et al., 1988). 
 
1.3.3. Molecular mechanism for glucagon-mediated glucose regulation 
 
Glucagon signals through its receptor on the cell surface (Figure 1.6). The binding of 
glucagon to the extracellular loops of the glucagon receptor results in conformational 
changes of the latter, leading to subsequent activation of the coupled G proteins. At least 
two classes of G proteins are known to be associated with and involved in the signal 
transduction of the glucagon receptor, namely Gs and Gq. The activation of Gs leads to 
activation of adenylate cyclase, increase in intracellular cAMP levels, and subsequent 
activation of PKA. The activation of Gq leads to the activation of phospholipase C, 
production of inositol 1,4,5-triphosphate, and subsequent release of intracellular Ca2+ 
(Authier et al., 2008; Burcelin et al., 1996; Christophe, 1996). Activation of glucagon 
receptors has been shown to increase intracellular Ca2+ in pancreatic -cells and 
hepatocytes (Gromada et al., 2007; Mayo et al., 2003). 
 
Figure 1.6 – Glucagon signaling pathway. PLC, Phospholipase C; PIP2, phosphatidylinositol 4,5-biphosphate; 
PGC-1, peroxisome proliferator-activated receptor- coactivator-1; PEPCK, phosphoenolpyruvate carboxykinase; 
G-6-Pase, glucose-6-phosphatase (Jiang et al., 2003). 
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Stimulation of PKA leads to increased glycogenolysis and gluconeogenesis via 
activation of glycogen phosphorylase, the rate-limiting step in glycogen breakdown, and 
increased expression of genes including phosphoenolpyruvate carboxykinase (PEPCK), 
the rate-limiting step in gluconeogenesis. Activated PKA also contributes to 
phosphorylation and inactivation of glycogen synthase, reducing the incorporation of 
glucose into glycogen. Further, PKA phosphorylates and inhibits pyruvate kinase, 
reducing glycolysis. These actions lead to mobilization of glucose as needed for normal 
fuel availability and maintenance of euglycemia (Figure 1.6) (Pickup et al., 2003).  
 
1.3.4. Role of glucagon in glucose homeostasis  
 
Glucagon is released into the bloodstream when circulating glucose is low. The main 
physiological role of glucagon is to stimulate hepatic glucose output, thereby leading to 
increases in glycemia. This provides the major counterregulatory mechanism for insulin 
in maintaining glucose homeostasis in vivo (Unger, 1971; Unger, 1985). 
Numerous ex vivo and in vitro studies have directly demonstrated that glucagon 
stimulates glucose output from intact perfused rat livers (Beuers et al., 1990; Doi et al., 
2001; Ikeda et al., 1989), resulting from increases in both glycogenolysis and 
gluconeogenesis. Similarly, glucagon also stimulates glucose output from primary 
hepatocytes in culture (Weigle et al., 1986; Weigle et al., 1984).  
Several lines of evidence indicate that glucagon is a sensitive and timely regulator of 
glucose homeostasis in vivo. Small doses of glucagon are sufficient to induce significant 
glucose elevations (Lins et al., 1983; Myers et al., 1991). The effect of glucagon can 
occur within minutes and dissipate rapidly (Dobbins et al., 1998). Glucagon is secreted 
from islets in a pulsatile fashion (Opara et al., 1988), and such pulsatile deliveries of 
glucagon are more effective in inducing hepatic glucose output (Komjati et al., 1986; 
Paolisso et al., 1989; Weigle et al., 1986). 
 
Insulin counters glucagon action on hepatic glucose output by activating 
phosphodiesterases10 that decrease cAMP levels (Furman et al., 2006; Furman et al., 
2004). Insulin action results in phosphorylation and inactivation of glycogen synthase 
kinase-3, allowing activation of glycogen synthase, and suppression of gluconeogenesis. 
Together, this leads to a decreased expression of gluconeogenic enzymes, including 
PEPCK and glucose-6-phosphatase (Figure 1.7). 
                                         
 
10 The phosphodiesterases (PDEs) are a superfamily of enzymes which catalyse the hydrolysis of the cyclic 
nucleotides cAMP and cGMP to their corresponding inactive 5-monophosphate counterparts. 
Presently, at least 11 different families of PDE isoenzymes are known. Some of them are characterized by 
substrate specificity (cAMP or cGMP), different kinetic properties and different tissue distribution (Pyne et al., 
2003). 
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Figure 1.7 – Regulation of glycogen metabolism by glucagon in the liver. Diagram outlines the effects of 
glucagon on glycogenolysis and glycogenesis in the liver. : promoted by glucagon; : inhibited by glucagon. 
 
1.3.5. Glucagon and hepatic GSH content  
 
Hormones, such as glucagon, that increase intracellular cAMP concentration and 
activate PKA, decrease the activity of -glutamylcysteine synthase and, as a 
consequence, decrease glutathione (GSH) production (Lu et al., 1991).  
GSH is synthesized from precursor aminoacids in virtually all cells. The liver plays a 
central role in the interorgan homeostasis of GSH and, is the only organ in two aspects of 
GSH biosynthesis. First, it has the unique ability to convert methionine to cysteine 
through transsulfuration. Secondly, it is the major source of plasma GSH, exporting GSH 
into plasma and bile at a rate that matches nearly all of its biosynthesis (Meister et al., 
1983).  
The synthesis of GSH from its constituent aminoacids, glutamate, cysteine, and 
glycine, involves two ATP-requiring enzymatic steps: (1) -glutamylcysteine synthase 
catalyzes the formation of an amide link between cysteine and glutamate, and (2) the 
product of this reaction, -glutamylcysteine, is linked to glycine by GSH synthase. The 
first step is rate-limiting and catalyzed by -glutamylcysteine synthase, regulated 
physiologically by (a) feedback competitive inhibition by GSH, and (b) the availability of 
its precursor, cysteine (DeLeve et al., 1990; Kaplowitz et al., 1985; Meister et al., 1983). 
Hormones that increase cytosolic Ca2+ and DAG, and activate PKC and calmodulin-
dependent kinases also decrease activity of hepatic -glutamylcysteine synthase (Lu et 
al., 1991). This short-term inhibitory control of GSH synthesis is thought to result from 
hormone-stimulated phosphorylation of -glutamylcysteine synthase (Lu et al., 1991). 
Activation of PKA and PKC also stimulates GSH efflux from the liver (Lu et al., 1990). 
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1.3.6. Role of glucagon and insulin in deregulation of glucose homeostasis  
 
There is ample evidence suggesting that glucagon plays an important role in initiating 
and maintaining hyperglycemic conditions in diabetic animals and humans. Insulin and 
glucagon are the key regulatory hormones for glucose homeostasis. The absolute levels 
and, even more so, the ratios of the two hormones are tightly regulated in vivo, 
depending on nutritional status (Cherrington, 1999; Unger, 1971). It has been reported 
that the absolute levels of glucagon or the ratios of glucagon to insulin are often elevated 
in various forms of diabetes, in both animal and human subjects (Burcelin et al., 1996; 
Unger, 1985; Unger, 1978). Chronic hyperglucagonemia is correlated with and, is at least 
partially responsible for increased hepatic glucose output and hyperglycemia in type 2 
diabetes (Consoli, 1992; Rizza et al., 1979a).  
It is controversial whether the number of glucagon receptors is altered in diabetic 
states. Most studies, however, appear to suggest that the number of glucagon receptors 
is reduced in diabetic subjects. Interestingly, even in the presence of fewer glucagon 
receptors, the ability of glucagon to stimulate cAMP production may remain unchanged or 
even be elevated (Birnbaumer et al., 1972; Burcelin et al., 1996). 
In healthy animals and human subjects, the levels of insulin increase immediately 
after a meal, whereas the levels of glucagon decrease. In type 2 diabetic subjects, 
however, the postprandial secretion of insulin is delayed and depressed, whereas that of 
glucagon is not suppressed or is even elevated (Basu et al., 2004; Butler et al., 1991; 
Larsson et al., 2000b; Mitrakou et al., 1990). Such abnormality in insulin and glucagon 
secretion is associated with and predictive of glucose intolerance in type 2 diabetic 
human subjects (Ahrén et al., 2001; Larsson et al., 2000a). The cause-and-effect 
relationship between hyperglucagonemia and hyperglycemia is strongly implied in studies 
showing that, suppression of postprandial hyperglucagonemia corrects postprandial 
hyperglycemia in type 2 diabetic subjects (Shah et al., 2000). Although, 
hyperglucagonemia results in glucose intolerance in diabetic subjects with impaired 
insulin secretion or in normal subjects whose insulin secretion is experimentally blocked, 
it does not produce the same effects when insulin secretion is intact (i.e., in normal 
healthy subjects) (Shah et al., 1999; Sherwin et al., 1976; Toft et al., 2002). Taken as a 
whole, the discussion above indicates that hyperglucagonemia plays an important role in 
initiating and maintaining hyperglycemia when combined with delayed or deficient insulin 
secretion, as in some cases of type 2 diabetes. 
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1.4. RELEVANCE OF THE PARASYMPATHETIC NERVOUS SYSTEM IN 
REGULATION OF GLUCOSE HOMEOSTASIS 
 
Since the observation by Claude Bernard in the 1850s that puncture of the floor of the 
fourth ventricle in dogs results in the appearance of transient glucosuria, the central 
nervous system has been implicated in the control of certain metabolic processes of 
energy homeostasis, mainly through neuroendocrine systems (Nonogaki, 2000). 
The autonomic nervous system is the primary neural mediator of physiological 
responses to internal and external stimuli. It is composed of 2 branches: the sympathetic 
nervous system (SNS) and the parasympathetic nervous system (PNS). Sympathetic 
fibers are carried primarily in the splanchnic nerve, while parasympathetic fibers travel in 
the vagus nerve.  
In respect to the gastrointestinal tract, the SNS mediates physiological responses to 
insults from external stimuli through activation of the splanchnic nerve, which releases 
norepinephrine from nerve terminals and epinephrine from the adrenal medulla. In 
contrast, through activation of the vagus nerve, the PNS mediates anabolic responses to 
internal stimuli from the viscera, and external stimuli originating from the sensory 
components of food (Teff, 2000).  
The majority of peripheral tissues are innervated by both PNS and SNS fibers. 
Typically, the 2 branches of the autonomic nervous system act in a reciprocal fashion to 
maximize the efficacy of tissue response, with an increase in activity in one branch 
coincident to a decrease in activity of the other (Puschel, 2004). The dual innervation and 
reciprocity of action enhance neural control over tissue function. However, under some 
physiological conditions, both branches of the autonomic system may be activated or 
inhibited at the same time (Teff, 2008)11.  
Activation of PNS occurs at the onset of and during meal ingestion. It is initiated when 
the sensory components of food stimulate receptors in the oropharyngeal region, 
stimulating fibers in the nucleus of the solitary tract, which then, send descending fibers 
to the dorsal motor nucleus of the vagus; and ultimately activating vagal efferent nerves 
(Berthoud et al., 1990). These fibers in turn, elicit the release of hormones from the 
endocrine pancreas (Laughton et al., 1987).  
Hormones released in response to oral sensory stimulation are considered cephalic 
phase reflexes as their release is dependent on neural stimulation rather than nutrient-
induced stimulation (Powley, 1977).  
                                         
 
11 Neural control of the endocrine pancreas is exemplary of both reciprocity and coactivation of autonomic 
activity (Ahrén et al., 1986). Insulin release from the pancreatic -cell is enhanced by vagal activation, but 
inhibited by norepinephrine released by the splanchnic nerve. In contrast, both PNS and SNS activation 
stimulate the release of glucagon from the -cell of the pancreatic islet during conditions of hypoglycemia (Teff, 
2008). 
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The vagus nerve innervates almost all tissues involved in the digestion, absorption, 
and metabolism of nutrients, and therefore has the potential to profoundly influence the 
metabolic processing of food (LeBlanc, 2000).  
The central nervous system modulates hepatic glucose production via parasympathetic 
and sympathetic fibers to the liver (Lautt et al., 1978b; Puschel, 2004; Shimazu, 1987). 
Hypoglycemia stimulates hepatic glucose production via glucose sensors in the 
hypothalamic region of the brain, which activate hepatic glycogenolysis via sympathetic 
fibers to the liver (DeFronzo et al., 1987; DeFronzo et al., 1983; Shimazu et al., 1965).  
The vagus nerve also plays an important role in the regulation of blood glucose levels 
through innervation of the liver and the pancreas, two organs critical for glucose 
homeostasis. At the level of the liver, vagal activation inhibits enzymes involved in 
gluconeogenesis and activates enzymes promoting glycogen synthesis (Shimazu, 1971), 
and the central nervous system-dependent decrease of hepatic glucose production is also 
mediated by vagal efferent fibers (Lautt et al., 1978b; Pocai et al., 2005). In humans, 
administration of the muscarinic agonist bethanechol decreases hepatic glucose 
production (Boyle et al., 1988).  
The vagus nerve also plays an important role in both acute insulin responses to a 
meal, and compensatory insulin responses during prolonged stimulation of the -cell. On 
a meal-to-meal level, vagal activation is involved in the regulation of early insulin release 
(Teff et al., 1993; Woods et al., 1977), enhances peak insulin responses (Teff et al., 
1996), and contributes to the rate at which insulin returns to baseline levels through 
hepatic insulin degradation (Chap et al., 1985). 
In fact, the liver is the most likely target site as it would be the tissue receiving the 
highest concentration of insulin over a brief period. As cephalic phase insulin accounts for 
such a small percentage of total insulin release, it is improbable that a response of insulin 
of this magnitude would significantly alter peripheral glucose uptake. However, the 
concentration in the portal vein would be significantly greater since approximately 50% 
of the insulin released from the pancreas undergoes hepatic degradation (Teff, 2000). 
Thus, at the level of the liver, neurally-mediated insulin release may be sufficiently large 
to initiate changes in hepatic glucose or insulin metabolism. 
The importance of portal nutrient delivery in the regulation of hepatic glucose uptake 
was first suggested by studies showing differences in splanchnic glucose uptake between 
oral and iv glucose administration (DeFronzo et al., 1978; Ferrannini et al., 1980). To 
account for these differences, an “intraportal signal” which activates net hepatic glucose 
uptake has been hypothesized (Adkins et al., 1987; Mittelman et al., 1997), and other 
neural factors, particularly ACh have been proposed as key regulators of hepatic glucose 
metabolism (Adkins-Marshall et al., 1992; Gardemann et al., 1986; Stumpel et al., 
1997). 
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Thus, an intact parasympathetic neural system is important for maintaining normal 
glucose metabolism in the liver, under postabsorptive and postprandial conditions, and 
the physiological significance of neurally-mediated insulin release is part of the portal 
signal, which contributes to the regulation of glucose metabolism and that this signal 
seems to be essential to occur prior to nutrient absorption. 
Additionally, a role for hepatic Ach in peripheral glucose metabolism was suggested by 
experiments demonstrating that sectioning the anterior hepatic nerve plexes or the 
administration of ipv atropine leads to insulin resistance with a decrease in glucose 
tolerance (Xie et al., 1995a; Xie et al., 1996b). 
 
1.5. THE HEPATIC INSULIN SENSITIZING SUBSTANCE (HISS) HYPOTHESIS 
 
After a meal, the body‟s dynamic response to insulin is approximately doubled in 
comparison to the fasted state. This has been mainly attributed to the increase in insulin 
secretion in response to a meal. However, a novel neurohumoral regulatory mechanism 
was described by which postprandial insulin action is potentiated and, when absent, 
results in severe postprandial insulin resistance. This novel mechanism involves the liver, 
as a key regulator in the modulation of peripheral tissue insulin sensitivity, and the 
release by the liver of the hepatic insulin sensitizing substance (HISS). The study of the 
HISS pathway is the main focus of our research group and is the basis of this PhD 
dissertation. 
 
Based on the HISS hypothesis, in the fed state a hepatic parasympathetic reflex is 
triggered leading to the release of acetylcholine (ACh) which activates M1 muscarinic 
receptors in the liver, leading to the generation of nitric oxide (NO) and, subsequently, to 
the release of a hormone referred to as HISS (Lautt, 1999). HISS then travels through 
the bloodstream to enhance skeletal muscle insulin-stimulated glucose uptake, 
consequently accounting, in rats, for 50-60% of the whole-body glucose uptake (Lautt et 
al., 2001). The hypoglycemic action of insulin in the postprandial state can therefore be 
divided into two components. The first component is insulin action per se, corresponding 
to the direct action of insulin on target cells, and is referred to as HISS-independent 
component. The second component of insulin action is dependent on the HISS pathway, 
which potentiates insulin action, and is referred to as HISS-dependent component. The 
response to insulin consists of a quite constant HISS-independent component and a 
larger, but highly regulated, HISS-dependent component that is greatest in the 
immediate postprandial state and least in the fasted state, when hypoglycemia is 
normally neither required nor desirable. Interruption of this reflex release of HISS by 
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surgical or pharmacological ablation leads to immediate severe (Latour et al., 2002b) 
insulin resistance (Xie et al., 1996b). 
 
Insulin resistance was first demonstrated in response to hepatic denervation in 1993 
(Xie et al., 1993). Surgical denervation of the anterior hepatic plexus results in insulin 
resistance, which is not further worsened by denervation of the posterior nerve plexus or 
bilateral vagotomy (Xie et al., 1993). Surgical denervation of the anterior plexus involves 
elimination of some of the sympathetic and afferent nerves, as well as, parasympathetic 
nerves12(Latour et al., 2002b). Administration of atropine results in insulin resistance of a 
magnitude similar to that produced by surgical denervation; the response to denervation 
is not further aggravated  by administration of atropine, nor is the response to atropine 
different by addition of hepatic denervation (Xie et al., 1995a; Xie et al., 1996b). 
Denervation-induced insulin resistance can be reversed by ipv ACh administration (Xie et 
al., 1996a).  
 
1.5.1. The role of nitric oxide and glutathione on HISS release 
 
Because many of the biological effects of ACh appear to be mediated by NO release, 
Lautt‟s group tested the hypothesis that the hepatic parasympathetic reflex release of 
HISS in the liver was also mediated through the generation of NO. Indeed, the 
comparison between iv and ipv administrations of the nitric oxide synthase (NOS) 
antagonists, revealed that hepatic NO synthesis is required for full postprandial insulin 
action13 (Sadri et al., 1999; Sadri et al., 1997). Additionally, the nitric oxide donor 3-
morpholinosydnonimine hydrochloride (SIN-1) was able to reverse insulin resistance 
produced by the NOS antagonist N-monomethyl-L-argine (L-NMMA)14, when administered 
into the portal vein, but not systemically. Moreover, SIN-1 is also able to reverse insulin 
resistance produced by hepatic surgical denervation (Sadri et al., 1999). Thus, these 
experiments support the hypothesis that the hepatic parasympathetic nerves act through 
the release of NO within the liver. 
Although compelling data demonstrate that ACh and NO are necessary for HISS 
secretion, it was not known whether, in the liver, activation of NOS is a downstream 
consequence of hepatic parasympathetic nerve stimulation or, in contrast, leads to ACh 
                                         
 
12 The presence of parasympathetic nerves in this nerve bundle was shown by the rapid decrease in hepatic 
glucose output, produced by electrical stimulation after elimination of the sympathetic nerve effects, by 
administration of both - and -adrenergic antagonists (Gardemann et al., 1986) or pre-treatment with 6-
hydroxydopamine, to destroy the sympathetic nerve terminals (Lautt et al., 1978a).  
13 The approach of using comparative responses to iv versus ipv drug administration allows assessment of the 
site of action as hepatic or extrahepatic. If the liver is the target organ, ipv administration will have a greater 
effect than the same dose administered iv; if extrahepatic tissues are the target, ipv administration will have a 
lesser effect.  
14 Administration of the NOS antagonist NG-nitro-L arginine methyl ester (L-NAME), produced the same hepatic 
insulin resistance as observed after L-NMMA administration.  
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release and ultimately to HISS secretion. It is known that binding of ACh to M1 
muscarinic receptors leads to NOS activation and NO synthesis (Lopez-Jaramillo et al., 
1990); however, NO can also stimulate the release of ACh in a number of physiological 
systems, like the central nervous system, or the enteric system (Leonard et al., 1997; 
Smith et al., 1998). Previous studies, revealed that ipv administration of ACh is not able 
to reverse the state of insulin resistance induced by hepatic NOS inhibition, whereas ipv 
administration of the NO donor, SIN-1, reverses the insulin resistance induced by either 
NOS inhibition or muscarinic antagonism (Guarino et al., 2004). Hepatic, but not the 
systemic, NO is necessary for the HISS-dependent insulin action. These observations 
suggest that HISS synthesis involves the binding of ACh to hepatic M1 muscarinic 
receptors, leading to activation of NOS and consequently the synthesis of hepatic NO 
(Figure 1.8). 
 
 
Figure 1.8 – Overview of the hepatic insulin sensitizing substance (HISS) synthesis/secretion pathway. 
Following a meal, hepatic parasympathetic nerves are stimulated and lead to the release of acetylcholine (ACh) 
that acts on hepatic M1 muscarinic receptors, activating the enzyme hepatic nitric oxide synthase (NOS), 
resulting in nitric oxide (NO) production, which together with reduced glutathione (GSH) result in the synthesis 
and/or release of the HISS from the liver. , Activation  
 
Several authors suggest that the impaired glucose tolerance observed after reduced 
glutathione (GSH) depletion is a direct effect of the lack of GSH in the liver (Khamaisi et 
al., 2000). Studies performed by Guarino et al. showed that hepatic GSH depletion, 
produced by administration of the -glutamylcysteine synthase inhibitor, leads to a state 
of insulin resistance similar to the one obtained after hepatic NOS blockade; and hepatic 
GSH administration after NOS blockade did not change the insulin resistance state 
observed. These results indicated that hepatic GSH depletion and NOS blockade affect 
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the HISS pathway at different steps, inhibiting the insulin-sensitizing signal in the liver 
(Guarino et al., 2003). 
Moreover, exogenous NO (by administration of SIN-1) was not able to restore insulin 
action in GSH-depleted rats, which suggests that both GSH and NO are required in the 
liver to allow full peripheral insulin action (Guarino et al., 2003). 
Further studies were performed to deepen the previous observations and was 
demonstrated that, while administration of GSH or NO by itself did not increase insulin 
sensitivity, co-administration of GSH with NO to the liver enhanced insulin action to 
values obtained only when HISS was present (Guarino et al., 2006). With these results 
one can consider that two different hepatic signals are needed for HISS 
synthesis/secretion: elevated NO levels and elevated GSH levels. 
 
In summary, after a meal, and after absorption of the meal nutrients, three signals 
seem to occur. The first corresponds to the increased of insulin levels to further increase 
glucose uptake at insulin-stimulated glucose tissues. A second signal is concerning to an 
increase of hepatic GSH levels. The third signal involves the hepatic parasympathetic 
activation. Thereby, the three signals together are responsible and fundamental for the 
HISS synthesis/release, which afterwards will increase glucose uptake at HISS sensitive 
tissues (Figure 1.9). 
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Figure 1.9 – The Hepatic insulin sensitizing substance (HISS) hypothesis. Following a meal, nutrients 
absorption and pancreatic insulin release will occur, and hepatic parasympathetic nerves are stimulated and 
lead to the release of acetylcholine (ACh) that acts on hepatic M1 muscarinic receptors, activating the enzyme 
hepatic nitric oxide synthase (NOS), resulting in nitric oxide (NO) production, which together with reduced 
glutathione (GSH) result in the synthesis and/or release of the HISS from the liver. HISS acts on skeletal 
muscle and accounts for 50-60% of the glucose disposal. Lack of HISS release results in insulin resistance. 
Adapted from (Lautt, 2004). 
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1.5.2. HISS action and the target organ of insulin resistance  
 
The studies described in previous sections are consistent with the hypothesis that 
hepatic parasympathetic nerves regulate the response to insulin, but do not specify on 
which tissues insulin sensitivity is regulated. To approach this problem, arterial–venous 
concentrations of glucose were measured after administration of atropine or denervation, 
and after the combination of both procedures. The intestines showed no response to 
insulin either before or after induction of insulin resistance. Similarly, the hepatic 
response to insulin was not significantly altered by induction of insulin resistance. In 
contrast, the glucose uptake across the hindlimbs was impaired by interruption of the 
hepatic parasympathetic reflex (Xie et al., 1996b). This suggests that, although the liver 
is the organ where HISS is synthesized, insulin resistance occurs in peripheral tissues. At 
this time Lautt‟s group could not conclude which specific tissues are involved, but the 
large muscle mass of the hindlimbs has led the authors to tentatively conclude that 
skeletal muscle is at least one of the tissues where glucose uptake is regulated by HISS 
(Xie et al., 1996b). 
Recent studies were performed in order to evaluate the major site of HISS action. In 
the in vivo incorporation of [3H]2-deoxy-glucose uptake into individual tissues (liver, 
adipose tissue, pancreas, skeletal muscle, heart, kidney), the authors observed that the 
skeletal muscle of denervated animals was affected, mainly the soleus and the EDL 
muscles. Surprisingly, this surgical procedure also affected the kidney and heart. 
However, the adipose tissue and the liver did not have any significant change on [3H]2-
deoxy-glucose incorporation, indicating that these tissues are not affected by HISS action 
(Fernandes et al., 2009). 
 
1.5.3. Prandial control of HISS release  
 
Insulin is a complex hormone that carries out a number of other growth-related 
functions and pulsatile insulin release occurs in conditions throughout the day. It would 
be biologically inappropriate for insulin released in the fasting state to produce the same 
magnitude of glucose uptake from blood, as is required in the absorptive postprandial 
state. 
In fasted rats, HISS is not released, thus assuring that insulin sensitivity is extremely 
low at a time when an insulin effect is neither useful nor desirable (Lautt et al., 2001). It 
was also demonstrated, in rats, the ability of insulin to release HISS from the liver, at a 
maximal level immediately after eating (2h post-feeding), and declining progressively 
with the duration of fasting until it was minor or insignificant after approximately a 24h 
fasting in both anesthetized (Lautt et al., 2001; Lautt et al., 1998a), and conscious 
animals (Latour et al., 2002c). In contrast, an 16-18h fast in either cats (Xie et al., 
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1995a; Xie et al., 1995b; Xie et al., 1993) or dogs (Moore et al., 2002), still leaves 25-
35% of the glucose disposal action of insulin being accounted by HISS release; and 24h 
fasting induces a 45% reduction in insulin action in mice (Latour et al., 2002a). 
Animals tested after feeding period (2h post-feeding) showed a high responsiveness to 
insulin, and a high HISS dependence, whereas increasing periods of fasting led to a 
decrease in insulin action, accounted by a decrease in the HISS-dependent component. 
The HISS-independent component was similar in rats that had been recently fed, or that 
had been subjected to a 6, 18, or 24h fast (Lautt et al., 2001). 
The glucose disposal effect of a bolus of insulin administered in the postprandial state 
is double that produced by administration of the same dose of insulin in the fasted state, 
or when the hepatic parasympathetic nerves have been blocked (Xie et al., 1996b).  
Regulation of HISS release by insulin is thus an effective means to sensitize the body 
to insulin released following a meal, but not in the fasted state. This suggests a 
physiological regulation by the hepatic parasympathetic nerves of the ability of insulin to 
release HISS. In this way, the parasympathetic nerves are said to play a permissive 
regulatory role in HISS release. Thus, in the fasted sate, a natural and regulated state of 
HISS-dependent insulin resistance (HDIR) exists (Lautt et al., 2001). The regulated 
production of HDIR in the fasted state would confer a protective role, minimizing the 
hypoglycemic effect of insulin in the absence of ingested glucose.  
Insulin secretion shows pulsatile or rhythmic secretion in fasted rats independent of 
arterial glucose (Bizot-Espiard et al., 1998), and only about one-half of the daily insulin 
secretion is meal related (Beyer et al., 1990). Conditioned reflex secretion of insulin is 
also able to reach early peaks at similar levels to those produced by a meal, even in the 
absence of a meal (Steffens et al., 1994). In such situations, it is not useful for insulin to 
exhibit full action since the result could be hypoglycemia. HISS, therefore, provides a 
useful physiological mechanism to selectively partition glucose to skeletal muscle, when 
glucose absorption is high, but would minimize uptake by muscle in the fasted state or, 
in any other state of HDIR (Lautt et al., 2001). 
HDIR is a state produced by fasting, and can be produced by any means that 
interrupts the parasympathetic signaling process, including hepatic surgical denervation 
(Xie et al., 1996b; Xie et al., 1993), blockade of hepatic muscarinic cholinergic receptors 
(Xie et al., 1996a), hepatic NOS blockade (Sadri et al., 1999), hepatic cyclooxygenase 
blockade (Sadri et al., 2000b) or hepatic guanylyl cyclase blockade (Correia et al., 2002; 
Guarino et al., 2004), or by depletion of hepatic glutathione levels (Guarino et al., 2003). 
Thereby, the HISS pathway (described in Figure 1.9) could be inhibited by any of the 
procedures described above. 
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1.5.4. Role of HISS-dependent insulin resistance (HDIR) in pathology 
 
Circumstantial evidence was provided suggesting that insulin resistance seen in 
several disease states might be accounted for, at least in part, by HDIR. These disease 
states include aging (Ribeiro et al., 2008), the spontaneously hypertensive rat (Ribeiro et 
al., 2007; Ribeiro et al., 2001b), sucrose fed rats (Ribeiro et al., 2001a; Ribeiro et al., 
2005), high-fat diet-induced obese rat (Afonso et al., 2007a; Afonso et al., 2010), 
genetically obese Zucker fa/fa rat (Afonso et al., 2007a; Afonso et al., 2007b; Ribeiro et 
al., 2001c), animals with liver disease induced by chronic bile duct ligation (Lautt et al., 
1998b) and adult offspring of fetal alcohol exposure (Minuk et al., 1998; Sadri et al., 
2005; Ting et al., 2006). 
Aging leads to insulin resistance that is attributable to reduced HISS-dependent insulin 
action. It was shown that HISS action decreased gradually with age in rats; however, 
while the HISS-independent component decreased until approximately 9 weeks of age, 
the HISS-dependent component remained stable until 9 weeks of age and decreased 
steadily with further aging (Ribeiro et al., 2008). 
Spontaneously hypertensive rats have been shown to develop progressive HDIR but 
the HISS-independent component of insulin action significantly increases so that, at 
some time points, the total insulin action may not be greatly impaired as a result of the 
increased HISS-independent insulin action. This is the only condition so far identified that 
might suggest that the HISS-independent component of insulin action could increase in a 
compensatory manner in the presence of HDIR (Ribeiro et al., 2007; Ribeiro et al., 
2001b). 
Sucrose feeding results in HDIR. After 9 weeks of feeding with normal rat chow and 
access to normal water or a 35% sucrose solution, we observed that the 35% sucrose 
solution produced insulin resistance that had HDIR characteristics. Comparing the 
sucrose fed rats with the standard diet group, the HISS-independent component 
remained unchanged, while the HISS-dependent component of insulin action was 
dramatically decreased, showing that the insulin resistance observed in the sucrose rats 
was due entirely to an impairment of HISS action (Ribeiro et al., 2001a; Ribeiro et al., 
2005). 
The insulin resistance noticed in the high-fat diet-induced obese rat model is quite 
different from the genetically Zucker fa/fa rats. In fact, the high-fat diet-induced obese 
rats are specifically HISS-dependent insulin resistant, but not HISS-independent insulin 
resistant; and diet enriched with fat leads to a progressive increase in adiposity, which 
correlates with the development of postprandial insulin resistance. Furthermore, since 
the high-fat diet-induction of obesity is more representative of obesity in humans, it 
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seems to be a better animal model to study the obesity-related pathophysiology (Afonso 
et al., 2007a; Afonso et al., 2010). 
In the genetically obese Zucker fa/fa rats, the insulin resistance seen is equally 
attributed to decreases in HISS-dependent and HISS-independent components of insulin 
action, thus suggesting that blockade of HISS release is not a primary phenomenon in 
this animal model but could be a defect common to both components (Afonso et al., 
2007a; Afonso et al., 2007b; Ribeiro et al., 2001c). 
Chronic bile duct ligation in rats leads, to complete HDIR by 10 days. These animals 
showed severe insulin resistance that was not made worse by the administration of 
atropine, thereby suggesting that the insulin resistance was HDIR; ipv administration of 
ACh resulted in restoration of insulin action (Lautt et al., 1998b). 
Exposure of the developing fetus to alcohol through the maternal drinking water has 
been shown to result in alcohol dose-related HDIR in the adult offspring and the HISS-
independent component of insulin action was not altered in the adult offspring. Drinking 
water containing 20% alcohol resulted in severe but not complete HDIR in the male 
offspring, but full HDIR in females (Minuk et al., 1998; Sadri et al., 2005). 
 
HDIR is suggested to occur in association with a wide range of chronic inflammatory 
states, and to contribute negatively as a strong risk factor for development of diabetes, 
obesity, cardiac and vascular disease. If the “HISS hypothesis” is correct, it represents a 
new paradigm impacting diagnosis and therapy of a broad spectrum of metabolic 
disorders. 
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1.6. PATHOLOGIES ASSOCIATED WITH INSULIN RESISTANCE 
 
Although insulin has a number of metabolic effects, insulin resistance is normally 
defined in terms of the blood glucose lowering effect of insulin. It is a state in which 
greater than normal insulin levels are required to elicit a quantitatively normal glucose 
response in the whole body, a tissue or at the cellular level. The term is often used 
interchangeably with diminished insulin action or decreased insulin sensitivity. The 
following sections will address the diseases most commonly associated with progression 
of insulin resistance, including type 2 diabetes (T2D) and obesity.  
 
1.6.1. Insulin resistance and Obesity 
 
Insulin resistance is strongly associated with obesity for which several mechanisms 
have been invoked. A number of circulating hormones, cytokines, and metabolic fuels, 
such as free fatty acids (FFA) that originate in the adipocyte, modulate insulin action.  
An increased mass of stored triglyceride, especially in visceral or deep subcutaneous 
adipose depots, leads to large adipocytes that are themselves resistant to the ability of 
insulin to suppress lipolysis. This results in increased release and circulating levels of FFA 
and glycerol, both of which aggravate insulin resistance in skeletal muscle and liver 
(Boden, 1997). Excessive fat storage, not only in adipocytes, but “ectopically” in non-
adipose cells, also has an important role (Danforth, 2000). For example, increased 
intramyocellular lipids are associated with skeletal muscle insulin resistance under some 
circumstances (Machann et al., 2004). 
 
Both in the basal state and after a hyperglycemic stimulus, obese people display a 
level of hyperinsulinemia that correlates with the degree of insulin resistance, in order to 
maintain normal glucose tolerance (Bonadonna et al., 1990). A number of factors present 
in obesity (elevated FFA levels, decreased adiponectin and increased adipocytokine 
levels) are responsible for induction of insulin resistance. However, as in the 
development of T2D, progressive deterioration of the metabolic state results in eventual 
failure of endogenous hyperinsulinemia to compensate fully for the insulin resistance, and 
impaired glucose tolerance develops (DeFronzo, 1988; DeFronzo et al., 1992).  
Studies have highlighted the inflammatory nature of adipose tissue in the setting of 
weight gain and obesity and thus have provided another mechanism to the development 
of insulin resistance (Hundal et al., 2002). A high body mass index (BMI), increased 
visceral fat and insulin resistance are associated with increased circulating inflammatory 
markers such as the acute phase protein, pro-inflammatory cytokines and soluble cell 
adhesion molecules (Ghanim et al., 2004; Maachi et al., 2004). In rodent models fed a 
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high fat “western diet”, the occurrence of hyperinsulinemia corresponded to an infiltration 
of activated macrophages into fat tissue. Moreover, in obese, insulin-resistant individuals 
circulating mononuclear cells (precursor cells of tissue macrophages) were reported to be 
in a pro-inflammatory state (Esposito et al., 2003). Such observations have led to the 
hypothesis that low-grade inflammation generated by adipose tissue and FFA is a key 
player in the development of insulin resistance and endothelial dysfunction, leading 
ultimately to the manifestation of diabetes and atherosclerosis. Several studies have 
noted elevated mean circulating cytokine levels (TNF-, IL-6), as well as, plasma FFA 
that, in a paracrine approach, inhibit insulin signaling pathways in peripheral tissues, and 
result in decreased whole body insulin-mediated glucose disposal (Maachi et al., 2004). 
Studies performed in our lab, showed that a diet enriched with fat (HFD) leads to a 
progressive increase in adiposity, which correlates with the development of postprandial 
insulin resistance. The major contribution to HFD-induced insulin resistance derives from 
the reduced contribution of the HPN pathway to overall postprandial insulin sensitivity. 
HFD induced overall postprandial insulin resistance, already present after 1 week (HFD-
1), and was further aggravated by 4 weeks on HFD (HFD-4). HISS-independent insulin 
action was unaltered during the HFD-1 and only slightly decreased in the HFD-4 group. 
On the other hand, the reduction in HISS-dependent insulin action paralleled the 
reduction in total postprandial insulin sensitivity: an impairment of about 65 % was 
observed after 1 week on the HFD (compared with control group) and, by 4 weeks on 
HFD, full HISS pathway-dependent insulin resistance had developed. The HISS pathway-
dependent insulin resistance associated with HFD, seems to be primarily responsible for 
the early effect that precedes the development of diabetes, as indicated by the 
observation that 1 week on HFD was not sufficient to affect HISS-independent insulin 
action, but was sufficient to impair the insulin-sensitizing action of the HPN pathway 
dramatically (Afonso et al., 2010). 
The insulin resistance of HFD-induced obesity model, is mechanistically different from 
that observed in other animal models of obesity, such as the genetically obese Zucker 
(fa/fa) rat, in which both components of insulin action were impaired in the same 
proportion (Afonso et al., 2007b), probably due to post-insulin receptor abnormalities at 
the level of the skeletal muscle (Brozinick et al., 1994; King et al., 1992). 
 
Visceral adiposity and insulin resistance 
 
While the relationship between insulin resistance and overall obesity is well 
established in cross-sectional and longitudinal studies, debate continues about which of 
the fat depots, visceral adipose tissue (VAT) or subcutaneous adipose tissue (SAT), is of 
greater importance in this relationship (Virtanen et al., 2005). 
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Several studies have been performed to address this question and some of them 
found a strong independent relationship between both visceral and subcutaneous 
adiposity and insulin resistance. According to Wagenknecht et al., VAT was a more potent 
predictor of insulin resistance than SAT (Wagenknecht et al., 2003). In another study, 
Gastaldelli and colleagues determined that visceral fat accumulation decreased peripheral 
insulin sensitivity and enhanced hepatic gluconeogenesis (Gastaldelli et al., 2002). It 
appears, however, that the deeper layer of SAT has an association with insulin resistance 
that bears resemblance to the pattern for VAT, whereas the superficial layer has a 
weaker association (Kelley et al., 2000). It also seems that accumulation of fat within the 
liver and muscle leads to insulin resistance in these tissues, resulting in elevated fasting 
plasma glucose levels (due to accelerated hepatic glucose production) and postprandial 
hyperglycemia (due to decreased insulin-mediated glucose uptake by muscle) (Bays et 
al., 2004; Bonadonna et al., 1990; Roden et al., 1996). 
 
Furthermore, it is recognized that plasma FFA are a central component of the insulin 
resistance syndrome in accordance with the “overflow hypothesis”15, in that when 
adipocyte storage capacity is exceeded, there is an overflow and accumulation of FFA in 
the form of toxic ceramide, long-chain fatty acyl CoA and sphingolipid in muscle, liver, 
pancreas and arteries, resulting in physiological features of insulin resistance (Miranda et 
al., 2005). Plasma FFA also contributes to activation of several inflammatory pathways, 
which hamper insulin signal transduction pathways in muscle tissue. 
 
Afonso et al. have shown that the decrease in insulin sensitivity observed in the HFD 
animals was correlated with the increase in adipose mass; the effect of adiposity is 
predominantly mediated by effects upon the HISS pathway-dependent component of 
insulin action. Indeed, there was a significant polynomial correlation between whole-body 
fat mass and HISS-dependent insulin action, which was similar to the correlation 
between whole-body fat mass and total insulin action, whereas the HISS-independent 
insulin action did not correlate with the whole-body fat mass (Afonso et al., 2010). On 
the other hand, the abdominal (regional) fat mass presents a linear correlation with both 
components of insulin action, although this correlation was stronger for total and for 
HISS-dependent than for the HISS-independent insulin action, as given by the adjusted-
R2 and linear regression slopes. These data suggests that both the HISS-dependent and -
independent components of insulin action decrease with adiposity; however the HISS-
independent insulin action tends to decrease at a slower rate. 
                                         
 
15 The overflow hypothesis proposes that as the size of an adipocyte increases, it will eventually reach a limit 
and be unable to store further lipid. Excess fatty acids then „overflow‟ to ectopic sites, including muscle and 
liver, leading to peripheral and hepatic insulin resistance, respectively (Sniderman et al., 2007; Unger, 2003). 
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The increase in abdominal fat pad and whole-body fat masses were correlated, 
suggesting that HFD does not induce fat accumulation in any specific site, but rather a 
general increase in adiposity, i.e., whole-body fat. Therefore, the development of HISS-
dependent insulin resistance does not seem to be associated with fat deposition in any 
particular depot (Afonso et al., 2010). 
 
1.6.2. Insulin resistance and Type 2 diabetes 
 
Diabetes is a metabolic disorder characterized by resistance to the action of insulin, 
insufficient insulin secretion, or both (The expert committee on the diagnosis and 
classification of diabetes mellitus, 2002). The major clinical manifestation of the diabetic 
state is hyperglycemia, resulting from defects in insulin secretion, insulin action, or both. 
Insulin deficiency and/or insulin resistance are also associated with disturbances in lipid, 
and protein metabolism (DeFronzo et al., 1992). 
Several pathogenic processes are involved in the development of diabetes. These 
range from autoimmune destruction of the pancreatic -cells, with consequent insulin 
deficiency to abnormalities that result in resistance to insulin action. The basis of the 
abnormalities in carbohydrate, fat, and protein metabolism in diabetes is deficient action 
of insulin on target tissues. Deficient insulin action results from inadequate insulin 
secretion and/or diminished tissue responses to insulin at one or more points in the 
complex pathways of hormone action. Impairment of insulin secretion and defects in 
insulin action frequently coexist in the same patient, and it is often unclear which 
abnormality, if either alone, is the primary cause of the hyperglycemia. 
 
The degree of hyperglycemia may change over time, depending on the extent of the 
underlying disease process. A disease process may be present but may not have 
progressed far enough to cause hyperglycemia. The disease process can cause impaired 
glucose tolerance (IGT) and/or impaired fasting glucose (IFG), without fulfilling the 
criteria for the diagnosis of diabetes (American Diabetes Association, 2010). 
 
Diagnosis and classification of diabetes and prediabetes 
 
The diagnosis of diabetes requires the identification of a glycemic cut-off point which 
discriminates normal individuals from those with diabetes. The present cut-off points 
reflect the level of glucose above which microvascular complications have been shown to 
increase (American Diabetes Association, 2010). 
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American Diabetes Association (ADA) has not previously recommended the use of 
glycosylated hemoglobin (HbA1c) for diagnosing diabetes, in part due to lack of 
standardization of the assay. However, HbA1c assays are now highly standardized, and 
their results can be uniformly applied both temporally and across populations. In a recent 
report (The expert committee on the diagnosis and classification of diabetes mellitus, 
2009), after an extensive review of both established and emerging epidemiological 
evidence, an international expert committee recommended the use of the HbA1c test to 
diagnose diabetes with a threshold of 6.5%, and ADA affirms this decision (Table II) 
(American Diabetes Association, 2010). The diagnostic test should be performed using a 
method certified by the National Glycohemoglobin Standardization Program and 
standardized or traceable to the Diabetes Control and Complications Trial reference 
assay. 
 
Table II - American Diabetes Association (ADA) criteria for the diagnosis of type 2 diabetes mellitus (T2D), 
impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). 
 FPG = fasting plasma glucose; 2h PG = 2h plasma glucose concentration during a standard oral glucose (75g) 
tolerance test. 
 
 
FPG 2h PG HbA1c 
Normal 
< 100mg/dl 
(< 5.6mmol/l) 
< 140mg/dl 
(< 7.8mmol/l) 
5.7-6.4% 
IGT ------- 
140-199mg/dl 
(7.8-11.0mmol/l) 
5.7-6.4% 
IFG 
100-125mg/dl 
(5.6-6.9mmol/l) 
------- 5.7-6.4% 
T2D* 
≥ 126mg/dl  
(≥ 7.0mmol/l) 
≥ 200mg/dl 
(≥ 11.1mmol/l) 
 6.5% 
 
When both tests are performed, IGT or IFG should be diagnosed only if diabetes is not diagnosed by the other 
test. *A diagnosis of diabetes needs to be confirmed on a separate day. 
 
To minimize the discrepancy between the fasting plasma glucose and 2h plasma 
glucose concentration measured during the oral glucose tolerance test (OGTT)16, cut-off 
values of ≥126mg/dl and ≥200mg/dl, respectively, were chosen. Although the ADA 
recommended use of the fasting plasma glucose concentration as the principal tool for 
the diagnosis of diabetes, the published results of the Diabetes Prevention Program 
(Diabetes Prevention Program Research Group, 2002) have given renewed emphasis to 
the OGTT, since diet/exercise, as well as, drug therapy were shown to slow/prevent the 
                                         
 
16 Usually by ingestion of a glucose load containing 75g anhydrous glucose in water, after an overnight 
fast. 
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progression of impaired glucose tolerance (IGT) to overt diabetes. It was hypothesized 
that the progression from normal glucose tolerance to IGT and then to T2D began with 
insulin resistance (Edelman, 1998), leading to a compensatory increase in insulin 
secretion and, in turn, to eventual pancreatic -cell exhaustion. Moreover, there is also 
some evidence that impaired insulin secretion is the initial, and main predisposing factor 
in diabetes (Gerich, 1998). 
It is presently considered that T2D is established if blood glucose level after an 
overnight fast is equal or over 126mg/dl, and/or the blood glucose level obtained 2h 
after an OGTT is equal or over 200 mg/dl, and/or the HbA1c 6.5%. It was established 
that the diagnosis of IGT only can be made from the 2h plasma glucose concentration 
(≥140 to 199mg/dl) during the OGTT. The Expert Committee recognized an intermediate 
group of subjects whose glucose levels, although not meeting criteria for diabetes, are 
nevertheless too high to be considered normal (The expert committee on the diagnosis 
and classification of diabetes mellitus, 2009). Impaired fasting glucose (IFG) is defined 
by a fasting plasma glucose ≥100mg/dl, but less than 125mg/dl (American Diabetes 
Association, 2010). 
Patients with IGT and/or IFG are referred to as having prediabetes, indicating the 
relatively high risk for development of diabetes in these patients. IGT and IFG states are 
not clinical entities in their own right, but rather risk factors for future diabetes, as well 
as, cardiovascular disease (Abdul-Ghani et al., 2009). IGT and IFG are associated with 
the metabolic syndrome, which includes obesity (especially abdominal or visceral 
obesity), dyslipidemia, and hypertension. It is worth mentioning that nutrition therapy 
aimed at producing 5-10% loss of body weight, exercise, and certain pharmacological 
agents have been often demonstrated to prevent or delay the development of diabetes in 
people with IGT. Many individuals with IGT are normoglycemic in their daily lives, and 
individuals with IFG or IGT may have normal or near normal HbA1c levels17 (American 
Diabetes Association, 2010).  
The fasting and postprandial glucose levels do not measure the same physiologic 
processes and, not surprisingly, they do not identify the same individuals as having 
diabetes. The fasting plasma glucose concentration is, in large part, determined by basal 
rate of hepatic glucose production (DeFronzo, 1988; DeFronzo et al., 1992). Thus, IFG 
primarily reflects hepatic resistance to the action of insulin. Under postabsorptive 
conditions, the majority of glucose is taken up by insulin-independent tissues (brain and 
liver) (DeFronzo, 1988); considering that tissue (muscle) glucose clearance is reduced in 
the postabsorptive state, in absolute terms, the muscle is responsible for only a small 
amount of glucose uptake in the basal state, in individuals with IFG (DeFronzo, 1988). 
                                         
 
17 It is reasonable to consider an HbA1c range of 5.7 to 6.4% as identifying individuals with high risk for future 
diabetes, and to whom the term prediabetes may be applied. 
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Moreover, basal insulin secretion is well preserved, even in individuals with overt T2D 
(DeFronzo, 1988; Reaven, 1988), and, therefore, cannot be explained the rise in fasting 
plasma glucose concentration in individuals with IFG. In contrast, the postprandial 
plasma glucose concentration primarily depends on insulin sensitivity in muscle and liver, 
as well as on insulin secretion by the pancreatic -cells (DeFronzo, 1988), and defects in 
both tissue (muscle) sensitivity to insulin and impaired insulin secretion are responsible 
for IGT. Although IFG and IGT are equally strong predictors of the development of future 
T2D (DECODE Study Group, 1999), the prevalence of IFG in the general population is 
significantly less than the prevalence of IGT (Gabir et al., 2000). The use of the fasting 
plasma glucose concentration (≥126mg/dl), as opposed to the 2h plasma glucose 
concentration during the OGTT (≥200mg/dl), also significantly underestimates the 
prevalence of diabetes in the general population (DECODE Study Group, 1999; Gabir et 
al., 2000). 
 
Figure 1.10 illustrates the curvilinear relation between normal -cell function and 
insulin sensitivity (Bergman, 1989). Deviation from this hyperbola, such as in the 
patients with IGT and T2D, occurs when -cell function is inadequately low for a specific 
degree of insulin sensitivity. Thus, -cell dysfunction is a critical component in the 
pathogenesis of T2D. However, not only deviation from the hyperbola, but also 
progression along the hyperbola affects glycemia. When insulin action decreases (as with 
increasing obesity), the system usually compensates by increasing -cell function. 
However, at the same time, concentrations of blood glucose at fasting and 2h after 
glucose load will increase mildly (Stumvoll et al., 2003). This increase may well be small, 
but over time becomes damaging because of glucose toxicity, and in itself a cause for -
cell dysfunction. Thus, even with (theoretically) unlimited -cell reserve, insulin 
resistance paves the way for hyperglycemia and T2D (Stumvoll et al., 2005). 
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Figure 1.10 - Hyperbolic relation between -cell function and insulin sensitivity. In people with normal glucose 
tolerance (NGT) a quasi-hyperbolic relation exists between -cell function and insulin sensitivity. With deviation 
from this hyperbola, deterioration of glucose tolerance (impaired glucose tolerance [IGT], and type 2 diabetes 
(T2DM)) occurs. Adapted from (Weyer et al., 1999a). 
 
Glucose dysfunction in type 2 diabetes 
 
Type 2 diabetic subjects manifest multiple disturbances in glucose homeostasis, 
including: (1) impaired insulin secretion; (2) insulin resistance in muscle, liver, and 
adipocytes; and (3) abnormalities in splanchnic glucose uptake (Cerasi, 1995; DeFronzo, 
1988). 
Early in the natural history of type 2 diabetes, insulin resistance is well established, 
but glucose tolerance remains normal because of a compensatory increase in insulin 
secretion. 
In type 2 diabetics, the fasting plasma insulin concentration is normal or increased, 
and basal insulin secretion (measured from C-peptide kinetics) is elevated. The 
relationship between the fasting plasma glucose (FPG) and insulin concentrations 
resembles an inverted U shape and it has been referred to as Starling‟s curve of the 
pancreas (Figure 1.11) (DeFronzo, 1988). As the fasting glucose rises from 80 to 
120mg/dl, the fasting plasma insulin concentration increases progressively. The 
progressive rise in fasting plasma insulin level can be viewed as an adaptive response of 
the pancreas to offset the progressive deterioration in glucose homeostasis. When the 
FPG exceeds 120mg/dl, the -cell is unable to maintain its elevated rate of insulin 
secretion, and the fasting insulin concentration declines precipitously. This decrease in 
fasting insulin level has important physiologic implications, because it is at this point that 
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hepatic glucose production (the primary determinant of the FPG concentration) begins to 
rise.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 - Starling‟s curve of the pancreas for insulin secretion. In normal-weight patients with IGT and 
mild diabetes, the plasma insulin response to OGTT increases progressively until the fasting glucose reaches 
120mg/dl. Thereafter, further increases in the fasting glucose concentration are associated with a progressive 
decline in insulin secretion. From (DeFronzo, 1988). 
 
The relationship between the mean plasma insulin response during an OGTT and the 
FPG concentration also resembles an inverted U-shaped curve (Figure 1.11) (DeFronzo, 
1988). The curve, however, is shifted to the left compared with the basal insulin 
secretory rate, and the glucose-stimulated insulin response begins to decline at a fasting 
glucose concentration of approximately 120mg/dl. A typical type 2 diabetic subject with a 
FPG level of 150–160mg/dl secretes an amount of insulin similar to that in a healthy 
nondiabetic individual; however, a „„normal‟‟ insulin response in the presence of 
hyperglycemia and underlying insulin resistance, is markedly abnormal. At FPG levels in 
excess of 150–160mg/dl, the plasma insulin response, when viewed in absolute terms, 
becomes insulinopenic. Finally, when the fasting glucose exceeds 200–220mg/dl, the 
plasma insulin response to a glucose challenge is markedly blunted. Nonetheless, the 
fasting hyperinsulinemia persists despite FPG concentrations as high as 250–300mg/dl, 
and 24h integrated plasma insulin and C-peptide profiles in lean type 2 diabetic patients 
remain normal. These normal day-long values result from the combination of elevated 
fasting and decreased postprandial insulin and C-peptide secretory rates (DeFronzo, 
2004). 
It should be emphasized that, even though the plasma insulin response is increased 
in absolute terms early in the development of T2D (FPG 120mg/dl), this does not mean 
that -cell function is normal. The -cell responds to an increment in plasma insulin by an 
increment in plasma glucose, and this response is modulated by the severity of insulin 
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resistance, that is, the more severe the insulin resistance, the greater the insulin 
response (DeFronzo et al., 1992). 
 
In summary, several studies are consistent in demonstrating that hyperinsulinemia 
precedes the development of T2D, and hyperinsulinemia is a strong predictor of the 
development of IGT and T2D. It should be emphasized, however, that overt diabetes 
(fasting glucose 126mg/dl) does not develop in the absence of a significant defect in -
cell function. 
 
1.7. METHODS AND INDEXES OF INSULIN SENSITIVITY ASSESSMENT 
 
Measurements of insulin sensitivity provide clinicians and researchers with excellent 
instruments to objectively evaluate the efficiency of both current and potentially useful 
interventional tools. 
It is of great importance to develop tools for quantifying insulin sensitivity/resistance 
in humans, which may be used to appropriately investigate the epidemiology, 
pathophysiological mechanisms, outcomes of therapeutic interventions, and clinical 
course of patients with insulin resistance. In this section, a new and some currently used 
methods for assessing insulin sensitivity, their applications, merits, and limitations will be 
discussed. 
 
1.7.1. Methods of insulin sensitivity/resistance assessment 
 
1.7.1.1. Hyperinsulinemic Euglycemic Glucose Clamp (HIEC) 
 
The hyperinsulinemic euglycemic clamp (HIEC), originally developed by DeFronzo is 
widely accepted as the “gold standard” for directly determining metabolic insulin 
sensitivity in humans (DeFronzo et al., 1979). After an overnight fast, insulin is infused 
intravenously at a constant rate that may range from 5 to 120mU/m2/min (dose per body 
surface area per minute, during 180min). This constant insulin infusion results in a new 
steady-state insulin level that is above the fasting level (hyperinsulinemic). 
Consequently, glucose disposal in skeletal muscle and adipose tissue is increased while 
hepatic glucose production (HGP) is suppressed. Under these conditions, a glucose 
analyzer is used to frequently monitor blood glucose levels at 5-10min intervals, while 
20% dextrose is given intravenously at a variable rate in order to “clamp” blood glucose 
concentrations in the normal range (euglycemic). After several hours of constant insulin 
infusion, steady-state conditions are typically achieved for plasma insulin, blood glucose, 
and the glucose infusion rate (GIR). Assuming that the hyperinsulinemic state is 
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sufficient to completely suppress HGP, and since there is no net change in blood glucose 
concentrations under steady-state clamp conditions, the GIR must be equal to the 
glucose disposal rate (M). Thus, whole body glucose disposal at a given level of 
hyperinsulinemia can be directly determined. M is typically normalized to body weight or 
fat-free mass to generate an estimate of insulin sensitivity. Alternatively, an insulin 
sensitivity index (SI) derived from clamp data can be defined as 
IxG
M
SIClamp

 , where 
M is normalized for G (steady-state blood glucose concentration) and ΔI (difference 
between fasting and steady-state plasma insulin concentrations) (Katz et al., 2000). 
The validity of glucose clamp measurements of insulin sensitivity depends on 
achieving steady-state conditions. “Steady-state” is often defined as a period greater 
than 30min (at least 1h after initiation of insulin infusion) during which the coefficient of 
variation for blood glucose, plasma insulin, and GIR are less than 5% (Chen et al., 2003; 
Katz et al., 2000). It is possible to use radiolabeled glucose tracer under clamp conditions 
to estimate hepatic glucose production, so that appropriate corrections can be made to M 
in the event HGP is not completely suppressed (Finegood et al., 1987; McMahon et al., 
1989; Radziuk et al., 2002; Rizza et al., 1981). An alternative approach is to use an 
insulin infusion rate sufficiently high to completely suppress HGP according to the insulin 
sensitivity/resistance of the population to be studied.  
M is routinely obtained at only a single insulin infusion rate, and therefore 
comparisons between M or SIClamp among different subjects is valid only if the same 
insulin infusion rate is used for all subjects. 
 
The principal advantage of the glucose clamp in humans is that, it directly measures 
whole body glucose disposal at a given level of insulinemia under steady-state conditions. 
Conceptually, the approach is straightforward and there are a limited number of 
assumptions that are clearly defined. In research settings where assessing insulin 
sensitivity/resistance is of primary interest and feasibility is not an issue, it is appropriate 
to use the glucose clamp technique.  
The main limitations of the HIEC approach are that it is time-consuming, labor 
intensive, expensive, and requires an experienced operator to manage technical 
difficulties. Another limitation is that the clamp utilizes steady-state insulin levels that 
may be supraphysiological. This results in a reversal of the normal portal to peripheral 
insulin gradient. Thus, the glucose clamp may not accurately reflect insulin action and 
glucose dynamics under physiological conditions that a dynamic test, such as, an oral 
meal or oral glucose load may determine. Further, in the HIEC insulin sensitivity is 
measured only under a steady-state condition, and therefore, the test does not 
realistically portray dynamic conditions such as those occurring after normal meals. 
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Because HIEC is dependent on steady-state conditions, insulin infusion is continuous for 
3h, and the subjects are in the fasted state. The results of the HIEC may be limited by 
these restraints, because insulin release is pulsatile (Hansen et al., 1982; Lang et al., 
1982; Lang et al., 1979; Porksen et al., 1996), and insulin action is sensitized in the 
postprandial state (Lautt et al., 2001). 
 
1.7.1.2. Insulin Tolerance Test (ITT) 
 
The insulin tolerance test (ITT) was one of the first methods developed to assess 
insulin sensitivity in vivo (Horgaard et al., 1929). In this method, a fixed bolus of regular 
insulin (0.1IU/kg bw) is given iv after an 8 to 10h fast. Blood samples are collected at 15 
and 5min before and 3, 6, 9, 12, 15, 20 and 30min after insulin injection, and the plasma 
glucose decrement is then measured. Glucose is injected at 30min to stop the fall in 
plasma glucose (Bonora et al., 1989; Inchiostro, 2005; Young et al., 1996). The faster 
the decline in glucose concentration, the more insulin sensitive the subject is. The slope 
of the linear decline in plasma glucose (KITT) can be calculated by dividing 0.693 by the 
plasma glucose half-time (50% from baseline): 
 
100x
t
693.0
K
2/1ITT
  
where t1/2 represents the half-life of plasma glucose decrease, and is calculated from the 
slope of least square analysis of the plasma glucose concentrations from 3 to 15min after 
iv insulin injection, when the plasma glucose concentration declined linearly. Normal KITT 
is >2.0%/min and values <1.5%/min are considered abnormal. This method gives an 
indirect estimate of overall insulin sensitivity. It has been to correlate with the HIEC in 
several studies (Akinmokun et al., 1992; Bonora et al., 1989). However, arterialization of 
blood was essential in the ITT, as data from standard venous blood measurements 
showed no significant relationship with HIEC-derived glucose disposal (Akinmokun et al., 
1992). 
Some of the drawbacks of this method include the supraphysiological insulin dose 
used, and also the fact that the test does not differentiate peripheral vs hepatic insulin 
resistance (Hirst et al., 1993). A major limitation of this test is the risk of hypoglycemia. 
Moreover, hypoglycemia triggers counterregulatory hormonal responses, which may 
interfere with insulin sensitivity and in turn slows the disappearance rate of glucose from 
plasma (Garber et al., 1976; Reaven, 1983). In this view, the fall in plasma glucose 
concentration would be a function of the interplay between insulin, on the one hand, and 
glucagon, catecholamines, growth hormone and cortisol, on the other. However, the 
counterregulatory response occurs at least 15 to 20min after insulin injection. Thus, the 
Chapter 1  General Introduction 
  PhD Thesis, Rita S. Patarrão 
 55 
glucose fall occurring in the first 15min after iv insulin administration is probably a 
function of insulin-stimulated glucose uptake by tissues, as well as, insulin-inhibited 
glucose output by the liver (Rizza et al., 1979b). 
A lower insulin dose method of 0.05IU/kg, or shortening the test to 15min was 
suggested as an attempt to decrease the risk of hypoglycemia (Chen et al., 1998; Hirst 
et al., 1993). The shorter version (Akinmokun et al., 1992; Bonora et al., 1989) derived 
from the notion that the counterregulatory hormone response occurs only after 20min of 
the insulin infusion (Monzillo et al., 2003; Rizza et al., 1979b). 
The advantages of the ITT include its simplicity, rapidity, use of a bolus injection of 
insulin and ability to measure insulin sensitivity in the fed or fasting state. The bolus 
injection of insulin mimics the physiological pulsatile release of insulin (Hansen et al., 
1982; Porksen et al., 1996). Furthermore, because glucose tolerance after a meal is 
dependent on insulin sensitivity, measuring insulin sensitivity in the prandial state is 
physiologically relevant. 
In conclusion, the ITT should be used with great caution in insulin sensitive individuals 
because of the increased risk of hypoglycemia, even when the smaller dose version of 
the test is used. The shorter ITT is a valid test in large-scale studies, especially when the 
site of resistance is not of importance. 
 
1.7.1.3. Insulin Suppression Test (IST) 
 
The insulin-suppression test (IST), another method that directly measures metabolic 
insulin sensitivity/resistance, was introduced by Shen et al. in 1970 and subsequently 
modified by Harano et al. (Harano et al., 1978; Shen et al., 1970). After an overnight 
fast, somatostatin (250μg/h) or the somatostatin analogue octreotide (25µg bolus, 
followed by 0.5µg/min) (Pei et al., 1994) is intravenously infused, to suppress 
endogenous secretion of insulin and glucagon. Simultaneously, insulin (25mU/m2/min) 
and glucose (240mg/m2/min) are intravenously infused over 3h. Blood samples for 
glucose and insulin determinations are taken every 30min for 2.5h, and then at 10min 
intervals from 150 to 180min of the IST. The constant infusions of insulin and glucose 
determine steady-state plasma insulin (SSPI) and glucose (SSPG) concentrations. The 
steady-state period is assumed to be from 150 to 180min after initiation of the IST. SSPI 
concentrations are generally similar among subjects. Therefore, the SSPG concentration 
will be higher in insulin resistant subjects and lower in insulin sensitive subjects, i.e., 
SSPG values are inversely related to insulin sensitivity. The IST provides a direct 
measure (through SSPG) of the ability of exogenous insulin to mediate disposal of an iv 
glucose load, under steady-state conditions, where endogenous insulin secretion is 
suppressed (Greenfield et al., 1981; Pickup et al., 2003). 
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The SSPG is a highly reproducible direct measure of metabolic actions of insulin, that 
is, less labor intensive and less technically demanding than HIEC. Indeed, since there are 
no variable infusions with the IST, steady-state conditions are more easily achieved with 
the IST than with HIEC.  
In research settings, the IST can be used for larger populations that may pose 
difficulties for application of HIEC (Yeni-Komshian et al., 2000). Many of the limitations of 
the IST are similar to those described for HIEC (with the exception that the IST is less 
technically demanding). Thus, it is impractical to apply the IST in large epidemiological 
studies or in the clinical care setting. SSPG under ideal conditions determines primarily 
skeletal muscle insulin sensitivity, and is not designed to reflect hepatic insulin sensitivity 
(Greenfield et al., 1981). 
 
1.7.1.4. Continuous Infusion of Glucose with Model Assessment (CIGMA) 
 
The continuous infusion of glucose with model assessment (CIGMA) is a procedure 
that assesses insulin sensitivity through the evaluation of the near steady-state glucose 
and insulin concentrations after a continuous infusion of glucose, with model assessment 
(Hosker et al., 1985). This method mimics postprandial glucose and insulin 
concentrations. CIGMA not only provides information about glucose tolerance and insulin 
sensitivity, but also about -cell function. Using a mathematic model of glucose 
homeostasis, glucose and insulin values are compared with known physiologic data of 
glucose, and insulin kinetics in response to glucose infusion, which are derived from 
healthy lean subjects with no family history of diabetes (Hosker et al., 1985). 
The glucose and insulin values used for CIGMA are obtained during the last 15min of 
the 60min continuous glucose infusion (5mg glucose/kg bw/min). Samples are collected 
at 5min intervals, to avoid the oscillatory variation in insulin concentration. The average 
is then compared with predicted values from the computer model. The median value for 
normal subjects is 1.35, and for diabetic patients with mild hyperglycemia is 4.0 (Hosker 
et al., 1985). 
There are two main advantages of CIGMA over HOMA. First, the insulin values that are 
measured in CIGMA are much higher than those in HOMA owing to the glucose stimulus 
and second, higher insulin concentration in CIGMA stimulates peripheral glucose uptake 
producing a steady-state glucose concentration, which is a better reflection of the 
peripheral insulin sensitivity (Monzillo et al., 2003; Vague et al., 2002). 
Although CIGMA is more practical, cheaper and less invasive than the FSIVGTT and 
HIEC procedure, the model incorrectly assumes that levels of insulin resistance at the 
liver and peripheral tissues are equal. Furthermore, in insulin-deficient subjects, where 
Chapter 1  General Introduction 
  PhD Thesis, Rita S. Patarrão 
 57 
the insulin response is insufficient to stimulate glucose uptake, the interpretation of 
CIGMA is difficult (Ferrannini et al., 1998). 
 
1.7.1.5. Oral Glucose Tolerance Test (OGTT)  
 
The oral glucose tolerance test (OGTT) is a simple test widely used in clinical practice 
to diagnose glucose intolerance and type 2 diabetes (American Diabetes Association, 
2007; Monzillo et al., 2003; Sievenpiper et al., 2000; Soonthornpun et al., 2003). After 
an overnight fast, blood samples for determinations of glucose and insulin concentrations 
are taken at 0, 30, 60, and 120min following a standard oral glucose load (75g) 
(American Diabetes Association, 2007). A diagnosis of diabetes is conferred if an 
individual has a plasma glucose level ≥200mg/dl as measured 2h after the ingestion of a 
75g glucose load. If an individual has a value in the range of 140-199mg/dl 2h post–
glucose load, is designated as having impaired glucose tolerance (American Diabetes 
Association, 2007). Oral glucose tolerance reflects the efficiency manner in which the 
body handles glucose after an oral glucose load. 
The OGTT mimics the glucose and insulin dynamics of physiological conditions more 
closely than conditions of the HIEC, IST or frequently sample intravenous glucose 
tolerance test (FSIVGTT) (Berthiaume et al., 2002; Steil et al., 2004). However, it is 
important to recognize that glucose tolerance and insulin sensitivity are not equivalent 
concepts. In addition to metabolic actions of insulin, insulin secretion, incretin effects, 
and other factors contribute importantly to glucose tolerance. Thus, the OGTT provide 
useful information about glucose tolerance but not insulin sensitivity/resistance per se 
(Caumo et al., 2000; Steil et al., 2004).  
The OGTT is technically quite simple to perform and certainly lower in cost than HIEC 
or FSIVGTT. These considerations have made the OGTT the glucose challenge test of 
choice in clinical situations (American Diabetes Association, 2007; American Diabetes 
Association, 2008). However, there are some problems with the OGTT that make it less 
desirable for use in research situations. First, there is variability in the rate of gastric 
emptying and glucose absorption from the gastrointestinal tract, causing some 
imprecision from the start. This variability can partially account for poorly reproducible 
results even within the same individual (American Diabetes Association, 2004). Second, 
glucose measurements in the standard OGTT do not give adequate information regarding 
the dynamics of glucose and insulin action (The expert committee on the diagnosis and 
classification of diabetes mellitus, 2003). 
The OGTT is a relatively crude measure of glucose tolerance. It does not measure the 
components of insulin sensitivity and insulin secretion. In light of this limitation, attempts 
have been made to obtain indices from OGTT data that might better reflect -cell function 
and insulin sensitivity (Avignon et al., 1999; Belfiore et al., 1998; Cederholm et al., 
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1990; Gutt et al., 2000; Matsuda et al., 1999; McAuley et al., 2001; Stumvoll et al., 
2001), which are reviewed below. 
 
1.7.1.6. Minimal model analysis of Frequently Sampled Intravenous Glucose 
Tolerance Test (FSIVGTT) 
 
The minimal model, developed by Bergman, Cobelli and colleagues in 1979, provides 
an indirect measure of metabolic insulin sensitivity/resistance based on glucose and 
insulin data obtained during a frequently sampled intravenous glucose tolerance test 
(FSIVGTT) (Bergman et al., 1979). After an overnight fast, an intravenous bolus of 
glucose (0.3g/kg bw) is infused over 2min starting at time 0.  
Currently, a modified FSIVGTT is used, where exogenous insulin (4mU/kg/min) is also 
infused over 5min beginning 20min after the iv glucose bolus (Finegood et al., 1990; 
Quon et al., 1994; Saad et al., 1997). Some studies use tolbutamide instead of insulin in 
the modified FSIVGTT, to stimulate endogenous insulin secretion (Bergman et al., 1987; 
Saad et al., 1997; Yang et al., 1987).  
Blood samples are taken for plasma glucose and insulin measurements at different 
time points, before and 180min after glucose infusion. The data obtained are then 
subjected to minimal model analysis using the computer program MINMOD (minimal 
model approach - MINMOD), to generate an index of insulin sensitivity (SI). 
The MINMOD is defined by two coupled differential equations with four model 
parameters (Figure 1.12). The first equation describes plasma glucose dynamics in a 
single compartment. The second equation describes insulin dynamics in a “remote 
compartment”. The structure of the MINMOD allows it to uniquely identify model 
parameters, which determine a best fit to glucose disappearance during the modified 
FSIVGTT. SI is calculated from two of these model parameters, and is defined as 
fractional glucose disappearance per insulin concentration unit (Bergman, 2005). 
In addition to SI, other minimal model parameters may be used to estimate a “glucose 
effectiveness” index (SG). SG is defined as the ability of glucose per se to promote its own 
disposal and inhibit hepatic glucose production (HGP) in the absence of an incremental 
insulin effect (i.e., when insulin is at basal levels). 
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Figure 1.12 - Schematic equations and parameters for the minimal model of glucose metabolism. Differential 
equations describing glucose dynamics [G(t)] in a monocompartmental “glucose space” and insulin dynamics in 
a “remote compartment” [X(t)] are shown at the top. Glucose leaves or enters its space at a rate proportional 
to the difference between plasma glucose level, G(t) and the basal fasting level, Gb. In addition, glucose also 
disappears from its compartment at a rate proportional to insulin levels in the “remote” compartment [X(t)]. In 
this model, t - time; G(t) - plasma glucose at time t;       I(t) - plasma insulin concentration at time t; X(t) - 
insulin concentration in “remote” compartment at time t; Gb - basal plasma glucose concentration; Ib - basal 
plasma insulin concentration; G(0) - G0 (assuming instantaneous mixing of the iv glucose load); p1, p2, p3 and 
G0 - unknown parameters in the model that are uniquely identifiable from FSIVGTT; glucose effectiveness (SG) - 
p1 and insulin sensitivity - p3/p2. Adapted from (Bergman, 2005). 
 
Minimal model analysis of the modified FSIVGTT is easier than HIEC method because 
it is slightly less labor intensive, steady-state conditions are not required, and there are 
no iv infusions that require constant adjustment. Unlike HIEC or IST, information about 
insulin sensitivity, glucose effectiveness, and -cell function can be derived from a single 
dynamic test. The minimal model generates excellent predictions of glucose 
disappearance during the FSIVGTT. 
In research settings, where assessing insulin sensitivity along with glucose 
effectiveness and -cell function is of interest, minimal model analysis of the insulin-
modified FSIVGTT may be appropriate. The minimal model approach is simpler than 
direct methods for determining insulin sensitivity. Nevertheless, it still involves iv 
infusions with multiple blood sampling over a 3h period, that is, nearly as labor intensive 
as the HIEC or IST. In addition, many limitations of minimal model analysis stem from 
the fact that the model oversimplifies the physiology of glucose homeostasis (Muniyappa 
et al., 2008). 
Another oversimplification of the minimal model involves lumping together effects of 
insulin to promote peripheral glucose utilization and suppress HGP. As insulin 
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sensitivity/resistance varies, the relative contribution of HGP to SI may vary significantly. 
Since the minimal model relies on a dynamic test to evaluate insulin sensitivity, 
estimates of SI are much less reliable in individuals with impaired insulin secretion and/or 
significant insulin resistance (when compared with healthy subjects). Under these 
conditions, the minimal model may overestimate SG to accurately predict the 
disappearance of glucose during the FSIVGTT. Indeed, estimates of SG are spuriously 
affected by differences in insulin secretory capacity (Finegood et al., 1996; Quon et al., 
1994). Moreover, for similar reasons, minimal model analysis often generates 
nonsensical negative values for SI in a substantial proportion of subjects with diabetes, 
who have minimal insulin secretory capacity and significant insulin resistance (Finegood 
et al., 1996; Katz et al., 2000). These nonsystematic errors inherent in the minimal 
model approach are highlighted by calibration model analysis, demonstrating that some 
simple surrogate indexes of insulin sensitivity have better absolute accuracy for 
predicting SIClamp than the minimal model-derived SI (Chen et al., 2005). 
 
1.7.1.7. Meal Tolerance Test (MTT) 
 
In an attempt to study the ability to regulate blood glucose in a more physiological 
situation than the OGTT, some authors measure the glycemic profile in response to the 
ingestion of a mixed meal constituted by carbohydrates, fat and proteins - meal tolerance 
test (MTT). 
The experimental procedure for the MTT is similar to the OGTT, that is, after an 
overnight fast (10-12h), a mixed meal18 (liquid or solid) is given and the glycemic profile 
is measured throughout 2h (Berthiaume et al., 2002; Caumo et al., 2000; Steil et al., 
2004); usually the insulin profile is also determined during the same period of time (Steil 
et al., 2004). 
 
The MTT is a “physiologic” variant of OGTT (Lefebvre et al., 1976) offering several 
advantages: (a) lack of artifactual postload hypoglycemia, thus making this test suitable 
for the study of postprandial hypoglycemia (Brun et al., 1995), a situation which is 
frequently due to high values of insulin sensitivity (Brun et al., 1996; Brun et al., 2000), 
but also to hyperinsulinism in a context of insulin resistance (Brun et al., 2000); (b) use 
of a physiologic stimulus triggering a cephalic phase proportional to palatability scores19 
                                         
 
18 The dose and the concentrations of the components of the mixed meal used in MTT are not standardized yet. 
19 The palatability was assessed with a 14cm visual analogue scale, ranging from “extremely unpleasant” to 
“extremely pleasant”. Just after eating, subjects were asked to mark a vertical line on the scale. For data 
analysis, the centre of the scale was considered as the zero value (neutral), and scores of palatability were 
measured as deviations in cm from the zero point. Thus, the scores ranged from -7 (distaste) to +7 (extreme 
pleasure) (Raynaud et al., 1999). 
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(Raynaud et al., 1999); (c) possibility to measure insulin sensitivity with a modified 
algorithm based on the minimal model (Caumo et al., 2000) as well as glucose 
effectiveness and insulin secretion (Mari et al., 2002); (d) potential for evaluating the 
physiologic effects of incretins (Rijkelijkhuizen et al., 2010). 
The MTT can represent a simple procedure, less unpleasant for the patient than the 
standard OGTT, and providing both a physiologic picture of glucoregulation, and a 
sophisticated and precise analysis of this glucoregulation, in terms of insulin sensitivity, 
glucose effectiveness, and insulin secretion (Aloulou et al., 2006). 
The -cell response is stronger after a mixed meal than after an OGTT with equal 
carbohydrate quantity, both for classical and model-based parameters. The higher 
response was mostly explained by higher -cell sensitivity during the meal, which may 
lead to lower glucose excursions (Rijkelijkhuizen et al., 2009). 
Several factors may contribute to differences in insulin secretion following an MTT 
compared with the OGTT. The MTT has a lower glycemic index than the OGTT, which may 
lead to lower glucose excursions (Wolever et al., 2006). Slower gastric emptying 
following the MTT due to larger volume (Doran et al., 1998), solid character (Achour et 
al., 2001), and fat content (Cunningham et al., 1989) will lead to a slower entry of 
nutrients into the circulation. 
The MTT might be considered as an additional tool for the assessment of metabolic 
abnormalities, in glucose-intolerant and insulin-resistant states (Berthiaume et al., 
2002). 
Thus, the MTT is a more physiological test than the OGTT, in regard to human diet, 
and is potentially able to give useful information concerning islet -cell function in the 
different categories of glucose intolerance  (Marena et al., 1992), but not insulin 
sensitivity/resistance per se (Caumo et al., 2000; Steil et al., 2004). 
As any other method that measures glucose tolerance, the MTT does not assess 
insulin sensitivity directly and may not be repeated in the same subject or animal on the 
same day. 
From a nutritional perspective, meals that are capable of producing meal-induced 
insulin sensitization (MIS) are advantageous, whereas meals that cannot produce MIS 
will result in nutrients being processed primarily as fat. Glucose and sucrose clearly are 
ineffective at serving as an appropriate feeding signal (Sadri et al., 2006). In addition, 
high-sucrose diets not only are not capable of activating MIS, but actually result in 
complete HISS-dependent insulin resistance after as short a period of feeding as 2 weeks 
on a 35% sucrose diet (Ribeiro et al., 2005). 
These observations may be directly related to the cause of the epidemic increase in 
insulin resistance, type 2 diabetes and obesity, in developed countries where refined 
sugar products make up a very large component of the normal diet. The demonstration 
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that MIS cannot be generated by these refined sugars, places added emphasis on the 
need for studies related to nutrient content of meals, especially in high risk groups. 
Sucrose and glucose are not capable of producing normal feeding signals thereby 
questioning the value of the oral glucose tolerance test for studies intended to quantitate 
responses to feeding (Sadri et al., 2006). 
 
1.7.1.8. Rapid Insulin Sensitivity Test (RIST) 
 
From all the methods above described, none of them proves to be a reliable way to 
assess insulin sensitivity/resistance, since most of them have non-physiological 
continuous infusion of insulin and/or glucose, which interfere with peripheral insulin 
sensitivity/resistance; take a long time to be performed; could not avoid counter-
regulatory responses to the hypoglycemia that follows an insulin bolus; could not allowed 
the assessment of insulin sensitivity in different conditions in the same subject, and in 
the same day; and it only evaluates insulin sensitivity resistance in the fasted state. 
Based on all of these drawbacks, it was necessary to develop another method for 
assessing insulin sensitivity/resistance. 
 
A new method for insulin sensitivity quantificarion, called the Rapid Insulin Sensitivity 
Test (RIST), was described and evaluated for use in rats (Lautt et al., 1998a; Xie et al., 
1996a), cats (Xie et al., 1995a; Xie et al., 1996c) and mice (Latour et al., 2002a). Minor 
modifications and further technical aspects of the RIST have been recently updated and a 
current operating procedure is described (Lautt et al., 1998a). The standard time line of 
the RIST, in rats, is shown in Figure 1.13. 
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Figure 1.13 - Rapid insulin sensitivity test (RIST) time line. Three stable arterial glucose levels determined at 
5min intervals established the ideal euglycemic baseline. Intravenous insulin infusion is administered over 5min 
with the glucose infusion and first arterial glucose sample beginning after 1min of glucose infusion. A variable iv 
glucose infusion is adjusted to maintain euglycemia based on arterial samples taken at 2min intervals 
throughout the test period. The RIST index is the total amount of glucose infused to maintain euglycemia over 
the test period, which is terminated when no further glucose infusion is required. The test period for the 
standard insulin dose in rats (50mIU/kg bw) is 30min, but different durations may be needed for higher doses, 
different conditions, or different species (Lautt et al., 1998a). 
 
Briefly, the RIST procedure, so far described in animals, is an euglycemic test and is 
carried out after establishing the glycemic baseline, which is done by taking arterial blood 
samples at 5min intervals until three consecutive measurements are stable. An insulin 
infusion is commenced (50mIU/kg administered over 5min) and, after 1min, glucose 
samples are taken at 2min intervals, and glucose is infused intravenously at a variable 
rate to maintain euglycemia. The test is completed when no more glucose is required. At 
the standard test dose of insulin of 50mIU/kg, the RIST is complete within 40min. The 
RIST index, the insulin sensitivity parameter, is simply the amount of glucose that had to 
be administered in order to maintain euglycemia after the bolus administration of insulin 
(Lautt et al., 1998a). 
 
One of the objectives of this thesis was to implement the RIST in humans, and the 
detailed methodology used will be introduced in chapter 3. In the remaining protocols of 
the PhD work, both in humans and in animals, the RIST was the selected methodology to 
evaluate insulin sensitivity. 
The primary technical difficulty with the RIST methodology is the need for rapid 
sampling of arterial blood. This was overcome by the use of an arterial-venous vascular 
shunt. The shunt, in rats, has been tested in various combinations, shunting from the 
femoral artery to the femoral vein or the carotid artery to the jugular vein. The shunt 
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drains blood from the artery, passes it through a segment of silicone catheter and, 
directs it back into the venous compartment. Arterial glucose samples are obtained by 
needle puncture into the silicone segment of the shunt and direct transfer of the blood 
sample (25µl) to a glucose analyzer capable of providing a reading within 1–2min. The 
arterial-venous loop allows iv infusions to be made through the shunt, and the perfusion 
pressure can be monitored through a side branch. Continuous monitoring of shunt blood 
pressure provides early warning of either venous or arterial obstruction. The arterial-
venous shunt, blood sampling and pressure monitoring method has great applicability for 
many in vivo studies. 
Another methodological issue relates to the basal glucose concentration determined 
before and after the RIST. A number of our previous studies demonstrate clearly that 
there is no mean change in basal blood glucose levels used as the euglycemic target 
when, for example, compared before and after denervation of the hepatic plexus or 
atropine. In addition, we have also determined that there is no correlation between the 
magnitude of the RIST index and basal glucose levels when compared using a large 
number of data points (Lautt et al., 1998a). Of more concern is the importance that 
glucose uptake or output should not change during the RIST. Whatever stimulus is used, 
including either ablation or stimulation protocols, the stimulus is administered prior to 
conducting the RIST, and a new stable glycemic baseline must be demonstrated. In 
addition, at the conclusion of the RIST index, the re-established baseline must not be 
significantly altered. In the event that such alteration occurs, it suggests that glucose 
output either increased or decreased during the test. This is usually obvious by 
comparing the shape of normal RIST curves with that obtained in the presence of the 
altered baseline. In such situations, the data must be excluded, and the RIST repeated 
(Lautt et al., 1998a). 
The RIST is not affected by anesthesia in rats (Latour et al., 2002b; Lautt et al., 
1998a) and is equally effective in anesthetized or conscious rats (Latour et al., 2002c). 
Insulin release normally occurs in a pulsatile manner, and hormones released in a 
pulsatile manner are best studied by pulsatile administration (Lautt, 2005). Based on this 
assumption, the iv insulin bolus administered at the beginning of the RIST mimics the 
physiological insulin action. It also avoids the vagal withdrawal and sympathetic 
activation induced by sustained hyperinsulinemia, during the HIEC (Latour et al., 2002a; 
Reid et al., 2002) and the hypoglycemia caused by the acute ITT (Reid et al., 2002). It 
does not alter levels of counter-regulatory hormones, such as catecholamines, 
somatostatin or glucagon (Xie et al., 1995a). Moreover, both insulinemia and glycemia 
return to basal levels after each RIST. 
The RIST is extremely sensitive and can be shown to generate dose–response 
relationships to insulin (Lautt et al., 1998a), which makes the RIST the most 
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advantageous method in the determination of small differences in insulin sensitivity. This 
method is able to be carried out routinely four sequential times in the same animal with 
high reproducibility (Lautt et al., 1998a), and is sufficiently versatile to permit paired 
experimental designs showing, in the same animal and on the same day. Both the 
accuracy and precision of the test can be assessed from determination of the deviation 
from the ideal euglycemic target (Lautt et al., 1998a). 
The majority of the insulin sensitivity tests are done in the fasted state, when insulin 
sensitivity would be logically anticipated to be at its lowest level. Studies performed by 
Lautt et al. indicated that the fasted state results in a very low insulin responsiveness. It 
is reasonable that insulin sensitivity should be under a regulatory mechanism such that in 
the fasted state insulin effect would be minimized, and inappropriate release of insulin 
would not, therefore, lead to life-threatening hypoglycemia. The RIST can be carried out 
in the fed state and it allows to determine full insulin sensitivity (Lautt et al., 2001). 
Furthermore, the RIST allows insulin sensitivity assessment before and after a meal, 
making it possible to be test both meal and drug effects on insulin sensitivity (Sadri et 
al., 2006). 
To summarize, the RIST is a quick method to evaluate insulin sensitivity, reproducible 
until 4 tests in the same animal and on the same day, utilizes a bolus of insulin to mimic 
pulsatile insulin release, and can be performed in the fed or fasting state. In addition, 
since the RIST is an euglycemic test, avoids hypoglycemia and prevents the activation of 
counter-regulatory hormones. 
The advantages of the RIST, in humans, in comparison with other insulin sensitivity 
tests will be discussed in detail in chapter 4. 
 
1.7.2. Simple surrogate indexes for insulin sensitivity/resistance 
 
1.7.2.1. Homeostasis Model Assessment (HOMA) 
 
The homeostasis model assessment (HOMA), developed in 1985, is a model of 
interactions between glucose and insulin dynamics, that is then used to predict fasting 
steady-state glucose and insulin concentrations, for a wide range of possible 
combinations of insulin resistance and -cell function (Matthews et al., 1985). The model 
assumes a feedback loop between the liver and -cell (Levy et al., 1998; Matthews et al., 
1985; Wallace et al., 2004); and glucose concentrations are regulated by insulin-
dependent hepatic glucose production, while insulin levels depend on the pancreatic -
cell response to glucose concentrations. Thus, deficient -cell function reflects a 
diminished response to glucose-stimulated insulin secretion. Likewise, insulin resistance 
is reflected by diminished suppressive effect of insulin on hepatic glucose production.  
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HOMA model describes this glucose-insulin homeostasis by a set of empirically derived 
non-linear equations. The model predicts fasting steady-state levels of plasma glucose 
and insulin for any given combination of pancreatic -cell function (HOMA%B) and insulin 
sensitivity (HOMA%S)20.  
In practical terms, most studies using HOMA employ an approximation described by a 
simple equation to determine a surrogate index of insulin resistance. This is defined by 
the product of the fasting glucose and fasting insulin, divided by a constant.  
The formula for the HOMA model is: 
 
22.5
(mmol/l)GlucoseFastingxIU/ml)(InsulinFastingHOMA   
 
The denominator of 22.5 is a normalizing factor; i.e., the product of normal fasting 
plasma insulin of 5µIU/ml and normal fasting plasma glucose of 4.5mmol/l obtained from 
an “ideal and normal” individual (Matthews et al., 1985). Therefore, for an individual with 
normal insulin sensitivity, HOMA = 1. It is important to note that, over wide ranges of 
insulin sensitivity/resistance, log (HOMA) transforms the skewed distribution of fasting 
insulin values to determine a much stronger linear correlation with HIEC estimates of 
insulin sensitivity (Katz et al., 2000). 
HOMA or log (HOMA) is extensively used in large epidemiological studies, prospective 
clinical trials, and research studies (Radikova, 2003; Wallace et al., 2004). In research 
settings where assessing insulin sensitivity/resistance is of secondary interest or 
feasibility issues preclude the use of direct measures by HIEC, it may be appropriate to 
use log (HOMA) (Wallace et al., 2004). 
 
1.7.2.2. Quantitative Insulin Sensitivity Check Index (QUICKI) 
 
Quantitative insulin sensitivity check index (QUICKI) is an empirically-derived 
mathematical transformation that uses fasting blood glucose and plasma insulin 
concentrations. It provides a reliable, reproducible, and accurate index of insulin 
sensitivity with excellent positive predictive power (Chen et al., 2005; Chen et al., 2003; 
Hanley et al., 2003; Katz et al., 2000; Mather et al., 2001). Since fasting insulin levels 
have a non-normal skewed distribution, log transformation improves its linear correlation 
with reference standard glucose clamp (SIClamp). However, as with 1/(fasting insulin) and 
                                         
 
20 An important caveat for HOMA%B (determined from fasting glucose and insulin concentrations) is that it 
imputes a dynamic -cell function (i.e., glucose-stimulated insulin secretion) from fasting steady-state data. In 
the absence of dynamic data, it is difficult, if not impossible, to determine the true dynamic function of -cell 
insulin secretion (Matthews et al., 1985). 
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the glucose/insulin ratio, this correlation is not maintained in diabetic subjects with 
fasting hyperglycemia and impaired -cell function, that is, insufficient to maintain 
euglycemia. To accommodate these clinically important circumstances where fasting 
glucose is inappropriately high, insulin is inappropriately low, application of logarithm to 
both fasting glucose, and fasting insulin provides a reasonable correction such that the 
linear correlation with SIClamp is maintained, in both diabetic and non-diabetic subjects. 
The reciprocal of this sum results in further transformation of the data generating an 
insulin sensitivity index that has a positive correlation with SIClamp.  
Thus, QUICKI is defined by the following formula: 
 
mg/dl)glucose,(fastinglogμIU/ml)insulin,(fastinglog
1QUICKI

  
 
QUICKI and HOMA were derived in a completely different conceptual fashion. 
Nevertheless, these two surrogate indexes are mathematically related, i.e, QUICKI is 
proportional to 1/log (HOMA). 
QUICKI is among the most thoroughly evaluated and validated surrogate index for 
insulin sensitivity. As a simple, useful, inexpensive, and minimally invasive surrogate for 
HIEC-derived measures of insulin sensitivity, QUICKI is appropriate and effective for use 
in large epidemiological or clinical research studies, to follow changes after therapeutic 
interventions, and for use in studies where evaluation of insulin sensitivity is not of 
primary interest (Abbasi et al., 2002; Katz et al., 2000). 
The major advantage of both the QUICKI and HOMA models is that they both require 
only one blood draw from a fasting patient. They thus do not require extensive technical 
expertise, and constitute a much lower cost per subject when compared with the HIEC or 
the FSIVGTT, making the QUICKI and HOMA models much more practical for use in 
large-scale epidemiologic studies, and for clinical situations (Wallace et al., 2004). 
However, the major disadvantage is that both of these methods fail to provide 
information about the stimulated glucose and insulin systems. Essentially, they provide 
information only about what is occurring with homeostatic mechanisms in the fasting 
state, largely reflecting insulin‟s effect on hepatic glucose production and not on 
peripheral glucose uptake, which is the more relevant aspect concerning insulin 
action/resistance. 
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1.7.2.3. Insulin sensitivity indexes based on OGTT 
 
Cederholm and Wibell Index 
 
The insulin sensitivity index proposed by Cederholm and Wibell (Katz et al., 1983) 
represents mainly peripheral insulin sensitivity and muscular glucose uptake, due to the 
dominant role of peripheral tissues in glucose disposal after an oral glucose load 
(Cederholm et al., 1990). 
 
The formula for the Cederholm index is: 
 
)Ilog(xGx120
mx19.0x180x15.1x)GG(75000
ISI
meanmean
1200
Cederholm

  
where, 75000 – oral glucose load in an OGTT in mg, G0 – fasting plasma glucose concentration (mmol/l), G120 – 
plasma glucose concentration in the 120th min of OGTT (mmol/l), 1.15 – factor transforming whole venous 
blood glucose to plasma values (not necessary, if glucose concentration is estimated in plasma), 180 – 
conversion factor to transform plasma glucose concentration from mmol/l into mg/dl, 0.19 – glucose space in 
liter per kg of body weight, m – body weight (kg), 120 – duration of OGTT (min), Imean – mean plasma insulin 
concentration during OGTT (mIU/l) and Gmean – mean plasma glucose concentration during OGTT (mmol/l). 
 
Values found in normal non-obese individuals were reported to be about 
7914mg.l2/mmol/mIU/min, lower in obese individuals, in subjects with impaired glucose 
tolerance and in patients with type 2 diabetes (Cederholm et al., 1990).  
 
Gutt et al. Index 
 
The ISI0,120 was adapted from the Cederholm insulin sensitivity index (Gutt et al., 
2000), by omitting the constant terms, and using the plasma glucose and insulin 
concentration from fasting (0min) and 120min samples from the OGTT (Gutt et al., 
2000).  
The ISI0,120 index is defined as:  
 
)Ilog(xGx120
mx19.0x)GG(75000
ISI
meanmean
1200
120,0

  
 
where, 75000 – oral glucose load in an OGTT in mg, G0 – fasting plasma glucose concentration (mg/dl), G120 – 
plasma glucose concentration in the 120th min of OGTT (mg/dl), 0.19 – glucose space in l/kg of body weight, m 
– body weight (kg), 120 – duration of OGTT (min), Imean – mean plasma insulin concentration during OGTT 
(mIU/l) and Gmean – mean plasma glucose concentration during OGTT (mmol/l).  
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The reference range for lean controls was 8939, for obese 5823 and for diabetic 
patients 2319mg.l2/mmol/mIU/min (Monzillo et al., 2003). 
 
Avignon et al. Index 
 
Avignon (Cobelli et al., 1987) proposed 3 insulin sensitivity indices : Sib (derived from 
fasting plasma insulin and glucose concentrations), Si2h (derived from plasma insulin 
and glucose concentrations in the 120th min of OGTT) and SiM (derived by averaging Sib 
and Si2h after balancing Sib by a coefficient of 0.137 to give the same weight to both 
indices): 
 
VDxGxI
10
Sib
00
8
  
VDxGxI
10
h2Si
120120
8
  
2
h2Si)Sibx137.0(
SiM

  
 
where, I and G represent the plasma concentrations of insulin (mIU/l) and glucose (mmol/l), respectively and, 
VD is the glucose distribution volume calculated using a monocompartmental model: VD=150ml/kg of body 
weight (Bergman et al., 1987). 
 
Matsuda et al. Index 
 
Originally proposed by Matsuda and DeFronzo (Matsuda et al., 1999), insulin 
sensitivity index-Matsuda (ISI(Matsuda)) is an whole body insulin sensitivity index that 
reflects a composite estimate of hepatic and muscle insulin sensitivity. This index is 
calculated from plasma glucose (mg/dl) and insulin (mIU/l) concentrations in fasting 
state and during OGTT. 
The formula for the Matsuda index is: 
 
meanmean00
)Matsuda(
IxGxIxG
10000
ISI   
 
where, 10000 – simplifying constant to get numbers from 0 to 12,  - correction of the nonlinear values 
distribution, G0 – fasting plasma glucose concentration (mg/dl), I0 – fasting plasma insulin concentration 
(mIU/l), Gmean – mean plasma glucose concentration during OGTT (mg/dl), from 0 to 120min and Imean – mean 
plasma insulin concentration during OGTT (mIU/l), from 0 to 120min. 
 
The insulin secretion/insulin resistance (disposition) index calculated as the product of 
insulin secretion measured with (I0–30/G0–30 or I0–120/G0–120) and ISI(Matsuda) (or 
modified ISI(Matsuda) using plasma glucose and insulin concentrations at 30min during the 
OGTT), had excellent power to predict onset of type 2 diabetes (Belfiore et al., 2001; 
Belfiore et al., 1998). 
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Belfiore et al. Index 
 
The condition for calculation of the Belfiore formula is the definition of the normal 
value for basal glucose and insulin concentrations, and for mean normal value for glucose 
and insulin areas during OGTT (Monzillo et al., 2003). The main point of the Belfiore 
formula is the comparison of insulin and glucose values measured (fasting, 0-1-2h areas 
or 0-2h areas) with the defined normal reference values. 
 
The ISIBelfiore index is defined as: 
1
I
I
x
G
G
2
ISI
N
S
N
S
Belfiore

  
 
where Gs, GN – plasma glucose concentrations expressed as fasting values or as areas obtained during a 
standard OGTT at 0 and 2h (0-2h areas are equal to       GS,N = G0 + G120) or at 0, 1 and 2h (0-1-2h areas 
equal to GS,N = ½G0 + G60 + G120, Is, IN – plasma insulin concentrations expressed as fasting values or as areas 
obtained during a standard OGTT at 0 and 2h (0-2h areas are equal to IS,N = I0 + I120) or at 0, 1 and 2h (0-1-2h 
areas equal to IS,N = ½I0 + I60 + I120. The subscripts S and N refer to “subjects” and “normal reference values”, 
respectively. 
 
Insulin sensitivity calculated using these formulas can achieve only values between 0 
and 2. In subjects with normal insulin sensitivity is it around 1; in overweight subjects, in 
subjects with impaired glucose tolerance, and with type 2 diabetes this value is below 1 
(Stumvoll et al., 2000; Stumvoll et al., 2001). 
 
Stumvoll et al. Index 
 
Stumvoll proposed a series of indices calculated from plasma glucose (mmol/l) and 
insulin (pmol/l concentrations during OGTT) (Stumvoll et al., 2001). The equations were 
generated using the multiple linear regression analysis and adapted to the availabilities 
of sampling times during OGTT, and of demographic parameters (BMI, age). 
An example equation could be the index of insulin sensitivity calculated from data 
obtained in 0, 60 and 120min of OGTT either with or without demographic data: 
 
ISIStumvoll = 0.222 – 0.00333 x BMI – 0.0000779 x I120 – 0.000422 x age 
ISIStumvoll = 0.156 – 0.0000459 x I120 – 0.000321 x I0 – 0.00541 x G120 
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McAuley et al. Index 
 
The authors proposed a formula for predicting insulin resistance in normoglycemic 
individuals (McAuley et al., 2001). Regression analysis was used to estimate the cut-off 
points and the importance of various data for insulin resistance (fasting concentrations of 
insulin, triglycerides, aspartate aminotrasnferase, BMI, waist circumference). A bootstrap 
procedure21 was used to find an index most strongly correlating with insulin sensitivity 
index, corrected for fat-free mass obtained by HIEC 





I
Mffm
 (DeFronzo et al., 1979). 
An insulin sensitivity index obtained from HIEC of  6.3 (expressed as glucose disposal 
rate in mg/kg/min divided by average plasma insulin concentration in mIU/l) was seen as 
a cut-off for individuals with insulin resistance. The combination of fasting insulin (mIU/l) 
and triglycerides (TAG, mmol/l) showed the best prediction of insulin resistance as 
follows:  
   00 TAGln31.0Iln28.063.2e
I
Mffm 






 
 
where, I0 – fasting plasma insulin concentration (mIU/l) and TAG0 – fasting plasma triglycerides concentration 
(mmol/l). 
 
1.7.2.4. Oral Glucose Insulin Sensitivity (OGIS) 
 
The oral glucose insulin sensitivity (OGIS) is a method for the assessment of insulin 
sensitivity from the OGTT. OGIS provides an index which is analogous to the index of 
insulin sensitivity obtained from the HIEC.  
This method calculates insulin sensitivity with a model-derived equation of the form: 
 
OGIS = f(G0, G90, G120, I0, I90, I120, DO) 
 
where G and I are glucose and insulin concentrations (subscripts represent time instant) and DO is the oral 
glucose dose (g/m2 body surface area). 
 
The function f is complex, but can be easily programmed on a spreadsheet (see 
http://www.isib.cnr.it/bioing/ogis/home.html, where a web-based calculator is also 
available). The expression of f contains some parameters, chosen to maximize the 
                                         
 
21 The bootstrap method is a very general re-sampling procedure for estimating the distributions of statistics 
based on independent observations. The bootstrap method is shown to be successful in many situations, which 
is being accepted as an alternative to the asymptotic methods. 
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agreement with the HIEC. Glucose and insulin can be given in either in common or 
international units (with appropriate parameters, see table 2 in (Mari et al., 2001)). 
OGIS is a predictor of the HIEC insulin sensitivity, expressed as glucose clearance 
M/G, normalized to body surface area. The units of OGIS are thus ml/min/m2 of body 
surface area. OGIS has been validated against an 120mU/min/m2 insulin infusion HIEC 
(by direct comparison of the glucose clearance values), instead of the more standard 
40mU/min/m2 used in the previous methods22. Formulas for a 3h and 2h OGTT are also 
available (Mari et al., 2001). 
OGIS exploits the known quantitative relationships between the observed data and the 
HIEC insulin sensitivity to attempt a genuine insulin sensitivity prediction. However, this 
advantage is limited by the necessity to use empirical assumptions, and to calculate 
parameters from regression (Mari et al., 2001). 
 
1.7.2.5. Rapid Insulin Sensitivity Test (RIST) Index 
 
The RIST index is the parameter used to evaluate insulin sensitivity that represents 
the total amount of glucose infused during the Rapid Insulin Sensitivity Test (RIST), ir 
order to maintain euglycemia after the exogenous bolus administration of insulin. It 
corresponds to the area under the curve of total glucose infused throughout the test 
(Lautt et al., 1998a). 
 
RIST Index = AUC of Glucose 
 
where AUC is the area under the curve (mg glucose/kg bw) during the RIST. 
                                         
 
22 OGIS has been validated for a 75g OGTT. Its use with other OGTT doses is possible, though not validated. 
OGIS requires glucose values at 0, 90, 120min and insulin values at 0 and 90min (2-h OGTT) or glucose values 
at 0, 120, 180 min and insulin values at 0 and 120min (3-h OGTT) (Mari et al., 2001).  
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2. HYPOTHESES AND OBJECTIVES 
 
The results presented in this PhD thesis concern mainly the establishment of the Rapid 
Insulin Sensitivity Test (RIST) in humans. Additionally, I aimed to study the Hepatic Insulin 
Sensitizing Substance (HISS)-dependent insulin action, a novel neurohumoral regulatory 
mechanism that controls insulin sensitivity, both in lean and overweight subjects. I also 
evaluated the involvement of the cholinergic system in HISS action, in humans. 
The animal studies intended to evaluate the contribution of the 3‟,5‟-cyclic adenosine 5‟-
monophosphate (cAMP) on HISS synthesis/release, since the relationship between HISS 
release and hepatic glutathione (GSH) content, and hepatic cAMP and GSH is well known. 
The hypotheses tested, in humans, were: 1) the RIST is a sensitive and reproducible 
test to evaluate insulin sensitivity in humans; 2) the activation of the HISS-dependent 
mechanism in response to the ingestion of a meal is responsible for the increased insulin 
sensitivity; 3) the HISS pathway is regulated by a cholinergic mechanism; and 4) the HISS-
dependent mechanism is compromised in overweight subjects. 
In animals, the general hypothesis tested was that glucagon-dependent activation of the 
intracellular cAMP pathway leads to a decrease in hepatic GSH content resulting in HISS-
dependent insulin resistance (HDIR).  
 
The first objective was to establish an insulin sensitivity test capable of evaluating 
insulin action in both the fasted and fed state, in both in lean and overweight humans, and 
to further characterize the physiology of regulation of insulin action by hepatic 
parasympathetic nerves, through the HISS pathway.  
 
The second objective was to determine if glucagon affects the intracellular cAMP 
pathway altering HISS action through hepatic GSH content. 
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2.1. THE HISS IN HUMANS 
 
The first specific objective of this work was to establish, for the first time, the Rapid 
Insulin Sensitivity Test (RIST) as a standard operating procedure in humans. Since the RIST 
was well established in rats (Lautt et al., 1998a), the human studies developed were based 
on the following hypothesis: in humans, the RIST is a diagnostic tool to quantify whole 
body insulin action. 
 
In animals, the HISS mechanism and the details of its regulation were discovered to some 
extent because development of the RIST, which is simply a transient euglycemic clamp to 
determine the dynamic glucose uptake response to a bolus of insulin. 
The usual means of assessing insulin sensitivity allowed testing only in the fasted state. 
However, in this condition, HISS release is absent. Taking this into account, the 
establishment of the RIST could provide a powerful research tool to assess insulin sensitivity 
both in the fasted and fed state. 
 
The second specific objective of this work was to test the concept of postprandial 
HISS-dependent insulin sensitization in healthy and overweight subjects. Since studies done 
in rats showed the relationship between HISS release and the prandial state, I postulate the 
following hypothesis: in lean healthy humans, feeding results in meal-induced insulin 
sensitization (MIS) that is HISS-dependent; overweight subjects have impaired MIS due to a 
compromise of HISS action. 
 
Animal studies have demonstrated that the HISS release in response to insulin is 
controlled by the prandial status so that, in the immediate postprandial state HISS release is 
maximal and decreases with the fast interval (Lautt et al., 2001; Sadri et al., 2006). HISS 
action in response to insulin is enhanced after a meal and is blocked by interfering with the 
hepatic parasympathetic nerves, ntric oxide levels and hepatic glutathione content (Guarino 
et al., 2003; Lautt et al., 2001; Sadri et al., 1998). Animal models of obesity were insulin 
resistant and had an impairment of HISS action (Afonso et al., 2010; Afonso et al., 2007b; 
Ribeiro et al., 2005). 
 
The third specific objective in the human studies was to determine whether HISS is 
regulated by a cholinergic mechanism in humans. The following hypothesis was tested: in 
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humans, the HISS-dependent component of insulin action is inhibited by a cholinergic 
antagonist. 
 
Studies in rats showed that atropine induces the same degree of insulin resistance as 
seen with hepatic parasympathetic surgical denervation, suggesting that atropine is effective 
in eliminating the hepatic parasympathetic component of peripheral insulin action (Teff et 
al., 1999b; Teff et al., 2004; Xie et al., 1996a; Xie et al., 1996b; Xie et al., 1994). This 
insulin resistance state can be reversed by intraportal (ipv) but not by intravenous (iv) 
infusion of acetylcholine (ACh). However, the HISS-independent component of insulin action, 
obtained after blockade of muscarinic receptors with atropine administration, was not 
affected by feeding or fasting (Xie et al., 1994) and this mechanism was only present in 
healthy rats.  
 
2.2. THE RELEVANCE OF GLUCAGON ON THE HISS PATHWAY 
 
In healthy subjects, glucagon levels increase in the fasted state and decrease in the 
immediate postprandial state (Ahren, 2006; Dunning et al., 2007; Fanelli et al., 2006; 
Young, 2005), opposite to the changes of hepatic GSH, which are increased in the fed state 
and decreased in the fasted (Tateishi et al., 1974). It has been observed that, in diabetic 
patients, plasma levels of glucagon are often abnormally high and may contribute to 
impaired glucose tolerance and other metabolic changes (Butler et al., 1991; Unger, 1978). 
In the fasted state and during the immediate postabsorptive state, the hyperglycemia 
observed in diabetic subjects may be caused not only by glucose underutilization, due to a 
deficiency or lack of insulin, but also by elevated concentrations of glucagon. These changes 
suggested that cAMP signaling pathway is upregulated, in insulin resistant subjects (Ahren, 
2006; Chen et al., 2004; Dunning et al., 2007; Fanelli et al., 2006; Henkel et al., 2005; 
Raju et al., 2005; Unger, 1978). 
Our group have recently proposed that the regulation of insulin action by the prandial 
status is dependent on hepatic GSH content (Guarino et al., 2003), which is known to be 
strongly related to the nutritional status (Tateishi et al., 1977; Tateishi et al., 1974; Taylor 
et al., 1996). Since hepatic GSH is a key factor for HISS action (Guarino et al., 2006), it was 
imperative to understand the mechanisms involved in the regulation of hepatic GSH levels. 
One important regulator of hepatic GSH levels is the cAMP pathway. It has been shown that 
as cAMP levels increase, GSH synthesis is inhibited (Goss et al., 1994; Higashi et al., 1976; 
Lu et al., 1990; Lu et al., 1991; Rozwadowski et al., 1995). Lu et al. reported that hormones 
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with effects mediated via cAMP/protein kinase A (PKA), such as glucagon, decrease plasma 
GSH levels due to an inhibition of the enzyme -glutamylcysteine synthase, which has a key 
role in GSH synthesis (Lu et al., 1991). 
 
The fourth specific objective in the rat studies was to determine the hepatic effect of a 
cAMP analogue on HISS-dependent insulin resistance. 
Hepatic GSH levels are controlled by the cAMP/PKA pathway and are apparently essential 
for HISS release. I therefore propose the following hypothesis: in fed rats, HISS-dependent 
insulin sensitivity is inhibited by a cAMP analog. 
 
The fifth specific objective in rat studies was to ascertain the role of glucagon on HISS-
dependent insulin action. 
Due to the relationship between glucagon and cAMP levels, and hepatic GSH, the 
proposed hypothesis is: glucagon acts via cAMP to decrease hepatic GSH levels, leading to 
an impairment of HISS synthesis/release resulting in an insulin resistance state responsible 
for the development of hyperglycemia and type 2 diabetes. 
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3. MATERIALS AND METHODS 
 
The human experiments were developed at the Medicine Unit of the Instituto Português 
de Oncologia (IPO), Lisboa, Portugal and the animal experiments were performed at the 
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Manitoba, 
Winnipeg, Canada. 
 
3.1. HUMAN STUDIES 
 
3.1.1. Subjects 
 
Lean healthy (aged 28.50.9 years, BMI 23.30.4 kg/m2) and overweight male subjects 
(aged 24.30.9 years, BMI 27.80.4 kg/m2) were admitted as outpatients to the Medicine 
Unit of IPO, Lisboa, between 9:00 and 9:30am. 
Clinical guidelines recommended that body mass index (BMI) be used to identify obesity 
(National Institutes of Health, 1998). The recommended standard definitions are: healthy 
lean, a BMI between 18.5 and 24.9 kg/m2; overweight, a BMI between 25 and 29.9 kg/m2; 
and obese, a BMI greater than or equal to 30 kg/m2. 
The recruited subjects had normal systolic and diastolic pressure, normal basal values of 
glycemia, insulin, C-peptide, lactate, HDL-cholesterol, LDL-cholesterol, total cholesterol and 
triglycerides in both fasted and fed state, according to the recommendations of the American 
Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) 
(Authors/Task Force Members et al., 2007; Revisions, 2009). 
None of the subjects had any history or signs of Type 2 diabetes mellitus or any disease 
requiring treatment at the time of study.  
The nature, purpose and potential risks of the study were carefully explained to each 
subject, who gave informed written consent (in appendix 1). The human study protocol was 
approved by the Ethics Committee of the IPO, Lisboa, Portugal and conformed to the 
standards set by the last revision of the Declaration of Helsinki. 
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3.1.2. Subject Preparation 
 
The study was performed with the subjects resting in a comfortable position and standard 
electrocardiogram (ECG) was monitored. 
All experiments began between 9:30 and 10:00am. An intravenous catheter was inserted 
in the median cubital vein in each forearm (Figure 3.1). One forearm was heated using a 
circulating water-controlled heating pad to produce "arterialized" venous blood for sampling 
representative of arterial blood (Nauck et al., 1992). The intravenous catheter inserted in 
the median cubital vein of this forearm was used only to collect blood samples. A second 
intravenous catheter, inserted in the median cubital vein, in the contralateral forearm, was 
used for the administration of insulin and glucose (to evaluate insulin sensitivity) and for 
atropine administration. 
 
 
Figure 3.1 - Representation of human veins of the upper limb. Adapted from (Seeley et al., 2003). 
 
 
 
 
 
 
 
Chapter 3  Materials and Methods 
  PhD Thesis, Rita S. Patarrão 
83 
 
3.1.3. Glycemia quantification 
 
The arterial glycemia was analyzed by the oxidase method with a glucose analyzer (1500 
YSI SPORT, YSI Inc., USA). 
Blood samples were collected from the "arterialized" median cubital vein with a 25l 
microsyringe (YSI Model 1501 Syringepet, YSI Inc., USA) and immediately injected into the 
glucose analyzer. 
 
The Glucose Analyzer 
 
The glucose analyzer 1500 YSI SPORT was developed to quantify glucose levels by the 
glucose oxidase (GOx) enzymatic method. The probe is fitted with a three-layer membrane 
containing immobilized GOx in the middle layer. Figure 3.2 shows an exploded view of the 
membrane and its relationship to the face of the probe.  
The face of the probe, covered by the membrane, is situated in a buffer-filled sample 
chamber into which a sample is injected.  
 
 
 
Figure 3.2 - Representation of the glucose analyzer sensor probe and enzyme membrane. The probe contains one 
membrane with three layers, in which the second layer contains the immobilized glucose oxidase (GOx) enzyme. 
The method is based on the glucose enzymatic oxidation (Reaction 1) and on the detection of the produced 
electrons by the formation of hydrogen peroxide. Adapted from Glucose Analyzer YSI 1500 Operations Manual (YSI, 
2001). 
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When the glucose contacts the immobilized enzyme (GOx), it is rapidly oxidized, 
producing hydrogen peroxide (H2O2) (Reaction 1). 
 
-D-Glucose + O2  
GOx
 Glucono--lactone + H2O2                    (1) 
 
The H2O2 is, in turn, oxidized at the platinum anode, producing electrons (Reaction 2). 
 
H2O2   
AnodePlatinum
 2H+ + O2 + 2e
-             (2) 
 
A dynamic equilibrium is achieved when the rate of H2O2 production and the rate at which 
H2O2 leaves the immobilized enzyme layer become constant. The equilibrium is indicated by 
a steady state response. The electron flow is linearly proportional to the steady state H2O2 
concentration and, therefore, to the concentration of glucose. 
The platinum electrode is held at an anodic potential and is capable of oxidizing many 
substances other than H2O2. To prevent these reducing agents from contributing to sensor 
current, the membrane contains an inner layer consisting of a very thin film of cellulose 
acetate. This film readily passes H2O2 but excludes chemical compounds with molecular 
weights above approximately 200Da. The cellulose acetate film also protects the platinum 
surface from proteins, detergents and other substances that could foul it.  
 
3.1.4. RAPID INSULIN SENSITIVITY TEST (RIST) IN HUMANS 
 
The Rapid Insulin Sensitivity Test (RIST) is a modified euglycemic clamp that quantifies 
the response to a exogenous bolus of insulin, and the glycemia is kept constant through iv 
glucose infusion, as previously described by Lautt and colleagues (Lautt et al., 1998a). At 
the beginning of the experiment (control RIST) and after pharmacological manipulation, the 
basal glycemia was established and the RIST was performed. 
 
Basal glycemia (Baseline) 
 
Subjects were allowed to stabilize prior to the first blood sampling. Blood samples were 
collected from the intravenous catheter and glycemia was analyzed by the oxidase method 
with a glucose analyzer (1500 YSI SPORT, YSI Inc., USA), as previously described. These 
blood samples were taken at 5min intervals until three successive stable glucose 
concentrations were obtained. The mean of these three concentrations is referred to as the 
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basal blood glucose level (baseline), and was used as the euglycemic target to be 
maintained during the RIST. 
 
The RIST in humans 
 
The RIST is a dynamic euglycemic clamp quantifying the response to an intravenous 
bolus of insulin (50mU/kg bw), administered over 30sec (t=0min). To maintain euglycemia, 
a 20% glucose infusion was started at a rate of 3mg glucose/kg/min, 1min after insulin 
bolus. Blood samples were drawn at t=1min and at 2min intervals for the remainder of the 
RIST. Based on blood glucose concentration, the infusion rate of glucose was adjusted to 
clamp the glycemia at baseline values, using an infusion pump (IVAC, Denmark). The RIST 
was complete when glucose infusion was no longer required to maintain euglycemia. 
As previously done in animals (Lautt et al., 1998a), the total amount of glucose infused 
during the RIST quantifies insulin sensitivity and is referred to as the RIST Index (mg 
glucose/kg bw) and corresponds to the area under the curve of total glucose infusion. The 
RIST Index is the parameter used to evaluate insulin sensitivity. 
 
3.1.5. QUANTIFICATION OF HISS ACTION  
 
The RIST provides two means of quantitating HISS-dependent insulin action. The first 
method utilizes the dynamics of the rates of glucose infusion obtained during the RIST. To 
obtain the mean curves representing the time-course from each test, we plotted the 
values of glucose infusion rate at 0.1min intervals. The HISS-dependent component curve 
was obtained by subtracting the fasted curve values from the corresponding fed curve 
values (Figure 3.3).  
 
 
 
 
 
 
 
 
 
Figure 3.3 – Schematic representation of the typical profile using the dynamic analysis of the pattern of glucose 
infusion during the Rapid Insulin Sensitivity Test (RIST), in rats. Control fed RIST (white area), 24h-Fast RIST 
(black area) and HISS-dependent component curve (grey area). 
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The second method uses the RIST index, that is, the total amount of glucose (mg 
glucose/kg bw) required to maintain euglycemia after a bolus of insulin (50mU/kg bw).  
The RIST index obtained in the fasted state, when HISS release is blocked, represents the 
HISS-independent component of insulin action. By subtracting the fasted-RIST index from 
the fed-RIST index, one quantifies the HISS-dependent component of insulin action (Figure 
3.4). 
 
 
 
Figure 3.4 - Schematic representation of the typical RIST index obtained in the fed and fasted state, in rats. By 
subtracting the fasted RIST index from the fed RIST index, the HISS-dependent component of insulin action could 
be quantified. 
 
3.1.6. Blood Samples  
 
At specific time points (-100, -80, -60, -40, -25, -15, -10, -5, 0, 1, 3, 5, 7, 9, 12, 15, 20, 
25, 30, 35, 45, 55 and 70min), when blood was collected for glycemia analysis, plasma and 
serum were also obtained and stored at -80ºC for determination of insulin, C-peptide, 
lactate, HDL-cholesterol, LDL-cholesterol, total cholesterol and triglycerides concentrations.  
The blood was collected by venipuncture into K3EDTA tubes (BD Vacutainer
, Franklin 
Lakes, USA) containing EDTA as anticoagulant, to obtain plasma and into a BD SSTTM tubes 
with gel and clot activator (BD Vacutainer, Franklin Lakes, USA), to obtain serum. The 
tubes were then centrifuged at 2750g for 10 minutes at 0ºC in a Beckman centrifuge 
(Beckman Coulter Allegra 6R Centrifuge, rotor GH-3.8A). 
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3.1.7. Human biochemical parameters analysis 
 
The human biochemical parameters analysis was performed using the plasma and serum 
samples collected at different time points during the experiment. All the samples were 
evaluated through the fully automated clinical chemistry analyzer (Olympus AU400 
Chemistry Analyzer). The principles of the method and the reactions behind each kit for each 
biochemical parameter analyzed are detailed below.  
 
Lactate 
 
Plasma lactate concentration was measured spectrophotometrically at 505nm using an 
enzymatic colorimetric kit (bioMérieux, 61192, France) with an Olympus analyzer (Olympus 
AU400 Chemistry Analyzer, USA).  
The principle of the kit is that the lactate present in the plasma sample is determined 
according to reaction 3: 
 
Lactate + O2   
OxidaseLactate
   Pyruvate + H2O2                                                    (3) 
 
 
The H2O2 formed is assayed according to a trinder type reaction (Reaction 4):  
 
H2O2 + 4-chlorophenol +4-aminoantipyrine  
(POD) Peroxidase
 Quinoneimine + 2H2O + HCl                    (4) 
 
The intensity of the measured coloration (quinoneimine) is proportional to the quantity of 
lactate present in the plasma sample. 
 
HDL-Cholesterol 
 
Serum HDL-cholesterol was measured spectrophotometrically at 500nm using an 
enzymatic colorimetric kit (Olympus, OSR6187, Ireland) with an Olympus analyzer (Olympus 
AU400 Chemistry Analyzer, USA).  
The principle of the kit is that anti-human-β-lipoprotein antibody present in reagent 1 of 
the kit, binds to lipoproteins other than HDL (LDL, VLDL and chylomicrons) (Reaction 5):  
 
LDL, VLDL, Chylomicrons  
 antibodynLipoproteiβhumanAnti
Antigen–Antibody complexes                  (5) 
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The antigen-antibody complexes formed block enzyme reactions, when reagent 2 of the 
kit is added (Reaction 6). The enzymes responsible for this reaction are cholesterol esterase 
(CHE) and cholesterol oxidase (CHO), present in the reagent 2 of the kit. 
 
HDL-Cholesterol + H2O2 + O2  
CHOandCHE
 Cholest-4-en-3-one + Fatty acid + H2O2               (6) 
  
HDL-cholesterol is quantified by the presence of an enzyme chromogen system, catalysed 
by POD (Reaction 7): 
 
H2O2 + 4-Aminoantipyrine + F-DAOS  
POD  Blue dye + 2H2O                                                    (7) 
 
LDL-Cholesterol 
 
Serum LDL-cholesterol was measured spectrophotometrically at 500nm using an 
enzymatic colorimetric kit (Olympus, OSR 6183, Ireland) with an Olympus analyzer 
(Olympus AU400 Chemistry Analyzer, USA).   
The principle of this kit is that a protecting agent, present in the reagent 1 of the kit, 
protects LDL from enzymatic reactions. All non-LDL lipoproteins (HDL, VLDL, chylomicrons) 
are broken down by reaction with CHE and CHO (Reaction 8): 
 
2LDL-Cholesterol + 2H2O2 + 2O2  
CHOandCHE
 2Cholest-4-en-3-one+2Fatty acid+ 2H2O2                   (8) 
  Protecting Reagent 
 
The H2O2 produced by this reaction is decomposed by catalase, present the in reagent 1 
of the kit. When reagent 2 of the kit is added, the protecting reagent is released from LDL 
and catalase inactivated by sodium azide (Reaction 9):  
 
2H2O2 + 4-Aminoantipyrine + H-DAOS  
POD  Blue dye + OH- + 3H2O                       (9) 
 
Total Cholesterol 
 
The Olympus Cholesterol reagent utilises an enzymatic colorimetric method to measure 
total cholesterol in human serum (Olympus, OSR 6116, Ireland) with an Olympus analyzer 
(Olympus AU400 Chemistry Analyzer, USA).  
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In this procedure, cholesterol esters in a sample are hydrolysed by CHE (Reaction 10):  
 
2 Cholesterol esters + 2H2O  
CHE  2 Cholesterol + 2 Fatty acid                        (10) 
 
The free cholesterol produced is oxidised by CHO to cholestene-3-one with the 
simultaneous production of H2O2 (Reaction 11), which oxidatively couples with 4-
aminoantipyrine and phenol in the presence of POD to yield a chromophore (Reaction 12): 
 
2 Cholesterol + 2 O2  
CHO  2 Cholestene-3-one + 2H2O2                   (11) 
2H2O2 + 4-Aminoantipyrine + Phenol  
POD  Quinoneimine + 4H2O                               (12) 
 
The red quinoneimine dye formed can be measured spectrophotometrically at 540/600nm 
as an increase in absorbance. 
 
Triglycerides 
 
Serum triglyceride was measured spectrophotometrically at 500nm using an enzymatic 
colorimetric kit (Olympus, OSR 6133, Ireland) with an Olympus analyzer (Olympus AU400 
Chemistry Analyzer, USA). 
This procedure is based on a series of coupled enzymatic reactions. The triglycerides in 
the sample are hydrolysed by a combination of microbial lipases to give glycerol and fatty 
acids (Reaction 13): 
 
Triglyceride + 3H2O  
Lipase  Glycerol + 3 Fatty acid                                       (13) 
 
The glycerol is phosphorylated by adenosine triphosphate (ATP) in the presence of 
glycerol kinase (GK) to produce glycerol-3-phosphate (Reaction 14): 
 
Glycerol+ ATP  
2Mg,GK  Glycerol-3-phosphate + ADP                           (14) 
 
The glycerol-3-phosphate is oxidised by molecular oxygen in the presence of glycerol 
phosphate oxidase (GPO) to produce H2O2 and dihydroxyacetone phosphate (Reaction 15): 
 
Glycerol-3-phosphate + O2  
GPO  Dihydroxyacetone phosphate + H2O2                  (15) 
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The H2O2 is used to oxidatively couple p-chlorophenol and 4-aminoantipyrine catalysed 
by POD to give a red dye with an absorbance maximum at 500nm (Reaction 16):  
 
H2O2+4-Aminoantipyrine+4-Chlorophenol  
POD Quinoneimine+HCl+2H2O                  (16) 
 
The increase in absorbance at 520/600nm is proportional to the triglyceride content of 
the serum sample. 
 
Insulin 
 
Plasma insulin concentration was measured by a radioimmunoradiometric assay (IRMA) 
kit (Biosource, INS-Irma KIP1251, Belgium). This assay is based on coated-tube separation 
and monoclonal antibodies (Mabs) Mab1, the capture antibodies, are attached to the lower 
and inner surface of the plastic tube. Calibrators or samples added to the tubes will at first 
show low affinity for Mabs1. Addition of Mab2, the signal antibody labelled with 125I, will 
complete the system and trigger the immunological reaction. After washing, the remaining 
radioactivity bound to the tube reflects the antigen concentration. The insulin antibody used 
is the human-specific antibody with no cross-reactivity to human proinsulin.  
The plasma samples (50µl), the kit controls (50µl) and the calibrators (50µl) were added 
to the coated tubes and incubated for 2h at room temperature. The content of each tube 
was aspirated. The tubes were washed with 2ml of working wash solution (diluted TRIS-
HCl). The content of each tube was again aspirated, washed with 2ml of wash solution 
(concentrated TRIS-HCl) and decanted. After the final washing, the tubes were stand upright 
for 2min and the remaining liquid was dropped. Lastly, the tubes were counted in a gamma 
counter (DPC Gamma Counter, USA) for 1min and the insulin concentration was calculated 
based on the calibration curve plotted. 
 
C-Peptide 
 
Plasma C-Peptide concentration was measured by the BioSource C-PEP II-RIA-CT kit, 
which is a radioimmunoassay for the in vitro quantitative measurement of  
human C-Peptide in plasma (Biosource, C-Pep II-RIA-CT KIP0409, Belgium). A fixed 
amount of 125I labelled Tyr-C-Peptide competes with the C-Peptide to be measured present 
in the plasma sample or in the calibrator for a fixed amount of antibody sites being 
immobilized to the wall of a polystyrene tube. After 3h incubation at room temperature, an 
aspiration step terminates the competition reaction. The tubes are then washed with 3ml of 
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wash solution and aspirated again. A calibration curve is plotted and the C-Peptide 
concentrations of the samples are determined by dose interpolation from the calibration 
curve.  
The plasma samples (100µl), the kit controls (100µl) and the calibrators (100µl) were 
added to the coated tubes. 50µl of 125I labeled Tyr-C-Peptide was dispensed into each tube. 
Tubes were shaked gently to liberate any trapped air bubbles and then incubated for 3h at 
room temperature. The content of each tube was aspirated. The tubes were washed with 
3ml of working wash solution (diluted TRIS-HCl). The content of each tube was again 
aspirated. After the washing, the tubes were place upright for 2min and the remaining liquid 
was dropped. Lastly, the tubes were counted in a gamma counter (DPC Gamma Counter, 
USA) for 1min and the C-peptide concentration was calculated based on the calibration 
curve plotted. 
 
3.2. ANIMALS STUDIES 
 
The animal experiments were performed at the Department of Pharmacology and 
Therapeutics, Faculty of Medicine, University of Manitoba, Winnipeg, Canada. 
 
3.2.1. Sprague-Dawley rats  
 
Male Sprague-Dawley rats weighing 319.47.6g (9-weeks old) from Charles River, St. 
Constant, Quebec, Canada were maintained in the animal house under controlled conditions 
(221ºC) on a 12h light/dark cycle. Rats had ad libitum access to standard rat chow diet 
(Prolab RMH 3000 5P00, Labdiet, USA) and with free access to normal tap water, for one 
week to adapt to the housing environment. 
Animals were treated according to the guidelines of the Canadian Council on Animal Care 
(CCAC), and the ethics committee on animal care at the University of Manitoba approved all 
protocols. 
The animals were kept anesthetised during the experiment and at the end of the 
protocols they were euthanized with a lethal injection of sodium pentobarbital in accordance 
with the guidelines of the CCAC. 
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3.2.2. Pre-surgical protocol and anesthesia 
 
All rats were fasted for 8h, and then allowed ad libitum access to food for 2h immediately 
before starting the surgical preparation. As HISS is only released in the fed state, the 
fasting-refeeding protocol assured a high level of HISS release in response to insulin (Lautt 
et al., 2001). All the experiments started at 8:00am. 
The methodology used was described by Lautt (Lautt et al., 1998a). The animals were 
weighed and anesthetized with an intraperitoneal (ip) injection of sodium pentobarbital 
(65mg/kg) (Somnotol, Biomeda-MTC Animal Health Inc., Cambridge, Ontario). 
 
The sodium pentobarbital (2mg/ml) was maintained throughout the experiment by 
continuous infusion (0.5ml/h/100g bw) into the jugular vein, using a polyethylene catheter 
(PE50, Intramedic, Beckton and Dickinson, USA) connected to an infusion pump (Genie, 
Kent Scientific Corporation, Litchfield, Massachusetts). After induction, anesthesia was 
tested regularly during the experiment using the tail pinch and the eyelid reflex. When 
necessary, intravenous (iv) supplements of pentobarbital sodium (65mg/kg) were 
administered, through the injection of the anesthetic by puncturing the silicone sleeve on 
the venous side of the arterial-venous loop (Section 3.2.3.3., Figure 3.5). 
Sodium pentobarbital was the selected anesthetic since it did not affect blood pressure 
significantly, nor insulin action (Lautt et al., 1998a). It had a small effect on autonomic 
nervous system activity (Best et al., 1984; Taborsky et al., 1984) and splanchnic 
hemodynamics (Kvietys et al., 1982), thus minimizing the introduction of biased results on 
insulin sensitivity evaluation (Penicaud et al., 1987). Comparing conscious animals and 
animals anesthetized with sodium pentobarbital, there were no changes regarding to glucose 
metabolism or in the plasma concentrations of glucose, insulin, glucagon and 
norepinephrine, as well as on their metabolic actions, since the temperature of the 
anesthetized animal was maintained approximately at 37ºC (Lang et al., 1987; Latour et al., 
2002c; Saha et al., 2005). The effects of sodium pentobarbital in the nutrient absorption 
were not significant when compared with other anesthetics (Yuasa et al., 1993) and there 
were no differences on its effects from the fasted to the fed state (Saha et al., 2005). 
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3.2.3. Surgical protocol 
 
The surgical procedures were adapted from those described by Lautt and colleagues 
(Lautt et al., 1998a).  
In the surgical procedure, all rats received a tracheotomy followed by a femoral artery-
femoral vein arterial-venous loop, left internal jugular vein cannulation and portal vein 
cannulation. 
In order to perform the surgical procedure, all the surgery was performed with surgical 
amplifier glasses (Optivisor DA-7, Donegan Optical Company, USA) and a cold light 
illuminator (KL750 Schott, USA). 
During all the surgical procedures, body temperature was monitored with a rectal probe 
and kept at 37.0±0.5°C, by means of a heated surgical table (Harvard Apparatus, Kent, 
England) and overhead lamp. 
 
3.2.3.1. Arterial-venous loop 
 
The arterial–venous loop or arterial-venous shunt, as shown in Figure 3.5, is a vascular 
shunt where the blood flows between the catheterized artery and vein. The arterial-venous 
loop allows multiple rapid arterial sampling, iv administration of drugs and solutions, and 
allows the measurement of mean arterial and venous pressure (Section 3.2.5.). Continuous 
monitoring of loop pressure identifies arterial or venous loop occlusions due to clotting or 
mechanical effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 - Arterial–venous loop. The blood flows into the loop from the artery into the vein, by a difference in 
pressure. The loop allows the sampling of arterial blood samples and intravenous administration of drugs by needle 
puncture into the silicone sleeve, as well as continuous monitoring of loop pressure. Brief occlusion of the venous 
outflow allows for monitoring arterial pressure. Adapted from (Lautt et al., 1998a). 
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The arterial-venous circuit consists of one-piece of silicone with 10cm of length to act as a 
sleeve (MasterFlex Platinum, Cole Parmer, USA) connected to two pieces of polyethylene 
tubing PE50, with 12cm in length each (Intramedic, Beckton and Dickinson, USA), acting as 
vascular catheters. The two pieces of PE50 tubing are connected to the silicone sleeve with a 
short reducer of polyethylene tubing, with 4mm in length (Tygon Micro–Bore, .04ID/.07OD, 
Cole Parmer, USA). 
The silicone sleeve is divided into two equal parts, one corresponding to the arterial side 
and the other to the venous side. The two parts of the silicone sleeve are attached to a 
polyethylene T-shaped connector (Raccordo T 4mm, Kartell Labware Division, Italy). The 
third opening of the connector is attached to a piece of polyethylene tubing PE90 with 
approximately 20cm long (Intramedic, Beckton and Dickinson, USA), which is then 
connected to a pressure transducer for the recording of the loop pressure which, when the 
silicone tubing toward the venous side of the circuit was closed by clamping, represented the 
systemic arterial blood pressure (Section 3.2.5.). 
Arterial blood continuously flows through the circuit into the venous side. Arterial blood 
samples can be taken from the loop via puncture of the silicone sleeve. 
The arterial-venous loop was prepared before the beginning of the experiment, having 
been previously primed with a heparin solution (200UI/ml). 
 
3.2.3.2. Tracheotomy 
 
The trachea was cannulated and the anesthetized animals were allowed to breathe 
spontaneously during all the experiment. It was performed an incision in the anterior wall of 
the trachea, below the isthmus of the thyroid (Figure 3.6) and the polyethylene tubing 
(PE240, Intramedic, Beckton and Dickinson, USA) of 2-2.5cm in length was inserted. 
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Figure 3.6 – Trachea. The tracheotomy is performed below the isthmus of the thyroid. Adapted from (Olds et al., 
1991). 
 
3.2.3.3. Femoral artery and femoral vein cannulation 
 
In order to cannulate the left femoral artery and femoral vein, we performed a small 
incision at the left rat groin and then the vessels were isolated (Figure 3.7). After the 
isolation procedure, first the femoral artery and then the femoral vein were cannulated, with 
the insertion of the polyethylene tubing PE50, connected to arterial-venous loop as 
described above (Section 3.2.3.1.). 
 
 
 
Figure 3.7 – Localization of the femoral artery and femoral vein. Adapted from (Olds et al., 1991). 
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3.2.3.4. Jugular vein cannulation 
 
In order to cannulate the left internal jugular vein, we performed a small skin incision 
above the clavical and to the left of midline and then the vein was isolated (Figure 3.8). 
Following, the vein was cannulated with polyethylene tubing PE50. A short length of silicone 
sleeve tubing intersects the polyethylene tubing and allows the infusion of drugs directly into 
the vein, by needle puncture into the silicone sleeve. 
The catheter is attached to an infusion pump (Genie, Kent Scientific Corporation, 
Litchfield, Massachusetts), to maintain anesthesia throughout the experiment by a 
continuous infusion of sodium pentobarbital and in the small portion of the silicone sleeve, 
the glucose solution during the insulin sensitivity test is infused, in order to do not 
contaminate arterial glycemia measured at the arterial-venous loop. 
 
 
 
Figure 3.8 – Internal jugular vein and some of the major blood vessels of the rat neck. Adapted from (Olds et al., 
1991). 
 
3.2.3.5. Portal vein cannulation 
 
The portal vein (Figure 3.9) was catheterized to administer drugs into the portal 
circulation and directly to the liver. 
After laparotomy, the portal vein was isolated. An intravenous polyurethane catheter 
(24G Optiva, iv catheter radiopaque ocrilon polyurethane, 19mm, Johnson & Johnson 
Medical Inc., Arlington, TX) was placed into the portal vein, between the splenic vein and the 
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cecal vein, to allow ipv infusions of pharmacological agents. The catheter was glued into 
place with a small drop of tissue adhesive (GluStich, Canada). Attached to the intravenous 
catheter was a connecting catheter from which ipv infusions were done. The connecting 
catheter was polyethylene tubing PE50 with a male luer slip end connector attached to the 
delivery end. This connector was obtained by cutting it from either a stopcock or from a 1ml 
syringe. The male luer slip end connector was glued to the polyethylene tubing such that the 
polyethylene tubing extends to the very tip of the male luer slip, thus allowing for low dead 
volume. A short length of silicone sleeve tubing intersects the polyethylene tubing and 
allows for direct ipv infusions, by needle puncture into the silicone sleeve. Prior to ipv 
infusions, a small amount of blood was drawn through the catheter in order to check the 
effectiveness of the line. The abdominal incision was covered with damp surgical gauze and 
a covering of Parafilm. 
 
 
 
Figure 3.9 – Schematic representation of the liver and the portal vein. The portal vein cannulation allows ipv 
infusions of pharmacological agents directly into the liver. Adapted from (Greene, 1963). 
 
3.2.4. Post-surgical protocol 
 
Immediately after the arterial-venous loop insertion and jugular vein cannulation, the 
supplemental sodium pentobarbital infusion was started (into the jugular vein), in order to 
keep the animal under anesthesia during all the experimental period, as previously 
described. Once in a while, 0.01-0.02ml of heparin (200UI/ml) was administered to the 
animals to prevent the clot formation. Following completion of surgery and before doing any 
type of procedure, the animal was allowed at least a 30min stabilization period. 
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Body temperature was monitored with a rectal probe and kept at 37.0±0.5°C during all 
the experiment by means of a heated surgical table (Harvard Apparatus, Kent, England) and 
overhead lamp. 
 
3.2.5. Blood pressure monitorization 
 
After the insertion of the arterial-venous loop, a polyethylene tube  
(PE 90) from the T-shaped connector which attaches the silicone sleeve and is designed to 
monitoring the loop pressure, was joined to a pressure transducer (National Instruments 
LabView, Austin, USA). A data acquisition system (National Instruments LabView, Austin, 
USA) combined with application software was used to record and analyze the mean arterial 
blood pressure. 
The pressure measured by the transducer and recorded by the data acquisition system is 
the mean systolic pressure. The measurement of the mean arterial pressure was performed 
by reading the pressure indicated during a brief clamping of the silicone sleeve on the 
venous side of the circuit. The measurement of the mean venous pressure was done by 
occlusion of the arterial side of circuit. Circuit loop pressure functions as an indicator of 
circuit resistance and flow. In case of obstruction of the circuit, for example by clot 
formation, a marked variation of the mean systolic pressure would be observed. If a problem 
with the loop patency occurs in the circuit, the loop can be cleared and flushed through the 
side branch connector.  
During the insulin sensitivity test, the mean blood pressure was continuously monitored 
and the blood flow through the arterial-venous loop was checked. 
 
3.2.6. Sampling of arterial blood 
 
Arterial blood samples were collected by puncturing the silicone sleeve on the arterial side 
of the arterial-venous loop. To avoid hemolysis of the samples, the samples were collected 
very slowly.  
The blood sampling was performed with a 25l automatic microsyringe (YSI Model 1501 
Syringepet, YSI Inc., USA) and the sample was immediately injected into the glucose 
analyzer. The quantification of arterial glycemia was performed by the oxidase method with 
a glucose analyzer (1500 YSI SPORT, YSI Inc., USA), as previously described in section 
3.1.3.. This method provides a rapid and efficient quantification of arterial glycemia. 
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3.2.7. Rapid Insulin Sensitivity Test (RIST) in animals 
 
The Rapid Insulin Sensitivity Test (RIST) was the selected method to quantify whole-body 
insulin sensitivity in animals.  
 
Basal glycemia (Baseline) 
 
After the stabilization period, the baseline glucose levels were determined by samples 
taken at 5min intervals and continued until 3 successive stable determinations were made. 
The mean of these three data points was used as the ideal euglycemic baseline to be 
maintained during the euglycemic clamp, and was used as the euglycemic target.  
 
The RIST in animals 
 
As mentioned earlier, the RIST measures the animal‟s hypoglycemic response to the 
exogenous insulin administration and glycemia is kept constant by iv variable infusion of 
glucose. 
After determination of basal glycemia, insulin (Novolin ge Toronto) 50mU/kg bw infusion 
is commenced using an infusion pump (Genie, Kent Scientific Corporation, Litchfield, 
Massachusetts) to administer the dose over 5min (in 0.5ml saline at 0.1ml/min). The 
beginning of the insulin infusion was considered time zero (t=0min). After 1min of insulin 
infusion, the first glucose sample is determined, and glucose infusion (100mg/ml, iv) is 
commenced at the rate of 2.5mg/kg/min with an infusion pump (Genie, Kent Scientific 
Corporation, Litchfield, Massachusetts). Arterial glucose levels were sampled at 2min 
intervals throughout the test period with glucose infusion rates adjusted to maintain animal‟s 
glycemia near to the baseline value established before starting the RIST. The RIST was 
considered finished when the blood glucose levels remained near to the baseline without any 
further glucose infusion. The time line for the RIST is shown in Figure 3.10. 
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Figure 3.10 – Rat typical profile of the Rapid Insulin Sensitivity Test (RIST). Three stable arterial glucose levels 
determined at 5min intervals established the ideal euglycemic baseline. Intravenous insulin infusion (50mU/kg bw) 
is administered over 5min with the glucose infusion and first arterial glucose sample beginning 1min after of insulin 
infusion. A variable iv glucose infusion is adjusted to maintain euglycemia based on arterial samples taken at 2min 
intervals throughout the test period. The RIST index is the total amount of glucose infused to maintain euglycemia 
over the test period, which is terminated when no further glucose infusion is required. From (Lautt et al., 1998a). 
 
The total amount of glucose infused during the RIST quantifies insulin sensitivity and is 
referred to as the RIST Index (mg glucose/kg bw) and corresponds to the area under the 
curve of total glucose infusion. The RIST Index is the parameter used to evaluate insulin 
sensitivity.  
After each RIST, the animal was allowed to stabilize approximately 30min prior to the 
following manipulation. Following each intervention or pharmacological manipulation, and to 
determine their effects on insulin sensitivity, a new RIST was performed, as soon as a new 
arterial baseline value was reached. 
A data acquisition system (National Instruments LabView, Austin, USA) combined with 
application software was used to record and analyze the mean arterial blood pressure, to 
calculate the RIST index, and to provide real-time monitoring of adherence to the 
euglycemic baseline. The software program calculated accuracy and precision of 
maintenance of the euglycemia target baseline. If either deviated by more than 5%, the 
entire RIST was determined to be invalid and was discard. 
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3.2.8. Drug administration 
 
Pharmacological agents were administered intravenously by puncturing the silicone sleeve 
on the venous side of the arterial-venous loop and intraportally directly into the portal vein. 
The administration of the drugs into the portal vein was done to directly deliver to the liver, 
the organ of HISS synthesis/release. 
The intraportal infusion rate of drugs was chosen based on preliminary studies done with 
saline; the continuous infusion at 0.0167ml/min infusion rate and the bolus infusion at 
0.04ml/min did not induce either metabolic or hemodynamic alterations. The systemic 
infusion rate of 0.1ml/min did not change arterial glycemia or mean arterial pressure (MAP).  
From the beginning of iv and ipv infusions, experiments have a maximum duration of 3h. 
The average amount of anesthetic, glucose, insulin and drugs infused in the animals was 
about 1ml/100g bw/h, which is in accordance with the recommendations to compensate for 
water loss by surgical intervention and for blood sampling (between 1 and 1.5ml/100g bw/h) 
(Akerstrom et al., 1989; Diehl et al., 2001; Van Zutphen, 2001). 
All the infusions (systemic (iv) and intraportal (ipv)) were performed with Genie pumps 
from Kent Scientific Corporation, Litchfield, Massachusetts. 
 
3.2.9. Animal biochemical parameters analysis 
 
Blood samples were collected before and after each RIST, for insulin analysis. For the 
plasma insulin quantification, the blood (30l) was collected into a 0.5ml eppendorf tube, 
centrifuged at 10000rpm (5585g) (Costar Mini Centrifuge, USA) for 5min at room 
temperature and the supernatant was placed in another labeled eppendorf and stored at –
30°C freezer. 
 
Plasma insulin quantification 
 
The plasma insulin levels were analyzed using the insulin assay kit Mercodia Ultrasensitive 
Rat Insulin ELISA (Enzyme-Linked Immuno-Sorbent Assay), which is a quantitative and 
colorimetric method for determination of insulin in rat plasma (Rat Ultrasensitive Insulin 
ELISA, Mercodia Inc., Sweden). 
This method is a solid phase two-site enzyme immunoassay. It is based on the direct 
sandwich technique, in which two monoclonal antibodies are directed against separate 
antigenic determinants on the insulin molecule. During incubation insulin in the sample 
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reacts with peroxidase-conjugated anti-insulin antibodies and anti-insulin antibodies bound 
to microtitration wells. A simple washing step removes unbound enzyme labelled antibody. 
The bound conjugate is detected by reaction with 3,3‟,5,5‟-tetramethylbenzidine (TMB). The 
reaction is stopped by adding H2SO4 to give a colorimetric endpoint that is read 
spectrophotometrically at 450nm. The determination of the insulin concentration in the 
plasma sample was performed using a calibration curve using standard solutions of insulin 
supplied with the kit. This method has a sensitivity of 0.13g/l. 
On the day of the plasma insulin analysis, 5l of plasma sample were added to anti-
insulin wells (96-well coated plate with mouse monoclonal anti-insulin). 50µl of enzyme 
conjugate (peroxidase conjugated mouse monoclonal anti-insulin) were added to each well 
and the plate was incubated at room temperature (18-25ºC) for 2h on a plate shaker at 
700-900 cycles per minute in an orbital movement. The plate was washed 6 times with an 
automatic washer (Multiwash Plus, TriContinent, USA) and 350µl of wash buffer were added 
to each well. The content of each well was aspirated completely. The previous procedure was 
repeated 5 times and after the final wash, the plate was inverted and tapped firmly against 
absorbent paper. 200µl of TMB were added to each well and the plate was again incubated 
at room temperature (18-25ºC) for 30min on a plate shaker at 700-900 cycles per minute in 
an orbital movement. The reaction was stopped adding 50µl of stop solution (0.5M H2SO4) to 
each well and the plate was placed on a shaker for approximately 5sec to ensure mixing of 
substrate and stop solution. Finally, the plate‟s absorbance was measured at 450nm in a 96 
well plate reader with 450nm filter (Biotek, Synergy HT, Biotek Instruments Inc., USA) 
and the insulin concentration in each well was calculated using the Gen5, Version 1.01.14 
software. 
 
3.3. EXPERIMENTAL PROTOCOLS 
 
3.3.1. Human studies 
 
In all human protocols, the body weight, height and mean arterial pressure (MAP) of the 
subjects were determined. The study was done with the subjects resting in a comfortable 
position and a standard electrocardiogram (ECG) was monitored.  
After a 24h (chapter 4, 5 and 6) or 14h (chapter 4 and 5) fasting period, blood samples 
were collected at -10, -5 and 0min before starting the fasted RIST or starting feeding the 
standardized test meal (described below), and blood glucose, plasma insulin, plasma C-
peptide, plasma lactate, serum HDL-cholesterol, serum LDL-cholesterol, serum total 
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cholesterol and serum triglycerides were measured, as previously described (section 3.1.7.). 
These values were referred to as basal levels prior to the fasted RIST (Figure 3.11) or 
feeding the standardized test meal (Figure 3.12). 
 
Figure 3.11 – Schematic representation of the experimental protocol before starting the 24h fast RIST. 
 
Figure 3.12 – Schematic representation of the experimental protocol before feeding the standardized test meal. 
 
 
Standardized test meal 
 
The subjects when tested in the postprandial state fed a standardized test meal (16 
Proalimentar cookies, caloric content 917kJ) and drank 500ml of mineral water. Table III 
shows the nutritional composition of the standardized test meal. 
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Table III – Composition of the standardized test meal according to the supplier (Proalimentar, Portugal). 
 
Standardized test meal composition 
Proteins 4.0g 
Carbohydrates 35.5g 
Saturated Lipids 6.8g 
Fibers 2.6g 
Sodium 0.35g 
 
3.3.1.1. Evaluation of the dynamic response to insulin in the fed state 
 
The experimental protocol described below was performed in lean healthy subjects and 
the results obtained are presented in Chapter 4. 
 
On the day before the study (14h prior to the beginning of the test), lean healthy male 
subjects were fed a regular dinner.  
On the day of the experiment, after 14h fasted glycemic baseline was achieved, subjects 
were fed the standardized test meal (described in Section 3.3.1.) and drank 500ml of 
mineral water. 
Blood samples were collected at specific time points during 100min after the standardized 
test meal, to quantify blood glucose and the biochemical parameters previously described 
(Section 3.1.7.). After this period of time, and after three successive stable glucose 
concentrations were obtained, the RIST was performed in the fed state (Figure 3.13). 
Each subject was tested on two different days in the same prandial state (fed state). 
 
Figure 3.13 – Schematic representation of the experimental protocol for the evaluation of the dynamic response to 
insulin in the fed state, in lean healthy subjects. 
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3.3.1.2. Evaluation of the dynamic response to insulin in the fasted and fed 
states 
 
The experimental protocol described below was performed in lean healthy and overweight 
subjects and the results obtained are presented in Chapter 4, 5 and 6. 
 
In this protocol, 24h prior to the beginning of the test, lean healthy and overweight male 
subjects were fed a regular breakfast (ham and cheese sandwich, orange juice and croissant 
with cheese or ham, 2720kJ caloric content). 
On the day of the experiment, after 24h fasted glycemic baseline was achieved, the RIST 
was performed in the fasted state. After the 24h fast RIST, subjects were fed a standardized 
test meal (described in Section 3.3.1.) and drank 500ml of mineral water. 
Blood samples were collected at specific time points during 100min after the standardized 
test meal, to quantify blood glucose and the biochemical parameters previously described 
(Section 3.1.7.). After this period of time, and after three successive stable glucose 
concentrations were obtained, a second RIST was performed in the postprandial state 
(Figure 3.14). 
Each subject was tested on the same day, and in two different nutritional states. 
Figure 3.14 – Schematic representation of the experimental protocol for the evaluation of the dynamic response to 
insulin in the 24h fast and fed state, in lean healthy and overweight subjects.  
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3.3.1.3. Effect of atropine administration on insulin sensitivity, in lean healthy 
subjects 
 
The experimental protocol described below was performed in lean healthy subjects and 
the results obtained are presented in Chapter 5. 
 
On the day before the study (14h prior to the beginning of the test), lean healthy male 
subjects were fed a regular dinner. 
On the day of the experiment, after 14h fasted glycemic baseline was achieved, subjects 
were fed the standardized test meal (described in Section 3.3.1.) and drank 500ml of 
mineral water. 
Blood samples were collected at specific time points during 100min after the standardized 
test meal, to quantify blood glucose and the biochemical parameters previously described 
(Section 3.1.7.). After this period of time, and after three successive stable glucose 
concentrations were obtained, the RIST was performed in the fed state (Figure 3.15). 
Each subject was tested on two different days in a double-blinded protocol. Intravenous 
infusions over 10min of either atropine (0.5 or 0.75mg) (low therapeutic dose with minor 
side effects (Brown et al., 1996)) or saline (control group) were administrated 50min after 
feeding the meal and 50min before starting the fed RIST (Figure 3.15). 
 
 
 
Figure 3.15 – Schematic representation of the experimental protocol for the evaluation of insulin sensitivity after 
HISS blockade with atropine 0.5 or 0.75mg, or saline, in lean healthy subjects. 
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3.3.2. Animal Studies 
 
In all animal protocols, male Sprague-Dawley rats weighing 319.47.6g (9-weeks old) 
were used. The animals were fasted for 8h, and then allowed ad libitum access to food for 
2h immediately before starting the surgical preparation. All the rats were tested under 
sodium pentobarbital anesthesia. 
The surgical procedures were performed as described in section 3.2.3. The RIST was the 
method used to assess the insulin sensitivity (Section 3.2.7.). The plasma insulin 
quantifications were performed as previously described in section 3.2.9. 
The results obtained with the experimental protocols described below are presented in 
chapter 7. 
 
3.3.2.1. Hepatic effect of DBcAMP, a cAMP analogue, on insulin sensitivity 
 
After the stabilization period, the baseline glucose levels in the fed state were determined 
and the first blood sample was taken for insulin analysis. The first control fed RIST was 
performed. After completing the first RIST, a new glycemic baseline was established and 
DBcAMP (N6,2‟-O-dibutyryladenosine 3‟,5‟-cyclic monophosphate), a cAMP analog, was 
infused ipv at different doses ranging from 0.01 to 1.0mg/kg, for 10min at an infusion rate 
of 0.04ml/min (Cervin et al., 1995). A minimum of a 30min stabilization period was allowed 
until establishing a new stable glycemic baseline. The second blood sample, after DBcAMP 
ipv infusion, was taken for insulin quantification. A second RIST was carried out after 
DBcAMP ipv infusion. Finally, the third blood sample was taken for insulin analysis (Figure 
3.16). 
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Figure 3.16 – Schematic representation of the experimental protocol for the evaluation of the hepatic effect of 
different doses of DBcAMP on insulin sensitivity. 
 
3.3.2.2. Hepatic effect of glucagon, on HISS-dependent insulin sensitivity 
 
This protocol was divided into 2 different series. In the first series, after the stabilization 
period, the baseline glucose levels in the fed state were determined. A control RIST was 
performed in the fed state. After completing the first RIST, a new glycemic baseline was 
established and glucagon was infused ipv at different doses ranging from 0.5ng/kg to 
20g/kg, for 10min at an infusion rate of 0.04ml/min (Carrillo et al., 1995). A minimum of a 
30min stabilization period was allowed until establishing a new stable glycemic baseline. A 
second RIST was carried out after glucagon ipv infusion (Figure 3.17). 
 
 
Figure 3.17– Schematic representation of the experimental protocol for the evaluation of the hepatic effect of 
different doses of glucagon on insulin sensitivity. 
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In the second series of this protocol, after the stabilization period, the baseline glucose 
levels in the fed state were determined. Then, a control fed RIST was performed. After 
completing the first RIST, a new glycemic baseline was established and N-monomethyl-L-
arginine (L-NMMA), a selective NOS inhibitor, was infused ipv at a dose of 0.73mg/kg for 
10min at an infusion rate of 0.04ml/min. The administration of L-NMMA was used to block 
the HISS pathway (Sadri et al., 1999). A minimum of a 30min stabilization period was 
allowed until establishing a new stable glycemic baseline. A second RIST was carried out 
after L-NMMA ipv infusion and a new glycemic baseline was established and then glucagon 
was infused ipv at 200ng/kg (the dose that produces a maximal inhibition on insulin 
sensitivity without affecting basal glycemia) for 10min at an infusion rate of 0.04ml/min. A 
minimum of a 30min stabilization period was allowed until establishing a new stable 
glycemic baseline and a third RIST was carried out after glucagon ipv infusion (Figure 3.18). 
 
Figure 3.18 – Schematic representation of the experimental protocol for the evaluation of the hepatic effect of 
glucagon 200ng/kg on HISS-dependent insulin sensitivity. 
 
3.4. STATISTICAL ANALYSIS 
 
The data presented during this dissertation are expressed as means  SEM of the mean 
(SEM). As applicable, the significance of the difference between mean values was calculated 
through Student‟s t tests, paired or unpaired (two-tailed), as the experimental design was, 
respectively, paired or unpaired and analysis of variance (ANOVA), one-way ANOVA or 
repeated measures ANOVA, followed by the Tukey-Kramer multiple-comparison test. 
RIST dynamic profiles data were analyzed using repeated measures ANOVA, followed by 
the Tukey-Kramer multiple-comparison test in each group. The curves representing the 
dynamic profile of the RIST were obtained from glucose infusion rates in 0.1min intervals.  
Area under the curve (AUC) was calculated for glucose, insulin and C-peptide with a 
computerized trapezoidal method (GraphPad Software). 
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Differences were accepted as statistically significant at p<0.05. Whenever p value is not 
indicated, differences are not statistically significant.  
The GraphPad Prism version 4.0 (GraphPad Software Inc., USA) was the software utilized 
to elaborate all the graphs and to perform all the statistical analysis.  
 
3.5. REAGENTS AND SOLUTIONS 
 
Human insulin (Humulin Regular) was obtained from Lilly, Lisbon, Portugal. Heparin, 
atropine, glucose and saline were purchased from BBraun, Lisbon, Portugal. All drugs were 
dissolved in saline (BBraun, Portugal). 
Sodium pentobarbital (Somnotol®) was obtained from Biomeda-MTC Animal Health Inc., 
Cambridge, Ontario. Human insulin (Novolin® ge Toronto) was purchased from Novo Nordisk 
(Mississauga, ON, Canada). Heparin was purchased from Pharmaceutical Partners of 
Canada, Richmond Hill, Ontario and saline from Baxter Corporation, Toronto, Ontario, 
Canada. 
D-Glucose, L-NMMA, DBcAMP and glucagon were purchased from Sigma Chemical Co. 
(St. Louis, MO, USA). Tissue adhesive was acquired from GluStich Inc., Canada. 
All chemicals were of the highest degree of purity on the market. All the solutions for in 
vivo administration were prepared in NaCl 0.9%. 
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4. THE RAPID INSULIN SENSITIVITY TEST (RIST) IN HUMANS 
 
4.1. INTRODUCTION AND AIMS 
 
Insulin sensitivity is of central relevance in many areas of clinical medicine and research. 
A number of techniques to determine insulin sensitivity have been proposed, including the 
oral glucose tolerance test (OGTT), the hyperinsulinemic-euglycemic glucose clamp method 
(HIEC) and the insulin tolerance test (ITT)  (Soop et al., 2000).  
Since its introduction into clinical investigation two decades ago, the HIEC has been 
established as the “gold standard” for the measurement of insulin sensitivity at the whole 
body level (Natali et al., 2000). Because HIEC is dependent on steady-state conditions, 
insulin infusion is continuous for 3h and the subjects are kept in the fasted state. The 
results of the HIEC may be limited by these restraints because physiological insulin release 
is pulsatile (Juhl et al., 2002; Porksen et al., 1996), and prolonged insulin infusion causes 
alterations in the autonomic nervous system (Van De Borne et al., 1999). 
In the ITT, an intravenous bolus of insulin is administered and insulin sensitivity is 
measured by the rate of decline of plasma glucose concentration (Hirst et al., 1993). 
Steeper slopes indicate greater insulin sensitivity. The advantages of the ITT include its 
simplicity, rapidity, use of a bolus injection of insulin, and the ability to measure insulin 
sensitivity in the fed or fasting state. Furthermore, because glucose tolerance after a meal is 
dependent on insulin sensitivity, measuring insulin sensitivity in the prandial state is 
physiologically relevant. The bolus injection of insulin mimics the physiological pulsatile 
release of insulin (Hansen et al., 1982). However, it does not allow rapid sequential testing; 
hypoglycemia and the activation of counter-regulatory hormones are undesired effects of the 
ITT (Young et al., 1996). 
In glucose tolerance tests, an oral glucose load is administered, and glucose and insulin 
levels are measured. It is important to note that glucose tolerance differs from insulin 
sensitivity. Glucose tolerance is measured by the rate of glucose disappearance from the 
blood. Insulin sensitivity involves the measurement of both glucose and insulin kinetics in 
response to a glucose load. In OGTT, concomitant hyperinsulinemia and normal or impaired 
glucose tolerance following a glucose load indicate insulin resistance (Bergman et al., 1985). 
As the other methods described above, it does not allow more than one test per day in a 
single subject. 
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Another method to quantify the insulin sensitivity is the Rapid Insulin Sensitivity Test 
(RIST). It has been only described in the literature in laboratory animals, such as rats, cats 
and mice (Latour et al., 2002a; Lautt et al., 1998a; Xie et al., 1996c).  The RIST has been 
developed to evaluate the dynamic response to insulin in both the fasted and fed states. The 
RIST index is the amount of glucose disposed following a bolus administration of insulin, as 
determined using a euglycemic clamp methodology. This transient euglycemic clamp can be 
repeated several times in the same animal and is sufficiently sensitive to allow dose-
response relationships to be established for the stimulatory effect of insulin (Lautt et al., 
2001) and the inhibitory effect of atropine (Takayama et al., 2000). The RIST was developed 
in order to avoid the hypoglycemia and the activation of counter-regulatory hormones 
caused by the ITT. The RIST is a rapidly sampled euglycemic clamp in response to a pulse of 
insulin (Lautt et al., 1998a).  
The current paradigm for insulin resistance focuses on peripheral defects in insulin 
signaling with the majority of studies being carried out in the fasted state. While there can 
be no question that diabetes imparts an enormous risk factor for the development of several 
diseases, the continued focus on the fasting state appears misdirected. The importance of 
the post-meal, rather than the fasting, metabolic status is amply demonstrated in a number 
of studies (Ceriello et al., 2008b; Lautt, 2004; Leiter et al., 2005; Monnier et al., 2007). 
The aim of the study described in this chapter was to develop the RIST as a standard 
operating procedure in humans, as a new method to assess insulin action in vivo, both in the 
fasted and fed state. This was based on the same procedure that was used in laboratory 
animals, but with some changes in order to adapt the same methodology to humans. There 
is not a gold standard test for evaluation of glucose homeostasis in the postprandial state, 
where major glucose excursions are deleterious. The need to develop a new test became 
emergent and was the first aim of the present thesis. 
 
4.2. PROTOCOLS 
 
4.2.1. Evaluation of the RIST reproducibility on 2 different days, in lean healthy 
subjects  
 
The RIST was the method used to evaluate insulin sensitivity (Chapter 3, Section 3.1.4.). 
For the evaluation of the RIST reproducibility, each lean healthy subject was tested on 
two different days in the fed state. 
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After a 14h fasting period, the subject was fed a standardized test mixed-meal and 
100min after the meal, the RIST was performed in the fed state. The detailed experimental 
protocol is described in chapter 3, section 3.3.1 and 3.3.1.1. 
 
4.2.2. Assessment of the RIST implementation, in lean healthy subjects  
 
In order to implement the RIST in humans, each lean healthy subject was tested on the 
same day in the fasted state and after ingesting the previously described test meal. 
In brief, after a 24h fasting period, the RIST was performed in the fasted state. After, the 
subject fed a standardized test meal and 100min after the meal, the RIST was performed in 
the fed state. The detailed experimental protocol is described in chapter 3, section 3.3.1 and 
3.3.1.2. 
 
4.3. RESULTS 
 
The aims of the study presented in this chapter were to test the Rapid Insulin Sensitivity 
Test (RIST) reproducibility and implement the RIST in human subjects, revealing the 
possibility to perform the test, in different prandial states, and more than one test in the 
same day. 
To evaluate the RIST reproducibility, the same subject was tested in the fed state on two 
different days. However, to implement the RIST in humans, in the same day, the volunteer 
was tested in the fasted state and after feeding a standardized test meal (fed state). 
Lean healthy male subjects (aged 27.22.3 years, BMI 22.50.9 kg/m2, n=6) admitted 
into this protocol had normal systolic (119.35.6mmHg, on day 1 and 114.04.0mmHg, on 
day 2) and diastolic blood pressure (65.72.9mmHg, on day 1 and 59.03.9mmHg, on day 
2). 
Basal fasting glucose levels measured on day 1 and day 2 were 81.03.4 and 
74.52.7mg/dl, respectively, and basal glucose levels measured on day 1 and day 2 100min 
after the meal were 106.06.3 and 101.12.5mg/dl, respectively. 
Basal glycemia, insulin and C-peptide levels increased with feeding, which is consistent 
with the ingestion and absorption of food. The other biochemical parameters did not change 
from the fasted to the fed state, even between the 2 different days. 
Table IV shows the fasting and postprandial basal levels of the biochemical parameters 
analyzed, measured in 2 different days, in the lean healthy subjects. 
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Table IV – Fasting and postprandial basal values of glycemia, insulin, C-Peptide, lactate, HDL-cholesterol, LDL-
cholesterol, total cholesterol and triglycerides of the lean healthy subjects, on day 1 and day 2 (n=6). Values are 
means±SEM. Unpaired t-test between day 1 and day 2. 
 
 
Prandial  
State 
Glycemia 
(mg/dl) 
 
Insulin 
(IU/ml) 
C-Peptide 
(ng/ml) 
Lactate 
(mg/dl) 
HDL- 
Cholesterol 
(mg/dl) 
LDL- 
Cholesterol 
(mg/dl) 
Total  
Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl) 
Fasted Day 1 
(n=6) 
 
81.03.4 
 
8.31.6 
 
1.80.2
 
 
10.20.2 
 
52.42.4 
 
65.65.8 
 
155.94.1 
 
40.56.0 
Fed Day 1 
(n=6) 
 
106.06.4 
 
36.16.6
 
 
7.60.9
 
 
9.90.8 
 
48.52.6 
 
68.96.9 
 
143.44.8 
 
42.34.9 
Fasted Day 2 
(n=6) 
 
74.52.7 
 
5.60.8
 
 
1.70.3
 
 
8.20.5 
 
48.73.9 
 
84.57.0 
 
148.710.1 
 
31.72.7 
 Fed Day 2 
(n=6) 
 
101.12.5 
 
35.45.8
 
 
8.51.1
 
 
9.40.7 
 
45.64.3 
 
78.07.7 
 
138.612.5 
 
31.95.6 
 
 
4.3.1. Evaluation of the RIST reproducibility on 2 different days, in lean healthy 
subjects 
 
Biochemical profiles after feeding the standardized test meal, on day 1 and day 2 
 
After subject‟s stabilization period and in regard to test the reproducibility of the RIST in 
the fed state, we first evaluated and compared the profiles of the biochemical parameters 
(glycemia, insulin, C-Peptide, lactate, HDL-cholesterol, LDL-cholesterol, total cholesterol and 
triglycerides) obtained after ingestion of the standardized test meal, on day 1 and day 2 
(Figure 4.1). 
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Figure 4.1 – Biochemical parameters (glycemia, insulin, C-Peptide, lactate, HDL-cholesterol, LDL-cholesterol, total 
cholesterol and triglycerides) profiles measured at specific time points during 100min after ingestion of the 
standardized test meal (0min) and before performing the RIST in the fed state (100min), for the evaluation of the 
RIST reproducibility, in lean healthy subjects (n=6). Results are means±SEM. One-way ANOVA, followed by the 
Tukey-Kramer multiple-comparison test. 
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As shown in Figure 4.1, the biochemical parameters profiles after ingestion of the 
standardized test meal were not statistically different when evaluated in the same subjects, 
on 2 different days. 
 
Comparison of the biochemical profiles during the postprandial RIST, on day 1 
and day 2 
 
The evaluation of the biochemical profiles during the RIST, on day 1 and day 2, is 
essential to test the reproducibility of the RIST in the fed state.  
 
The RIST is an euglycemic clamp, therefore euglycemia after the exogenous bolus of 
insulin was maintained throughout the test, through a variable rate of exogenous glucose 
infusion. The insulin levels, after the exogenous insulin bolus, reached a peak that returned 
to the baseline value afterwards. The C-peptide levels were maintained during the fed RIST. 
The lactate levels showed a slight increase during the postprandial RIST. The HDL-
cholesterol, LDL-cholesterol, total cholesterol and triglycerides profile was also preserved 
during the fed RIST (Figure 4.2). 
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Figure 4.2 – Biochemical parameters (glycemia, insulin, C-Peptide, lactate, HDL-cholesterol, LDL cholesterol, total 
cholesterol and triglycerides) profiles measured at specific time points during the RIST in the fed state, on day 1 
and day 2, in lean healthy subjects (n=6). Results are means±SEM. One-way ANOVA, followed by the Tukey-
Kramer multiple-comparison test. 
 
Variability of the dynamic profiles and postprandial insulin action of the RIST, on 
day 1 and day 2  
 
Since the usual means of assessing insulin sensitivity required testing in the fasted state, 
it becomes very valuable to develop a new method to estimate the insulin sensitivity in the 
fed state. 
 
The glucose intake profile during the RIST can be estimated from the rate of glucose 
infusion required to maintain the euglycemia during the RIST. The quantification of the total 
amount of glucose (mg glucose/kg bw) required to maintain euglycemia after a bolus of 
insulin (50mU/kg bw), that corresponds to the area under the curve, and is called RIST 
index. 
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Below, on Figure 4.3, are represented the mean dynamic curves of postprandial RIST for 
lean healthy subjects in day 1 and day 2. Additionally, the mean characteristics of the 
dynamic curves (action peak magnitude, peak time and action curve duration) are shown on 
Table V. 
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Figure 4.3 – Comparison of the RIST profiles on the fed state in day 1 and day 2. Mean profile using the dynamic 
analysis of the pattern of glucose infusion during the Rapid Insulin Sensitivity Test (RIST). The mean RIST curves 
were obtained by averaging glucose infusion rates at 0.1min intervals throughout the test. Fed RIST Day 1 (simple 
line) and the RIST obtained in the fed state on day 2 (bold line), n=6. 
 
As shown in Figure 4.3, the dynamic profiles for the postprandial RIST in day 1 and day 2 
were practically superimposed, which shows that the RIST in the postprandial state can be 
reproduced. This allows us to proceed with pharmacological manipulation, as it will be shown 
in chapter 5. 
 
Table V - Comparison of the RIST dynamic curve main properties on the fed state in day 1 and day 2, n=6. Values 
are means±SEM. Paired t-test. 
 
 Peak (mg glucose/kg/min) 13.30.6
 
Fed RIST Day 1 Peak time (min) 25.91.6
 
 Duration (min) 94.9  6.8
 
 Peak (mg glucose/kg/min) 12.21.1
 
Fed RIST Day 2 Peak time (min) 37.57.5
 
 Duration (min) 97.04.7
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The results aforementioned can be further analyzed by calculating the area under each 
dynamic curve. That parameter is called RIST index, and the RIST indexes obtained from the 
fed day 1 and fed day 2 dynamic curves, are presented bellow, on Figure 4.4. The RIST 
index obtained in the fed state, on both day 1 and day 2, showed similar values (700.374.6 
vs 672.662.1mg glucose/kg bw). 
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Figure 4.4 - Each volunteer was submitted to the RIST, but at 2 different days, in the fed state. The results 
obtained showed that there is a variability which is negligible between days, indicating that the RIST in the fed state 
is reproducible, in lean healthy humans, n=6. Results are means±SEM. Paired t-test. 
 
4.3.2. Assessment of the RIST implementation, in lean healthy subjects 
 
Since the reproducibility of the RIST in the postprandial state was appraised, the 
subsequent step was to implement the RIST as a means of demonstrating the dynamic 
action of insulin and meal-induced insulin sensitization (MIS). The subjects were analyzed in 
the 24h fasted and postprandial states, in the same day. 
 
Lean healthy male subjects (aged 27.71.7 years, BMI 24.60.4 kg/m2, n=3) admitted 
into this protocol had normal systolic (119.74.7mmHg) and diastolic blood pressure 
(65.34.7mmHg). 
Basal fasting glucose levels were 75.31.8mg/dl and glucose levels measured 100min 
after the meal were 91.01.0mg/dl (p<0.05). 
Table VI shows the fasting and postprandial levels of the biochemical parameters 
analyzed, in lean healthy subjects. 
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Table VI - Basal values of glycemia, insulin, C-Peptide, lactate, HDL-cholesterol, LDL-cholesterol, total cholesterol 
and triglycerides of the lean healthy subjects, in the fasted and fed state (n=3). Values are means±SEM. *=p<0.05 
and **=p<0.01 between fasted and fed state. Paired t-test. 
 
Prandial 
State 
Glycemia 
(mg/dl) 
 
Insulin 
(IU/ml) 
C-Peptide 
(ng/ml) 
Lactate 
(mg/dl) 
HDL- 
Cholesterol 
(mg/dl) 
LDL- 
Cholesterol 
(mg/dl) 
Total  
Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl) 
 
Fasted 
 
75.31.8* 5.30.4** 1.70.3** 10.30.2** 58.62.6 57.91.7** 158.84.7 67.224.7 
 
Fed 
 
100.710.0* 32.911.1** 7.60.6** 11.40.1** 55.51.9 52.31.9** 149.34.5 59.210.9 
 
Comparison of the biochemical profiles during the fasted and postprandial RIST 
 
The evaluation of the biochemical profiles during the RIST, at this time, in the fasted and 
fed state was achieved. The biochemical parameters analyzed during the fasted and the fed 
RIST were: glycemia, insulin, C-peptide, lactate, HDL-cholesterol, LDL-cholesterol, total 
cholesterol and triglycerides. 
 
Inasmuch as the RIST was performed in two different prandial states, intrinsic 
dissimilarities were expected. The food ingestion led to higher levels of glucose and to an 
increase of insulin and C-peptide secretion. The lactate levels at the beginning of each RIST 
were similar, and increased with the same profile in both RIST‟s; the lactate levels were 
higher in the fed RIST than in the fasted RIST. The lipid profile, given by the HDL-
cholesterol, LDL-cholesterol, total cholesterol and triglycerides levels, did not evidence 
differences between the fast and fed state (Figure 4.5). 
All the biochemical parameters, except insulin and lactate levels, analyzed during the 
RIST in the fasted and fed state, remained stable in comparison to their basal levels. 
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Figure 4.5 – Biochemical parameters (glycemia, insulin, C-Peptide, lactate, HDL-cholesterol, LDL-cholesterol, total 
cholesterol and triglycerides) profiles measured at specific time points during the RIST in the fasted and fed state, 
in lean healthy subjects (n=3). Results are means±SEM. *=p<0.05, **=p<0.01 and ***=p<0.001 between fasted 
and fed state. One-way ANOVA, followed by the Tukey-Kramer multiple-comparison test. 
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Assessement of the RIST dynamic profiles in different prandial states, in lean 
healthy subjects    
 
A dynamic curve was obtained at the end of each RIST. Below (Figure 4.6) are 
represented the mean dynamic curves calculated for each experimental protocol condition: 
the fasted and fed state. 
 
(A)         (B) 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 – Comparison of the RIST profiles on the 24h-fast (A) and fed state (B). Mean profile using the dynamic 
analysis of the pattern of glucose infusion during the 24h fast and fed Rapid Insulin Sensitivity Test (RIST). The 
mean RIST curves were obtained by averaging glucose infusion rates at 0.1min intervals throughout the test. RIST 
obtained after 24h-fast (simple line) and postprandial RIST (bold line), n=3. 
 
As shown in Figure 4.6, the RIST dynamic curves were different in the 24h-fasted and fed 
group. The action peak magnitude, peak time and action curve duration were higher in the 
postprandial group in comparison with the 24h-fast group. 
On Table VII are detailed the main characteristics of the abovementioned profiles. 
 
Table VII - Comparison of the RIST dynamic curve main properties on the 24h-fast and fed state, n=3. Values are 
means±SEM. *,£,& =p<0.05 between fasted and fed state. Paired t-test. 
 
 Peak (mg glucose/kg/min) 7.3 ± 1.2* 
24h-Fast RIST Peak time (min) 15.9 ± 1.3£ 
 Duration (min) 44.2 ± 5.0& 
 Peak (mg glucose/kg/min) 15.0 ± 0.6* 
Postprandial RIST Peak time (min) 25.0 ± 0.6£ 
 Duration (min) 86.4 ± 8.7& 
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Effect of fasting and feeding on insulin sensitivity, in lean healthy subjects 
 
The representation of the area under the fasted and fed RIST dynamic curves showed in 
Figure 4.6 corresponds to the total amount of glucose infused in each RIST (RIST index). 
After the 24h fasting period, the RIST index was 224.438.9mg glucose/kg bw (n=3). 
After feeding the standardized test meal the RIST index increased to 647.7104.9mg 
glucose/kg bw, p<0.05 (Figure 4.7) which represents an increase of 193.625.8% in insulin 
sensitivity from the fasted to the fed state. 
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Figure 4.7 - Standardized test meal increases insulin sensitivity in healthy volunteers (n=3). Results are 
means±SEM. *=p<0.05. Paired t-test. 
 
4.4. DISCUSSION 
 
The results showed in this chapter describe the rapid insulin sensitivity test (RIST), as a 
new method for quantification of insulin sensitivity both in fasted and fed human subjects, 
providing results in close agreement with data from rats (Latour et al., 2002c; Lautt et al., 
2001; Sadri et al., 2006), cats (Xie et al., 1996c) and mice (Latour et al., 2002a). 
 
Methodological considerations 
 
The RIST in laboratory animals was performed using arterial blood samples. However, in 
humans arterial sampling is not routinely feasible therefore we used a method that is well 
recognized for the standard hyperinsulinemic euglycemic clamp determinations. The 
procedure is based on the principle that heating the forearm results in a thermal-induced 
vasodilatation that essentially bypasses the nutritive capillary bed of the forearm and 
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provides venous blood from which significant amounts of glucose have not been extracted 
(Nauck et al., 1992)23.  
 
Biochemical profiles before and during the fasted and fed RIST 
 
The RIST just started when stable glucose concentrations were obtained. This glucose 
value is the euglycemic target to be maintained during the RIST. Since the RIST is an 
euglycemic clamp, the euglycemia after a bolus of insulin should be kept during the test, by 
a variable rate of glucose infusion. This is the major parameter to take in account to perform 
the RIST. If the euglycemia is not achieved during the RIST, the test can not be considered 
reliable. The accurancy and precison of the RIST should not be higher than 5%, otherwise 
the entire test is determined to be invalid and is discard. 
After the exogenous insulin bolus of 50mU/kg bw, the insulinemia peaked in a similar way 
both in the fasted and fed state, coming back to initial basal level. However, the fasted and 
fed insulin profiles were not superimposed, since the way that the insulin levels declined was 
different. The C-peptide levels, that indicate how endogenous insulin is secreted, were 
maintained during the fasted and fed RIST and were higher in the fed than in the fasted 
state. More studies need to be performed in order to ascertain if some factor other than the 
direct effect of insulin must account for the sensitized glucose disposal response to insulin 
after the standardized test meal (Figure 4.5 and Figure 4.7). 
Lactate levels were higher during the fed than in the fasted RIST and showed a slight 
increase during both fasted and postprandial RIST. Although lactate is usually seen as a 
metabolic by-product that serves as a substrate for gluconeogenesis, lactate has an 
important role in modulating insulin sensitivity (Choi et al., 2002). Basal lactate levels are 
elevated in patients with glucose intolerance (Consoli et al., 1992), high lactate levels 
reduce glucose uptake by skeletal muscle (Choi et al., 2002; Lombardi et al., 1999) and 
mRNA of GLUT4 glucose transporters (Lombardi et al., 1999). Lactate infusion in the artery 
induces an increase in pancreatic secretion of insulin (Federspil et al., 1980), which is 
consistent with the hyperinsulinemia observed in situations of insulin resistance. 
Since the lactate levels were similar and stable before starting the fasted and fed RIST, it 
seems that the exogenous insulin bolus infusion (transitory hyperinsulinemia) was the 
stimulus for the lactate output from skeletal muscle. The results are in agreement with the 
                                         
 
23 Our preliminary data showed that before heating the forearm, pO2 was 34.00.8mmHg and increased to 
85.21.9mmHg after heating the forearm (Patarrão et al., unpublished observations). 
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observations from Consoli et al., where the researchers showed that the skeletal muscle is a 
major site of lactate uptake and release during hyperinsulinemia  (Consoli et al., 1992). 
In these lean healthy subjects, the lipid profile, given by HDL-cholesterol, LDL-
cholesterol, total cholesterol and triglycerides profile, was preserved during both fasted and 
fed RIST. 
 
The RIST versus other methods to evaluate insulin sensitivity 
 
Comparing the RIST with other insulin sensitivity techniques, the RIST has a shorter time 
duration. In the fasted state, the glucose infusion required to maintain baseline euglycemia 
after insulin administration (50mU/kg bw) reached a peak after 15.91.3min and the 
response was completed after 44.25.0min (Table VII); in the fed state, the glucose infusion 
required after insulin administration reached a peak after 25.91.6, 37.57.5 or 25.00.6min 
and the response was completed after 94.96.8, 97.04.7 or 86.48.7min, as shown in 
Table V and Table VII, respectively. 
All of the other currently used methods evaluate insulin sensitivity only in the fasted state 
at the time when physiological insulin sensitivity would be expected to be at its lowest level. 
This study confirms that the RIST is an effective tool to quantify human whole-body insulin 
sensitivity in both fasted and fed state. The RIST could be performed in the fed state and 
can be reproduced on two different days, having the same results. On the other hand, more 
than one RIST could be performed in the same subject and on the same day, allowing us to 
design paired experiments, such as the comparison of the degree of insulin sensitivity in the 
fasted and fed state (Figure 4.7). 
Since the RIST involves maintaining arterial euglycemia throughout the entire test period, 
it does not cause an uncomfortable situation, because the subjects were not subjected to 
hypoglycemia and there is no counter-regulatory response, providing an advantage over the 
insulin tolerance test (ITT) (Gelding et al., 1994; Hirst et al., 1993). 
Although the hyperinsulinemic euglycemic clamp (HIEC) is currently considered the “gold 
standard” technique used to evaluate insulin sensitivity, it is non-physiological since high 
insulin levels are not usually sustained for long periods after a meal (Clark et al., 2003). 
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Insulin delivery pattern and the RIST 
 
Insulin is secreted in discrete secretory bursts at 4min intervals with regulation 
accomplished through modulation of burst size (Song et al., 2000). As a result, hepatocytes 
(directly exposed to portal venous blood in hepatic sinusoids) are exposed to an insulin 
concentration wavefront with oscillations of 29–72IU/ml in the fasting state and increasing 
to 144–720IU/ml after meal ingestion (Porksen et al., 1996; Song et al., 2000). Regulation 
of insulin delivery to extrahepatic tissues depends on both the rate of insulin secretion and 
the extent of hepatic insulin clearance (Meier et al., 2005). In addition to minute-by minute 
regulation of insulin secretion, pancreatic -cells also adapt over a longer period to overall 
demand. 
Increased actions of insulin on muscle, adipose and liver tissues have been reported when 
the hormone is delivered in a pulsatile versus a constant manner; thus indicates a possible 
role for the insulin release pattern in the modulation of insulin action at circumstances with 
special needs, in terms of glucose homeostasis (Juhl et al., 2002). The prolonged insulin 
infusion causes suppression of hepatic glucose production and endogenous insulin release 
(DeFronzo et al., 1979). With the HIEC, a steady-state glucose level cannot be maintained 
at a constant glucose infusion rate using constant insulin infusion over a 3h period (Bergman 
et al., 1985; Doberne et al., 1981). Furthermore, it is stated that hyperinsulinemia reduces 
the cardiac vagal tone, suggesting that the prolonged infusion of insulin that occurs during 
the HIEC may also inhibit the hepatic branch of the vagus (Van De Borne et al., 1999), 
resulting in insulin resistance mechanisms. 
 
The current study suggests that the RIST provides a new powerful tool to characterize 
insulin action not only in the fasted, but also in the fed state, in the same day at the same 
human subject, with reproducible results. With the RIST, the same subject can be submitted 
to the test at two different days, in the same prandial state, having no differences between 
days. Therefore, with the RIST one can design paired experiments, allowing us to proceed 
with pharmacological manipulations. 
In the future, the RIST can be used in clinical practice and may provide a mean to detect 
the prediabetic state. At this stage, early insulin resistance can be detected well before the 
impairment of the direct effect of insulin, at a time when lifestyle interventions can be 
readily tested. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. THE HISS IN LEAN 
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5. THE HISS IN LEAN HEALTHY HUMANS 
 
5.1. INTRODUCTION AND AIMS 
 
The published observations made in animals, suggest that the dynamic response to 
insulin is approximately doubled following a meal. This phenomenon of meal-induced insulin 
sensitization (MIS) and the signalling systems that regulate MIS have been demonstrated in 
rats (Lautt et al., 2001; Sadri et al., 2006). Administration of a mixed meal to rats, either by 
voluntary consumption of solid rat chow (Latour et al., 2002c), or by intragastric injection 
(Sadri et al., 2006) results in an approximate doubling of the dynamic glucose disposal in 
response to insulin. The MIS phenomenon is explained by the HISS (Hepatic Insulin 
Sensitizing Substance) hypothesis. HISS is suggested to be released from the liver in 
response to pulses of insulin. In rats and dogs, denervation of the liver or atropine 
administration results in insulin resistance that is not dependent upon altered glucose 
uptake of the splanchnic system, including the liver, but is a defect occurring, mostly, in 
skeletal muscle (Moore et al., 2002; Xie et al., 1996b). Thus, HISS acts in skeletal muscle, 
but not liver or intestine, to stimulate glucose uptake (Xie et al., 1996b). 
It has been suggested that the absence of HISS release following a meal, indicating a 
state of HISS-dependent insulin resistance (HDIR), represents a prediabetic state that 
accounts for postprandial hyperglycemia and compensatory hyperinsulinemia (Lautt, 2007). 
In rats, HISS release occurs only in the fed state and accounts for approximately 55% of the 
glucose disposal response to insulin. In conscious and anaesthetized rats, HISS-dependent 
component of insulin action decreases progressively to insignificance by 24h of fasting 
(Latour et al., 2002c; Lautt et al., 2001). 
Consistent with the parasympathetic permissive feeding signal, hepatic denervation 
impaired the development of HISS action in response to a meal (Sadri et al., 2006). The MIS 
process is abolished by the administration of atropine so that the RIST index in fed animals 
after atropine is similar to the RIST index determined in the fasted state (Sadri et al., 2006). 
The central objective of study described in this chapter was to test the hypothesis that, in 
lean healthy humans, the ingestion of a mixed meal results in significant insulin sensitization 
(MIS). Furthermore, this MIS is inhibited using a cholinergic antagonist, atropine. This study 
shows, for the first time, the physiological relevance of the HISS-dependent mechanism for 
overall insulin action in humans. 
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5.2. PROTOCOLS 
 
5.2.1. Evaluation of the dynamic response to insulin in the fasted and fed states, 
in lean healthy subjects 
 
In these experiments, the main goal was to compare the dynamic response to insulin in 
the fasted and fed states. 
Therefore, each lean healthy subject was tested on the same day in the fasted and fed 
state. 
Shortly, a first RIST was performed after a 24h fasting period. The subject was then fed a 
standardized test meal and 100min afterwards, a second RIST was performed (in the fed 
state). The detailed experimental protocol is described in chapter 3, section 3.3.1 and 
3.3.1.2.  
 
5.2.2. Effect of atropine administration on insulin sensitivity, in lean healthy 
subjects 
 
The major objective in these experiments was to evaluate the effect of atropine infusion 
on HISS action.  
Thereby, each lean healthy subject was tested on two different days in a double-blinded 
protocol. 
Summarily, after a 14h fasting period, the subject fed a standardized test meal and 
intravenous infusions over 10min of either atropine (0.5 or 0.75mg) or saline (control group) 
were administrated 50min after feeding the meal and 50min before starting the fed RIST. 
The detailed experimental protocol is described in chapter 3, section 3.3.1 and 3.3.1.3.  
 
5.3. RESULTS 
 
Lean healthy male subjects (aged 27.01.9 years, BMI 22.71.1 kg/m2, n=7) admitted 
into this protocol had normal systolic (117.13.8mmHg) and diastolic blood pressure 
(63.62.9mmHg). 
Basal fasting glucose levels were 72.91.8mg/dl and glucose levels measured 100min 
after the meal increased to 104.85.1mg/dl (p<0.001). 
Table VIII shows basal fasting and postprandial levels of the biochemical parameters, of 
the lean healthy subjects. 
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Table VIII – Fasting and postprandial basal values of glycemia, insulin, C-Peptide, lactate, HDL-cholesterol, LDL-
cholesterol, total cholesterol and triglycerides of the lean healthy subjects (n=7). Values are means±SEM. 
***=p<0.001, **=p<0.01 and *=p<0.05 between fasted and fed state. Paired t-test. 
 
 
 
5.3.1. Evaluation of the dynamic response to insulin in the fasted and fed states, 
in lean healthy subjects 
 
5.3.1.1. Comparison of the fasted and fed RIST dynamic profile, in lean healthy 
subjects 
 
Figure 5.1 shows the mean dynamic curves of 24h-fast and fed insulin action for lean 
healthy subjects. The mean dynamic curve for the HISS-dependent component is also 
presented, calculated by subtracting each 24h-fast dynamic curve from the corresponding 
fed dynamic curve (Figure 5.2). Moreover, the main characteristics of the dynamic curves 
(action peak magnitude, peak time, and action curve duration for 24h-fast and postprandial 
curves; and action peak magnitude, peak time, action curve onset and duration for HISS-
dependent component curves) are shown on Table IX. 
 
Prandial 
State 
Glycemia 
(mg/dl) 
 
Insulin 
(IU/ml) 
C-Peptide 
(ng/ml) 
Lactate 
(mg/dl) 
HDL- 
Cholesterol 
(mg/dl) 
LDL-
Cholesterol 
(mg/dl) 
Total 
Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl) 
 
Fasted 
 
72.91.8*** 5.40.6** 1.50.2*** 9.30.5 52.72.9* 76.18.0** 158.66.7* 36.53.8 
Fed 
 
 
104.85.1*** 
 
39.56.4** 9.11.0*** 10.10.7 48.93.7* 68.38.3** 145.810.3* 35.05.5 
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Figure 5.1 - Mean dynamic curves for the Rapid Insulin Sensitivity Test (RIST) performed on 24h-fast (simple line) 
and postprandial (bold line) states, in lean healthy subjects, n=7. The mean dynamic RIST curves were obtained by 
averaging glucose infusion rates at 0.1min intervals throughout the test.  
 
In the postprandial group, all the dynamic parameters (action peak magnitude, peak 
time, and action curve duration) were higher in comparison to the 24h-fast group (Figure 
5.1 and Table IX). 
Based on animal studies, the difference between the 2 curves from Figure 5.1, was 
plotted to show the dynamic action of the HISS-dependent component of insulin action as 
shown in Figure 5.2 and Table IX. 
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Figure 5.2 - Mean dynamic profile curve for the HISS-dependent component of insulin action, calculated from the 
difference between the curves in Figure 5.1, in lean healthy subjects. HISS action began at 6.32.3min after the 
onset of insulin administration, n=7. 
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The mean characteristics of the dynamic profiles of the RISTs obtained both in the fasted 
and in the fed states are summarized in Table IX. 
 
Table IX - Dynamic profile characteristics of the 24h-fast RIST, postprandial RIST and the HISS-dependent 
component of insulin action, n=7. Values are means±SEM. #,§,@,€=p<0.001 between fasted state, fed state and 
HISS-dependent component. $,&,£=p<0.05 between fasted state, fed state and HISS-dependent component. 
Repeated measures ANOVA, followed by the Tukey-Kramer multiple-comparison test. 
 
 Peak (mg glucose/kg/min) 8.0 ± 0.8# 
24h-Fast RIST Peak time (min) 16.1 ± 2.2&,§ 
 Duration (min) 41.9 ± 2.9@,€ 
 Peak (mg glucose/kg/min) 13.3 ± 0.7#,$ 
Postprandial RIST Peak time (min) 28.4 ± 3.0&,£ 
 Duration (min) 90.5 ± 5.0@ 
 Onset (min) 6.3 ± 2.3 
HISS-dependent component Peak (mg glucose/kg/min) 10.4 ± 0.8$ 
 Peak time (min) 40.8 ± 4.7§,£ 
 Duration (min) 90.4 ± 5.0€ 
 
 
5.3.1.2. Effect of fasting and feeding on insulin sensitivity, in lean healthy 
subjects 
 
The area under each dynamic curve, from the results abovementioned (Figure 5.1), 
provides the RIST index for each prandial state. There was a significant increase in the total 
insulin sensitivity after the mixed meal. 
After the 24h fasting period, the RIST index was 215.520.8mg glucose/kg bw (n=7). By 
contrast, the standardized test meal ingestion led to an increase of the RIST index to 
681.260.9mg glucose/kg bw, p<0.001 (Figure 5.3), which represents an increase in 
232.146.3% in insulin sensitivity. 
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Figure 5.3 - Standardized test meal increases insulin sensitivity in lean healthy volunteers (n=7). Results are 
means±SEM. ***=p<0.001. Paired t-test. 
 
If one considers that the 24h-fast induces a complete abolishment of HISS mechanism, 
then the contribution of the HISS-dependent component of total insulin action in the 
postprandial state was 67.53.0%, and the contribution of the HISS-independent component 
to total insulin action was 32.53.0%. 
 
5.3.1.3. Plasma insulin and C-Peptide levels during the fasted and fed RIST, in 
lean healthy subjects 
 
The evaluation of plasma insulin and C-peptide levels during the RIST was done in both 
the fasted and the fed state (n=7). As long as the RIST was performed in the fasted and fed 
state, inherent differences were anticipated. The meal ingestion led to an increase of insulin 
and C-peptide secretion. 
In the fasted state, the basal plasma insulin and C-peptide levels were 5.40.6IU/ml and 
1.50.2ng/ml, respectively. Immediately after the bolus injection of 50mU/kg bw of insulin, 
the plasma insulin levels reached a value of 487.344.0IU/ml and plasma C-peptide levels 
remained stable and not statistically different from basal levels throughout the 24h-fast RIST 
(1.50.2ng/ml); by the end of the fasted RIST (42min), plasma insulin levels had returned 
to basal plasma levels (8.50.9IU/ml). 
Subjects were fed a standardized test meal and 100min after (the time required to 
achieve stable glucose), the basal plasma insulin and C-peptide levels in the fed state were 
39.56.4IU/ml (p<0.01) and 9.11.0ng/ml (p<0.001), respectively. Immediately after the 
bolus injection of 50mU/kg bw of insulin (1min after starting the RIST), insulinemia reached 
a value of 501.630.2IU/ml, that was not statistically different from the peak level obtained 
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in the fasted state (487.344.0IU/ml) and plasma C-peptide levels remained stable and not 
statistically different from basal levels (8.50.9ng/ml, p<0.001). 
Insulin levels in both fed and fasted state had returned to baseline 42min after insulin 
administration (fasted: 8.50.9IU/ml vs fed: 43.85.9IU/ml, p<0.05). At this time 
(42min), plasma C-peptide levels were also stable (fasted: 1.50.2ng/ml vs fed: 
8.81.1ng/ml, p<0.05). 
Although the RIST in the fed state continued until 90min, the insulin levels at 42min had 
already returned to baseline levels and at the end of the postprandial RIST, plasma insulin 
levels were maintained at basal plasma levels (40.55.5IU/ml) and C-peptide levels were 
not altered from fed basal levels (8.91.3ng/ml). 
The plasma insulin and C-peptide profiles for both fasted and fed state are illustrated in 
Figure 5.4 and Figure 5.5, respectively. 
 
 
(A)        (B) 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 - Plasma insulin level profiles obtained before (from -100min to 0min) and during the RIST. The regular 
line represents the insulin level profile obtained for the 24h-fast RIST (A) and the bold line represents the insulin 
level profile obtained for the fed RIST (B). Results are means±SEM, n=7. 
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(A)        (B) 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 - Plasma C-peptide level profiles obtained before (from -100min to 0min) and during the RIST. The 
regular line represents the C-peptide level profile obtained for the 24h-fast RIST (A) and the bold line represents 
the C-peptide level profile obtained for the fed RIST (B). Results are means±SEM, n=7.  
 
Insulin levels were measured when insulin action was completed at the end of the 24h-
fast RIST (42min) and at this same time point at the fed RIST. These values were not 
statistically different from basal levels (24h-Fast RIST – basal: 5.40.6IU/ml vs end of 24h-
fast RIST: 8.50.9IU/ml; Fed RIST – basal: 39.56.4IU/ml vs end of 24h-fast RIST: 
43.85.9 IU/ml). 
 
5.3.2. Effect of atropine administration on insulin sensitivity, in lean healthy 
subjects 
 
The lean healthy male subjects (aged 29.71.5 years, BMI 23.90.6 kg/m2) admitted into 
this protocol had normal systolic (115.52.3mmHg, n=10) and diastolic blood pressure 
(61.72.0mmHg, n=10).  
Table X shows basal control and atropine 0.5 (n=6) and 0.75mg (n=4) fed levels of the 
biochemical parameters, of the lean healthy subjects. 
 
 
 
 
 
 
-20 -10 0 10 20 30 40 50 60 70 80
2
4
6
8
10
12
14
16
C-Peptide Profile 24h-Fast
RIST
Time (min)
C
-
P
e
p
ti
e
 L
e
v
e
ls
(
n
g
/
m
l)
-100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80
2
4
6
8
10
12
14
16
C-Peptide Profile Fed
RIST
Standardized
test meal
Time (min)
C
-P
e
p
ti
e
 L
e
v
e
ls
(
n
g
/
m
l)
Chapter 5  The HISS in lean healthy subjects 
  PhD Thesis, Rita S. Patarrão 
139 
 
Table X - Basal values of glycemia, insulin, C-peptide, lactate, HDL-cholesterol, LDL-cholesterol, total cholesterol 
and triglycerides values of the lean healthy subjects, in the control fed, atropine 0.5 (n=6) and 0.75mg (n=4) fed 
state. Values are means±SEM. *=p<0.05 between control postprandial and atropine 0.5mg and control postprandial 
and atropine 0.75mg. Paired t-test. 
 
 
Glycemia 
(mg/dl) 
 
Insulin 
(IU/ml) 
C-Peptide 
(ng/ml) 
Lactate 
(mg/dl) 
HDL- 
Cholesterol 
(mg/dl) 
LDL- 
Cholesterol 
(mg/dl) 
Total 
Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl) 
Control 
Postprandial 
(n=6) 
101.13.1 28.72.7 8.61.1* 8.70.6 46.63.1 83.53.4 136.93.4 55.77.9* 
Atropine 0.5mg 
Postprandial 
(n=6) 
 
94.05.7 
 
21.23.8 4.70.6* 7.50.6 48.13.4 75.95.5 131.44.4 37.63.8* 
Control 
Postprandial 
(n=4) 
101.94.9* 30.53.9*
 
7.31.5
 
9.10.9 50.62.0 82.92.6 143.53.9 52.613.1 
Atropine 0.75mg 
Postprandial 
(n=4) 
78.32.7* 14.21.6*
 
4.70.6
 
11.51.8 
 
52.53.6 
 
 
92.55.0 
 
 
170.08.1 
 
48.29.6 
 
5.3.2.1. Biochemical profiles after feeding the standardized test meal, on control 
fed and atropine 0.5 and 0.75mg fed groups 
 
The evaluation of the biochemical profiles, obtained after ingestion of the standardized 
test meal (t=0min), was performed in the control fed and atropine 0.5 and 0.75mg fed 
groups (Figure 5.6). 
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Figure 5.6 – Biochemical parameters (glycemia, insulin, C-Peptide, lactate, HDL-cholesterol, LDL-cholesterol, total 
cholesterol and triglycerides) profiles measured at specific time points during 100min after ingestion of the 
standardized test meal (0min) and before performing the RIST in the fed state (100min), on control fed and 
atropine 0.5mg (n=6) and 0.75mg (n=4) fed groups, in lean healthy subjects. Results are means±SEM. *=p<0.05 
and ***=p<0.001 between control fed and atropine 0.5 or 0.75mg fed state. One-way ANOVA, followed by the 
Tukey-Kramer multiple-comparison test. 
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As shown in Figure 5.6, the infusion of saline (control fed) versus infusion of atropine 
0.5mg and atropine 0.75mg after ingestion of the standardized test meal, only the atropine 
dose of 0.75mg altered the lactate profile. Nonetheless, 100min after the food ingestion all 
the levels returned to their basal levels. 
 
5.3.2.2. Comparison of the control fed and atropine 0.5mg fed RIST dynamic 
profiles, in lean healthy subjects 
 
The mean dynamic profiles of total postprandial insulin action as well as the dynamic 
profiles obtained after atropine 0.5mg administration are shown below, in Figure 5.7. The 
mean dynamic curve for the HISS-dependent component is also presented, calculated by 
subtracting each atropine 0.5mg dynamic curve from the corresponding control fed dynamic 
curve (Figure 5.8). 
Additionally, the main characteristics of the dynamic curves (action peak magnitude, peak 
time, and action curve duration for postprandial and atropine 0.5mg postprandial curves; 
and action peak magnitude, peak time, action curve onset and duration for HISS-dependent 
component curves) are shown in Table XI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 – Effect of saline (control) and atropine 0.5mg on postprandial RIST profiles. Mean dynamic curves for 
the Rapid Insulin Sensitivity Test (RIST) performed on control fed (bold line) and post-atropine 0.5mg fed (simple 
line) conditions, in lean healthy subjects, n=6. The mean RIST curves were obtained by averaging glucose infusion 
rates at 0.1min intervals throughout the test. 
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In the post-atropine 0.5mg group, all the dynamic parameters (action peak magnitude, 
peak time, and action curve duration) were lower in comparison to the postprandial group. 
This was due to the inhibition of the HISS-dependent component (Figure 5.7 and Table XI). 
Assuming that atropine 0.5mg abolished HISS action, the difference between the 2 
curves from Figure 5.7, was plotted to show the dynamic action of the HISS-dependent 
component of insulin action (Figure 5.8 and Table XI). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 - Mean dynamic profile curve for the HISS-dependent component of insulin action calculated from the 
difference between the curves in Figure 5.7, in lean healthy subjects after atropine 0.5mg administration. HISS 
action begins at 20.04.8min after the onset of insulin administration, n=6. 
 
 
The characteristics of the dynamic profiles of the RISTs obtained, in lean healthy subjects, 
both in the fed state and after atropine 0.5mg infusion are summarized in Table XI. 
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Table XI - Dynamic profile characteristics for the control postprandial RIST, atropine 0.5mg postprandial and the 
HISS-dependent component of insulin action, in lean healthy subjects (n=6). Values are means±SEM. $,#=p<0.05 
between control fed state, atropine 0.5mg postprandial state and HISS-dependent component.€,£,&=p<0.01 between 
control fed state, atropine 0.5mg postprandial state and HISS-dependent component. Repeated measures ANOVA, 
followed by the Tukey-Kramer multiple-comparison test. 
 
 Peak (mg glucose/kg/min) 11.2 ± 0.8€ 
Control Postprandial RIST Peak time (min) 37.5 ± 7.1 
 Duration (min) 95.6 ± 5.4£ 
 Peak (mg glucose/kg/min) 9.5± 0.9$ 
Atropine 0.5mg Postprandial RIST Peak time (min) 26.7 ± 2.0# 
 Duration (min) 73.5 ± 6.9£,& 
 Onset (min) 20.0 ± 4.8 
HISS-dependent component Peak (mg glucose/kg/min) 6.8 ± 0.9€,$ 
 Peak time (min) 61.0 ± 8.5# 
 Duration (min) 95.9 ± 5.3& 
 
5.3.2.3. Effect of atropine 0.5mg infusion on insulin sensitivity, in lean healthy 
subjects 
 
The glucose uptake induced by the insulin action after blocking the HISS pathway, with 
atropine, corresponds to the HISS-independent insulin sensitivity. 
The total postprandial insulin sensitivity was significantly decreased after atropine 0.5mg 
infusion. Therefore, the atropine 0.5mg dose was able to induce inhibition of HISS action. 
These results, which are consistent with animal data, showed that atropine blocks MIS by 
blocking HISS release. 
In the control fed group (after saline infusion), the RIST index was 627.483.9mg 
glucose/kg bw (n=6). In the atropine 0.5mg group, the RIST index decreased to 
395.164.3mg glucose/kg bw (p<0.01) (Figure 5.9). 
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Figure 5.9 - Atropine 0.5mg decreased postprandial insulin sensitivity in lean healthy subjects (n=6). Results are 
means±SEM. *=p<0.05. Paired t-test. 
 
These results represent a partial inhibition of HISS release induced by atropine 0.5mg of 
approximately 56.511.6%, based on the assumption that full HISS blockade would result in 
a similar RIST index to the 24h fasting level from fasted and fed lean healthy subjects 
protocol. 
 
5.3.2.4. Comparison of the control fed and atropine 0.75mg fed RIST dynamic 
profiles, in lean healthy subjects 
 
Figure 5.10 shows the mean dynamic profiles of total postprandial insulin action as well 
as the dynamic profiles obtained after atropine 0.75mg administration. Further, the mean 
dynamic curve for the HISS-dependent component is also presented, calculated by 
subtracting each atropine 0.75mg dynamic curve from the corresponding control fed 
dynamic curve (Figure 5.11). 
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Figure 5.10 – Effect of saline (control) and atropine 0.75mg on postprandial RIST profiles. Mean dynamic curves 
for the Rapid Insulin Sensitivity Test (RIST) performed on control fed (bold line) and post-atropine 0.75mg fed 
(simple line) conditions, in lean healthy subjects, n=4. The mean RIST curves were obtained by averaging glucose 
infusion rates at 0.1min intervals throughout the test. 
 
In addition, the main characteristics of the dynamic curves (action peak magnitude, peak 
time, and action curve duration for postprandial and atropine 0.75mg postprandial curves; 
and action peak magnitude, peak time, action curve onset and duration for HISS-dependent 
component curves) are shown on Table XII. 
 
As seen previously in section 5.3.2.2. for the post-atropine 0.5mg group, in the post-
atropine 0.75mg group all the dynamic parameters (action peak magnitude, peak time, and 
action curve duration) were lower in comparison to the postprandial group. However, the 
main difference between the 2 dynamic profiles was the action curve duration that was lower 
in the atropine 0.75mg fed group (Figure 5.10 and Table XII). 
Assuming that atropine 0.75mg abolished HISS action, the difference between the 2 
curves from Figure 5.10, was plotted to show the dynamic action of the HISS-dependent 
component of insulin action (Figure 5.11 and Table XII). 
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Figure 5.11 – Mean dynamic profile curve for the HISS-dependent component of insulin action calculated from the 
difference between the curves in Figure 5.10, in lean healthy subjects after atropine 0.75mg administration. HISS 
action begins at 22.67.0min after the onset of insulin administration, n=4. 
 
The characteristics of the dynamic profiles of the RISTs obtained, in lean healthy subjects, 
both in the fed state and after atropine 0.75mg infusion are summarized in Table XII. 
 
Table XII - Dynamic profile characteristics for the control postprandial RIST, atropine 0.75mg postprandial and the 
HISS-dependent component of insulin action, in lean healthy subjects (n=4). Values are means±SEM. £,§=p<0.001 
between control fed state, atropine 0.75mg postprandial state and HISS-dependent component. $=p<0.05 between 
control fed state, atropine 0.75mg postprandial state and HISS-dependent component. Repeated measures ANOVA, 
followed by the Tukey-Kramer multiple-comparison test. 
 
 Peak (mg glucose/kg/min) 11.8 ± 1.3 
Control Postprandial RIST Peak time (min) 27.2 ± 3.2$ 
 Duration (min) 103.5± 5.8£ 
 Peak (mg glucose/kg/min) 9.3± 1.3 
Atropine 0.75mg Postprandial RIST Peak time (min) 30.3 ± 3.8 
 Duration (min) 65.9 ± 9.4£,§ 
 Onset (min) 22.6 ± 7.0 
HISS-dependent component Peak (mg glucose/kg/min) 7.5 ± 1.3 
 Peak time (min) 57.7 ± 11.8$ 
 Duration (min) 103.3 ± 5.7§ 
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5.3.2.5. Effect of atropine 0.75mg infusion, on insulin sensitivity, in lean healthy 
subjects 
 
In this section, the effect of atropine 0.75mg infusion (in the fed state) on insulin 
sensitivity is presented. Since the atropine 0.5mg dosage was already tested in terms of 
insulin sensitivity, the following aim of this study was to analyze if a higher dose of atropine 
(0.75mg) is able to decrease even more the total postprandial insulin sensitivity in 
comparison to the atropine 0.5mg infusion results, due to the atropine-induced inhibition of 
HISS release/action.  
In the control fed group (after saline infusion), the RIST index was 669.490.0mg 
glucose/kg bw (n=4). In the atropine 0.75mg group, the RIST index decreased to 
378.8107.1mg glucose/kg bw (p<0.05) (Figure 5.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 - Atropine 0.75mg decreased postprandial insulin sensitivity in lean healthy subjects (n=4). Results 
are means±SEM. *=p<0.05. Paired t-test. 
 
These results represent a partial inhibition of HISS release induced by atropine 0.75mg of 
approximately 68.521.9%, based on the assumption that full HISS blockade would result in 
a similar RIST index to the 24h fasting level from fasted and fed healthy lean protocol. The 
atropine 0.5mg dose only induced an inhibition of HISS release of 56.511.6% and with a 
dose increase, the percentage of inhibition of insulin sensitivity also increased (Figure 5.13). 
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Figure 5.13 - Insulin sensitivity decreases after atropine 0.5mg infusion of 56.511.6% (n=6) and after atropine 
0.75mg of 68.521.9% (n=4), in lean healthy volunteers. Results are means±SEM. Unpaired t-test. 
 
5.3.2.6. Effect of atropine 0.5mg on plasma insulin and C-Peptide levels after 
feeding the standardized test meal and during the fed RIST, in lean healthy 
subjects 
 
Since it is well described that atropine infusion affects endogenous insulin secretion (Teff 
et al., 1999b), the assessment of plasma insulin and C-peptide levels was done in both the 
control fed state and after atropine 0.5mg infusion (n=6). 
The insulin and C-peptide levels determined 100min after the standardized test meal and 
50min after either control saline or atropine 0.5mg infusion were: insulin levels - 28.72.7 
and 21.23.8IU/ml, respectively and C-peptide levels - 8.61.1 and 4.70.6ng/ml 
(p<0.01), respectively.  
The administration of atropine 0.5mg significantly decreased postprandial plasma insulin 
and C-peptide levels, during the meal absorption. The mean area under the curve (AUC) for 
insulin measured from 60 to 100min postingestion decreased from 1316114.4 for control 
fed to 768.1150.6IU/ml/40min for post-atropine 0.5mg fed, p<0.05 (Figure 5.14, left 
insert). 
AUCs for C-peptide were also significantly reduced from 60 to 100min postingestion 
(341.033.5 to 202.625.7ng/ml/40min for control fed and post-atropine 0.5mg fed, 
respectively, p<0.01) (Figure 5.15 , left insert). 
However, the molar ratio of C-peptide to insulin after the standardized test meal was not 
significantly different between the control fed and atropine 0.5mg fed groups (0.2660.026 
and 0.3010.052, respectively), suggesting that hepatic extraction of insulin was not 
different between the two groups. 
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Moreover, 1min after the exogenous insulin bolus, the insulin levels increased to similar 
concentration and the C-peptide levels did not differ from basal plasma levels in both groups 
(666.681.2IU/ml and 8.41.2ng/ml in the control fed group and 583.664.8IU/ml and 
5.60.9ng/ml in the post-atropine 0.5mg group). 
At the end of the control fed RIST and the post-atropine 0.5mg RIST, plasma insulin 
levels returned to basal plasma levels (control fed RIST: 38.35.3IU/ml; post-atropine 
0.5mg RIST: 27.24.2IU/ml) and the C-peptide levels did not change from basal plasma 
levels (control fed RIST: 7.60.8ng/ml; post-atropine 0.5mg RIST: 5.80.9ng/ml). 
The effect of atropine 0.5mg during the fed RIST did not alter the insulin and C-peptide 
AUCs in the control fed and atropine 0.5mg fed RIST. The mean AUC for insulin measured 
during the control fed and atropine 0.5mg fed RIST was similar (5431572.4 and 
5260451.7IU/ml, respectively) (Figure 5.14, right insert). AUCs for C-peptide were not 
altered during the control fed and atropine 0.5mg fed RIST (80.324.5 and 82.527.9ng/ml, 
respectively) (Figure 5.15, right insert).  
The molar ratio of C-peptide to insulin during the RIST was not significantly different 
between the control fed and atropine 0.5mg fed groups (0.0140.004 to 0.0160.005), 
suggesting that hepatic extraction of insulin was not different during the control fed and 
atropine 0.5mg RIST. 
During the RIST, the insulin concentration profiles were super-imposable and not 
significantly different at any time point (Figure 5.14). The plasma C-peptide profiles for both 
the control fed state and after atropine 0.5mg are represented in Figure 5.15. 
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Figure 5.14 - Plasma insulin level profiles obtained after standardized test meal, atropine 0.5mg infusion and 
during the RIST. The regular line represents the insulin level profile obtained for the control fed RIST and the bold 
line represents the insulin level profile obtained for the post-atropine 0.5mg RIST. Results are means±SEM, n=6. 
One-way ANOVA, followed by the Tukey-Kramer multiple-comparison test. Left insert: Insulin area under the curve 
(AUC) calculated by the trapezoid rule for the 60 to 100min after saline (Control Fed) or atropine 0.5mg (Atropine 
0.5mg Fed) infusion and before starting the fed RIST. Intravenous infusions over 10min of either atropine 0.5mg or 
saline were administrated 50min after feeding the meal and 50min before starting the fed RIST. Right insert: 
Insulin area under the curve (AUC) calculated by the trapezoid rule for Control Fed and Atropine 0.5mg Fed RIST. 
Results are means±SEM, n=6. *=p<0.05. Paired t-test. 
 
 
 
 
 
 
 
 
-100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80
50
100
150
200
250
300
350
400
450
500
550
600
650
700
750
800
850
Standardized test
meal
Insulin Profile Atropine 0.5mg Fed
Insulin Profile Control Fed
RIST
Atropine 0.5mg
infusion
Time (min)
I
n
s
u
li
n
 L
e
v
e
ls
(

I
U
/
m
l)
Control Fed Atropine 0.5mg Fed
0
500
1000
1500
2000
*
I
n
s
u
li
n
A
U
C
6
0
-1
0
0
m
in
(

I
U
/
m
l/
4
0
m
in
)
Control Fed Atropine 0.5mg
0
1000
2000
3000
4000
5000
6000
7000
I
n
s
u
li
n
A
U
C
 R
I
S
T
(

I
U
/
m
l)
Chapter 5  The HISS in lean healthy subjects 
  PhD Thesis, Rita S. Patarrão 
152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 - Plasma C-peptide level profiles obtained after standardized test meal, atropine 0.5mg infusion and 
during the RIST. The regular line represents the C-peptide level profile obtained for the control fed RIST and the 
bold line represents the C-peptide level profile obtained for the post-atropine 0.5mg RIST. Results are means±SEM, 
n=6. One-way ANOVA, followed by the Tukey-Kramer multiple-comparison test. Left insert: C-peptide area under 
the curve (AUC) calculated by the trapezoid rule for the 60 to 100min after saline (Control Fed) or atropine 0.5mg 
(Atropine 0.5mg Fed) infusion and before starting the fed RIST. Intravenous infusions over 10min of either atropine 
0.5mg or saline were administrated 50min after feeding the meal and 50min before starting the fed RIST. Right 
insert: C-peptide area under the curve (AUC) calculated by the trapezoid rule for Control Fed and Atropine 0.5mg 
Fed RIST. Results are means±SEM, n=6. **=p<0.01. Paired t-test. 
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5.3.2.7. Effect of atropine 0.75mg on plasma insulin and C-Peptide levels after 
feeding the standardized test meal and during the fed RIST, in lean healthy 
subjects 
 
As previously described for the atropine 0.5mg dose and with the purpose to estimate the 
atropine‟s effect on insulin secretion, the assessment of plasma insulin and C-peptide levels 
were done in both the control fed state and after atropine 0.75mg infusion (n=4).  
The insulin and C-peptide levels determined 100min after the standardized test meal and 
50min after either atropine 0.75mg or control saline administration, that is, before starting 
the postprandial RIST were: insulin levels - 30.53.9 and 14.21.6IU/ml, respectively and 
C-peptide levels - 7.31.5 and 4.70.6ng/ml, respectively.  
As previously stated for the atropine 0.5mg dose, the administration of atropine 0.75mg 
also significantly decreased postprandial plasma insulin and C-peptide levels, during the 
meal absorption. The mean AUC for insulin measured from 60 to 100min postingestion 
decreased from 1401185.9 for control fed to 746.957.2IU/ml/40min for post-atropine 
0.75mg fed, p<0.05 (Figure 5.16, left insert). 
The C-peptide AUC for the atropine 0.75mg fed group was not found to be statistically 
different from the C-peptide AUC for the control fed group from 60 to 100min postingestion, 
although there was a trend toward an attenuation (319.549.0 to 233.328.9ng/ml/40min 
for control fed and post-atropine 0.75mg fed, respectively) (Figure 5.17, left insert). 
However, the molar ratio of C-peptide to insulin after the standardized test meal was not 
significantly different between the control fed and atropine 0.75mg fed groups (0.2380.040 
to 0.2820.016), suggesting that hepatic extraction of insulin was again not different 
between the two groups. 
Additionally, 1min after the exogenous insulin bolus, insulin levels spiked to similar 
concentration and C-peptide levels did not alter from the basal plasma levels in both groups 
(738.285.2IU/ml and 7.91.7ng/ml in the control fed group, and 673.769.2IU/ml and 
4.60.4ng/ml in the post-atropine 0.75mg group). 
At the end of the control fed and the post-atropine RIST, plasma insulin levels returned to 
basal plasma levels (control fed RIST: 37.65.5IU/ml; post-atropine 0.75mg RIST: 
22.01.7IU/ml) and C-peptide levels did not change from basal plasma levels (control fed 
RIST: 6.81.2ng/ml; post-atropine 0.75mg RIST: 3.90.5ng/ml). 
The effect of atropine 0.75mg during the fed RIST did not alter the insulin and C-peptide 
AUCs in the control fed and atropine 0.75mg fed RIST. The mean AUC for insulin measured 
during the control fed and atropine 0.75mg fed RIST was similar (5404681.9 and 
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4736596.9IU/ml, respectively) (Figure 5.16, right insert). AUCs for C-peptide were not 
altered during the control fed and atropine 0.75mg fed RIST (46.014.0 and 44.47.3ng/ml, 
respectively) (Figure 5.17, right insert). 
The molar ratio of C-peptide to insulin during the RIST was not significantly different 
between the control fed and atropine 0.75mg fed groups (0.0080.002 to 0.0100.002), 
suggesting that hepatic extraction of insulin was not different during the control fed and 
atropine 0.75mg RIST. 
During the RIST, the insulin concentration profiles were super-imposable and not 
significantly different at any time point (Figure 5.16). The plasma C-peptide profile for both 
the control fed state and after atropine 0.75mg is represented in Figure 5.17. 
 
 
Figure 5.16 - Plasma insulin level profiles obtained after standardized test meal, atropine 0.75mg infusion and 
during the RIST. The regular line represents the insulin level profile obtained for the control fed RIST and the bold 
line represents the insulin level profile obtained for the post-atropine 0.75mg RIST. Results are means±SEM, n=4. 
One-way ANOVA, followed by the Tukey-Kramer multiple-comparison test. Left insert: Insulin area under the curve 
(AUC) calculated by the trapezoid rule for the 60 to 100min after saline (Control Fed) or atropine 0.75mg (Atropine 
0.75mg Fed) infusion and before starting the fed RIST. Intravenous infusions over 10min of either atropine 0.75mg 
or saline were administrated 50min after feeding the meal and 50min before starting the fed RIST. Right insert: 
Insulin area under the curve (AUC) calculated by the trapezoid rule for Control Fed and Atropine 0.75mg Fed RIST. 
Results are means±SEM, n=4. *=p<0.05. Paired t-test. 
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Figure 5.17 - Plasma C-peptide level profiles obtained after standardized test meal, atropine 0.75mg infusion and 
during the RIST. The regular line represents the C-peptide level profile obtained for the control fed RIST and the 
bold line represents the C-peptide level profile obtained for the post-atropine 0.75mg RIST. Results are 
means±SEM, n=4. One-way ANOVA, followed by the Tukey-Kramer multiple-comparison test. Left insert: C-peptide 
area under the curve (AUC) calculated by the trapezoid rule for the 60 to 100min after saline (Control Fed) or 
atropine 0.75mg (Atropine 0.75mg Fed) infusion and before starting the fed RIST. Intravenous infusions over 
10min of either atropine 0.75mg or saline were administrated 50min after feeding the meal and 50min before 
starting the fed RIST. Right insert: C-peptide area under the curve (AUC) calculated by the trapezoid rule for 
Control Fed and Atropine 0.75mg Fed RIST. Results are means±SEM, n=4. Paired t-test. 
 
 
5.4. DISCUSSION 
 
The current chapter demonstrated for the first time the existence of the meal-induced 
insulin sensitization (MIS) and also the pharmacological blockade of HISS release using 
atropine, in humans, using the RIST as the index of dynamic insulin sensitivity.  
Similar to animal studies, the RIST index in these human studies was dramatically 
increased following a meal. These data suggest that postprandial dynamic response to 
insulin is accounted by the MIS process, resulting in 232.146.3% sensitization to the insulin 
bolus compared to responses determined after a 24h fast.  
Control Fed Atropine 0.75mg
0
20
40
60
80
100
120
140
160
180
C
-P
e
p
ti
d
e
 A
U
C
 R
I
S
T
(
n
g
/
m
l)
 Control Fed Atropine 0.75mg
0
100
200
300
400
500
C
-P
e
p
ti
d
e
A
U
C
 6
0
-1
0
0
m
in
(
n
g
/
m
l/
4
0
m
in
)
 
-100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80
2
4
6
8
10
12
14
16
C-Peptide Profile Control Fed
C-Peptide Profile Atropine 0.75mg Fed
Standardized test
meal
RIST
Atropine 0.75mg
infusion
Time (min)
C
-P
e
p
ti
e
 L
e
v
e
ls
(
n
g
/
m
l)
Chapter 5  The HISS in lean healthy subjects 
  PhD Thesis, Rita S. Patarrão 
156 
 
The present data further suggests that, as in animals, the MIS process in humans has 
been confirmed to be dependent upon cholinergic mechanisms. 
Our data are consistent with the hypothesis that the decreased physiological insulin 
sensitivity observed in the fasted state is potentiated following a meal and iv atropine 
administration suppresses the MIS. The partial blockade of MIS by atropine is consistent 
with the hypothesis that a hepatic parasympathetic “feeding signal” is necessary for insulin 
to cause the release of HISS from the liver. The differences observed between the dynamic 
profiles of glucose infusion in the fasted and fed state suggest that HISS action has an 
additive insulin-like effect.  
 
The feeding signal in humans 
 
The use of the RIST in humans provided data consistent with results derived from cats, 
rats, and mice (Latour et al., 2002a; Lautt et al., 1998a; Xie et al., 1996c). Blockade of 
HISS-dependent insulin action results in a decrease of glucose disposal of approximately 
55% in the fed state in rats (Lautt et al., 2001), cats (Xie et al., 1995a) and dogs (Moore et 
al., 2002). The HISS-dependent component of insulin action decreases progressively with 
the duration of fasting to become insignificant after a 24h fast in rats (Lautt et al., 2001). 
For the purpose of estimating the HISS-dependent and HISS-independent components of 
insulin action in the human studies and based on animal data, we have assumed that a state 
of full physiological HISS-dependent insulin resistance exists after a 24h-fast (Latour et al., 
2002c; Lautt et al., 2001) and the only glucose disposal effect producedin the fastes state is 
due to the direct action of insulin. 
The RIST index in response to insulin was increased after the meal and represents the 
HISS contribution for the total response which was approximately 67.5% in humans. The 
MIS shown here is compatible with the same phenomenon shown in animal models and is 
consistent with the HISS hypothesis.  
Feeding stimulates the release of acetylcholine (Ach) from hepatic parasympathetic 
nerves, which activates muscarinic receptors (Xie et al., 1996a), leading to the production of 
hepatic nitric oxide (NO) and subsequent release of HISS (Guarino et al., 2004; Sadri et al., 
1999). Guarino and colleagues showed that hepatic glutathione (GSH) elevation in response 
to a meal was also essential for HISS release (Guarino et al., 2003). Regarding the nature of 
the feeding signal, it was shown, in rats, that in the fed state, MIS can be completely 
inhibited by blocking hepatic muscarinic receptors, hepatic nitric oxide synthase or hepatic 
GSH synthesis, resulting in a RIST index similar to that seen in the fasted state (Guarino et 
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al., 2003; Lautt et al., 2001; Sadri et al., 1999; Sadri et al., 2000a). Thus it is clear that 
both elevated hepatic GSH and NO, which are increased in the fed state, are required for 
insulin to result in HISS release (Guarino et al., 2006).  
We show here that in fed human subjects, MIS was partially inhibited by blocking the 
muscarinic receptors using atropine at the doses of 0.5 and 0.75mg (56.511.6% and 
68.521.9%, respectively), as seen in Figure 5.13. The HISS-independent component of 
insulin action obtained after iv infusion of atropine was not completely abolished, since the 
RIST index after atropine 0.5 and 0.75mg infusion was not the same as the one obtained 
after a 24h-fast RIST; these doses of atropine used were the highest therapeutic doses 
ethically permissible and that had minor side effects (Brown et al., 1996)24.  
Atropine produces dose-related suppression of HISS action in rats (Takayama et al., 
2000) and cats (Xie et al., 1995a) and thus is able to completely block MIS (Sadri et al., 
2006). Atropine produces no notable effect in animals where HISS release is already 
inhibited by fasting or inhibition of NO synthase or denervation.  
Based on rat and cat dose-response curves, we observed that, in humans, the inhibition 
obtained after atropine 0.5 and 0.75mg infusion was partial and, to achieve a total blockade 
of HISS, so that the post-meal RIST index returns to levels seen in the fasted state, the 
atropine dose should be increased. We estimate that an atropine dose of 4mg in humans 
should produce a full block of HISS release. However, this experimental protocol in humans 
is not acceptable and the doses of atropine of 0.5 and 0.75mg have already a significant 
effect on insulin sensitivity. 
 
The atropine 0.5 and 0.75mg effect on the biochemical parameters after feeding 
the standardized test meal 
 
At the onset of and during meal ingestion, the parasympathetic nervous system is 
activated, eliciting ACh release at multiple tissue sites, including the pancreas  (Ahrén et al., 
1986; Teff, 2000; Teff, 2008) and liver (Lautt, 1983; Lautt, 1980; Puschel, 2004). Vagal 
efferent activity at the level of the pancreas stimulates neurally mediated insulin release, 
which results in significant increases of this hormone in the portal vein (Campfield et al., 
1983). 
In this study, during food assimilation, the two doses of atropine (0.5 and 0.75mg) 
infused 50min after food ingestion, generated similar biochemical profiles (glycemia, insulin, 
                                         
 
24 Takayama et al. showed a sensitive response to atropine with the ED50 for the intraportal route being much less 
than for the iv route, thus confirming that the atropine-induced inhibition of HISS action is secondary to blockade of 
hepatic cholinergic receptors (Takayama et al., 2000). 
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C-peptide, lactate, HDL-cholesterol, LDL-cholesterol, total cholesterol and triglycerides) and, 
there were no differences in the profiles after saline (in the control fed group) or atropine 
0.5 and 075mg infusion. 
Following meal ingestion, there was a rise in the glycemia, insulin and C-peptide plasma 
levels, which were expected due to food absorption; and 100min after food ingestion the 
plasma levels returned to their postprandial basal levels. The lipid profile given by the HDL-
cholesterol, LDL-cholesterol, total cholesterol and triglycerides levels, was maintained stable 
over the 100min after the meal. However, the lactate levels for the atropine 0.75mg fed 
group (Figure 5.6) showed a different profile in comparison to the control fed group. This 
difference could be attributable to the interindividual variability (due to the lower number of 
individuals that were included in this protocol), since it was described that following atropine 
administration the lactate levels were not altered (Boyle et al., 1988). 
Concerning the basal values for all the biochemical parameters (Table X), postprandial 
levels of glucose were lowered by atropine 0.75mg (p<0.05), possibly the result of atropine 
delaying gastric empting (Katschinski, 2000; Teff et al., 1999a) or inhibiting intestinal 
glucose absorption (Stumpel et al., 1997). On the other hand, the atropine 0.5mg dose did 
not change the basal glucose levels, which are in accordance with the results from Boyle et 
al. (Boyle et al., 1988).  
Neither plasma insulin nor C-peptide basal levels were altered by atropine infusion.  
The atropine 0.75mg dose decreased basal plasma insulin levels. It is well described that 
the effect of muscarinic blockade on plasma insulin was the result of multiple factors and not 
solely of a direct inhibition on insulin release. One contributing factor may have been the 
inhibition of the insulin secretagogue, glucagon-like peptide-1 (GLP-1), which was shown to 
be under direct cholinergic control (Balks et al., 1997).  
Moreover, the basal plasma C-peptide levels decreased after atropine 0.5 infusion, which 
is in agreement with results from other authors (Schneeberger et al., 1991; Teff et al., 
1996; Teff et al., 2004).  
The postprandial basal levels of triglycerides were decreased by atropine 0.5mg. These 
differences could be attributable to the interindividual variability and additional studies will 
be necessary to address this difference. 
In summary, since the basal levels (used as baseline values to start the RIST) of the 
biochemical parameters analyzed before control fed and atropine fed RIST were similar 
(Table X), the different responses observed in the insulin action could not be assigned to 
them. 
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The infusion of atropine 0.5 or 0.75mg, 50min after feeding the standardized test meal 
decreased insulin and C-peptide AUC (Figure 5.14, left insert; Figure 5.15, left insert;Figure 
5.16, left insert; Figure 5.17, left insert). However, the molar ratio of C-peptide to insulin 
after the meal was not different between the control fed and atropine 0.5 or 0.75mg groups, 
suggesting that the hepatic extraction of insulin was not affected during the meal 
assimilation by the atropine administration. 
 
HISS pharmacodynamics and insulin action 
 
During the RIST, the plasma insulin and C-peptide profiles and the AUC for insulin and C-
peptide following the bolus administration of insulin in the fed state were not altered by 
atropine 0.5 or 0.75mg infusion (Figure 5.14, right insert; Figure 5.15, right insert; Figure 
5.16, right insert; and Figure 5.17, right insert). The molar ratio of C-peptide to insulin 
during the control fed and atropine 0.5 or 0.75mg fed RIST was not altered between the two 
groups, indicating that hepatic insulin extraction was not affecting the insulin response. Even 
with the superimposable insulin profiles during the control fed and atropine 0.5 or 0.75mg 
fed RIST, there was a significant decrease in the response to insulin in the fed state after 
atropine 0.5 and 0.75mg (Figure 5.9 and Figure 5.12). This decrease in insulin sensitivity, 
indicates that this insulin response to the exogenous bolus of insulin could not be only due 
to the plasma insulin levels.  
The plasma insulin and C-peptide levels profiles obtained during the RIST for the two 
doses of atropine tested were similar. However, looking at the RIST index values and 
percentage of inhibition obtained for the two doses, they were different and dose-related, 
that is, increasing the atropine dose leads to a decrease of insulin sensitivity and an increase 
of the percentage of inhibition. The lack of effect of atropine on baseline and spike insulin 
levels confirms data from cats (Xie et al., 1995a) and rats (Latour et al., 2002b). In cats, 
atropine produced a dose-related HDIR but did not alter baseline insulin, glucagon, or 
catecholamines nor the peak insulin levels attained following insulin administration (Xie et 
al., 1995a)  
These data suggest, for the first time in humans, that some factor other than insulin 
accounts for the difference in dynamic insulin action. 
Peak insulin levels in fed and fasted state (1min after administration of the insulin bolus) 
did not differ significantly either with or without previous atropine administration (Figure 5.4 
(A) and (B), Figure 5.14 and Figure 5.16). Although the insulin levels were higher during the 
RIST in the fed state, the data are not consistent with the MIS being accounted for only by 
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reduced insulin clearance. Termination of insulin action from the administered bolus is 
determined by the time at which no further administration of glucose is required to maintain 
euglycemia. In the fasted state, this time point was reached after 40min (Figure 5.1 and 
Table IX). Insulin concentrations determined after 50min had returned to baseline levels 
(Figure 5.4 (A)). To determine if the prolonged effect of the insulin bolus in the fed state 
could be attributed to prolonged elevation in insulin, insulin levels were also determined at 
the 40min time point of the postprandial RIST, at which time the glucose disposal response 
was well maintained at approximately 50% of the maximal response and continued until the 
end of the postprandial RIST. However, the insulin concentration measured in the fed state 
at 40min had already returned to the pre-administration basal concentration (Figure 5.4 
(B)). Moreover, endogenous insulin secretion during the 24h-fast and fed RIST was not 
altered, since the C-peptide levels did not change along the RIST (Figure 5.5 (A) and Figure 
5.5 (B)). Thus, the glucose disposal in the fasted state can be attributed only to insulin 
whereas the prolonged action in the fed state cannot. The differences observed related to 
the peak magnitude, peak time, and total duration between the fasted and fed RIST suggest 
that HISS has an additive rather than a synergistic insulin-like action (Table IX). 
The increased glucose disposal determined from the second RIST (performed on the same 
day, after the meal) is not secondary to delayed effects from the first fasted RIST. The RIST 
index in the fed state in 24h fast vs fed protocol was the second RIST and was equivalent to 
the control fed RIST in the atropine 0.5 and 0.75mg protocol, carried out in the same 
subjects, where only one RIST was carried out. The RIST indexes in these fed subjects were 
681.260.9mg glucose/kg bw in 24h fast vs fed protocol, 627.483.9mg glucose/kg bw in 
fed controls from the atropine 0.5mg protocol and 669.490.0mg glucose/kg bw in fed 
controls from the atropine 0.75mg protocol (not statistically different). Insulinemia was 
reduced to baseline at 40min in both the fed and fasted states, yet the glucose disposal 
effect was considerably prolonged after the meal.  
In animal studies, it has been demonstrated that four sequential RISTs are reproducible 
with no “priming effects” detectable (Lautt et al., 1998a). Further, insulin action tested in 
rats using a similar MIS protocol as used here showed a fasting RIST index that was 
dramatically sensitized following a meal but which was then returned to the level seen in the 
fasting state following blockade of HISS release by atropine (Sadri et al., 2006).  
Concerning that the bolus administration of insulin results in a non-physiological spike of 
insulin and that may have numerous indirect effects was also addressed in the animal 
studies, where dose-response curves for insulin showed that HISS-dependent component of 
insulin action in the fed state was similar (≈55%) over the entire insulin dose range of 5-
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100mU/kg bw (Lautt et al., 2001). If the insulin dose of 50mU/kg is administered over 30 
seconds, 5 minutes or 10 minutes, the RIST index is similar, thus showing lack of impact of 
a bolus spike in insulin concentration (Reid et al., 2004). Thus, the human data reported in 
this chapter are consistent with the animal data, indicating that some factor other than the 
direct effect of insulin must account for the sensitized glucose disposal response to insulin 
after a meal. 
 
In these studies, we tested the MIS and HISS hypothesis demonstrating the ability to 
compare dynamic insulin action in the fed and fasted state. We report the first evidence of 
MIS and support the utility of the RIST in humans (Patarrão et al., 2007). This study is 
consistent with the studies in several other species demonstrating that the MIS process is 
regulated by hepatic parasympathetic nerves. 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. THE HISS IN OVERWEIGHT 
HUMANS
  
Chapter 6  The HISS in overweight subjects 
  PhD Thesis, Rita S. Patarrão 
165 
 
6. THE HISS IN OVERWEIGHT HUMANS 
 
6.1. INTRODUCTION AND AIMS 
 
As shown in the previous chapters, in the normal healthy state, feeding results in a rapid 
meal-induced insulin sensitization (MIS). The MIS process, in lean healthy subjects, resulted 
in approximately 232% sensitization in response to a pulse of insulin, compared to 
responses determined after a 24h fast and it is dependent upon cholinergic mechanisms 
(Patarrão et al., 2008). The mechanism of MIS has been demonstrated to result from the 
release and action of the hepatic insulin sensitizing substance (HISS). For MIS to occur, a 
permissive feeding signal must be delivered to the liver through parasympathetic nerves, 
mediated by cholinergic muscarinic receptor activation and generation of nitric oxide (Sadri 
et al., 2006) in the presence of an increase of hepatic glutathione (GSH), which result in 
HISS release (Guarino et al., 2006). The most straightforward method to quantify MIS is to 
compare insulin sensitivity in the fasted and in the fed state. Alternatively, HISS can be 
readily quantified by determining insulin sensitivity in the fed state and then tested again 
after the parasympathetic signal has been eliminated by surgical denervation of the liver, or 
atropine blockade of hepatic muscarinic receptors, or inhibition of hepatic nitric oxide 
production (Lautt, 1999; Lautt, 2003b).  
The prandial state insulin sensitivity (and consequently MIS) as become more relevant in 
recent years (Ceriello et al., 2008b; Ceriello et al., 2004). In fact, the first 
pathophysiological alterations in glucose homeostasis are observed in the fed rather than in 
the fasted state, which highlights the need to study postprandial insulin sensitivity. 
The transition from the early metabolic abnormalities that forerun diabetes, impaired 
glucose tolerance (IGT) and impaired fasting glucose (IFG), to overt diabetes may take 
many years; however, current estimates indicate that most individuals (perhaps up to 70%) 
with these prediabetic states eventually develop diabetes (Nathan et al., 2007). The natural 
history of both IGT and IFG is variable, with 25% progressing to diabetes, 50% remaining 
in their abnormal glycemic state, and 25% reverting to normal glucose tolerance over an 
observational period of 3–5 years (Gabir et al., 2000; Stern et al., 2005). Individuals who 
are older, overweight, obese and have other diabetes risk factors are more likely to progress 
towards diabetes (Nathan et al., 2007). 
Obesity has long been recognized to be associated with insulin resistance (Afonso et al., 
2007a; Afonso et al., 2010; Kahn et al., 2006; Utzschneider et al., 2006); however, the 
mechanisms underlying such relationship remain unclear and can vary according to the way 
obesity is induced. 
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Moreover, studies in rats suggested that the insulin resistance seen in the high-fat diet 
(HFD)-induced obese rat model is quite different from the genetically modified obese Zucker 
(OZR) and diabetic Zucker (ZDF) rat: the HFD rats are mainly HISS-dependent insulin 
resistant while the OZR and ZDF show impairment of both HISS action as well as the insulin 
action per se (independent of HISS) to the same extent (Afonso et al., 2007a; Afonso et al., 
2010). Furthermore, adiposity correlates strongly and negatively with the degree of HISS 
action (Afonso et al., 2010; Lautt et al., 2008; Ming et al., 2010). 
Therefore, the main objective of the study presented in this chapter was to test the 
hypothesis that insulin resistance in moderately overweight subjects, in comparison with the 
control lean subjects, is due to MIS impairment and that impairment will only be seen in the 
postprandial state. 
 
6.2. PROTOCOLS 
 
6.2.1. Evaluation of the dynamic response to insulin in the fasted and fed state, 
in lean healthy and overweight subjects 
 
In these experiments, the main goal was to compare the dynamic response to insulin in 
the fasted and fed states, in both lean healthy and overweight subjects.  
Therefore, each lean healthy and overweight subject was tested on the same day in the 
fasted and fed state.  
Shortly, after a 24h fasting period, the RIST was performed in the fasted state. After, the 
subject was fed a standardized test meal and 100min after, a second RIST was performed 
(postprandial RIST). The detailed experimental protocol is described in chapter 3, section 
3.3.1 and 3.3.1.2. 
 
6.3. RESULTS 
 
Four overweight male subjects (aged 24.30.9 years, n=4) admitted into this protocol 
had normal systolic blood (133.06.5mmHg) and diastolic blood pressure (69.05.5mmHg) 
and seven lean healthy male subjects (aged 27.01.9 years, n=7) admitted into this 
protocol had normal systolic blood (117.13.8mmHg) and diastolic blood pressure 
(63.62.9mmHg). The body mass index between lean healthy and overweight subjects were 
different (22.71.1kg/m2 and 27.70.4kg/m2, respectively, p<0.01). 
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Basal fasting glucose levels and glucose levels measured after the meal were identical for 
the overweight and lean healthy subjects (Table XIII). 
 
Table XIII shows basal fasting and postprandial levels of biochemical parameters, of both 
lean and overweight subjects. Beyond plasma insulin levels, all the biochemical parameters 
remained stable during the RIST in comparison to their basal levels. 
 
Table XIII – Fasting and postprandial basal values of glycemia, insulin, C-Peptide, lactate, HDL-cholesterol, LDL-
cholesterol, total cholesterol and triglycerides of both overweight (n=4) and lean subjects (n=7). Values are 
means±SEM. *,#=p<0.05 between lean and overweight subjects. Unpaired t-test between fasted lean and fasted 
overweight, and fed lean and fed overweight. 
 
 
 
6.3.1. Characterization of insulin action, in overweight and lean healthy subjects  
 
6.3.1.1. Evaluation of glucose, insulin and C-Peptide profiles after feeding the 
standardized test meal, in overweight and lean subjects 
 
The assessment of glucose, insulin and C-peptide profiles, obtained after ingestion of the 
standardized test meal (t=0min), was performed in lean and overweight groups and it is 
shown in Figure 6.1 and Table XIV. 
 
 
 
 
 
 
 
Prandial 
State 
Subjects Glycemia 
(mg/dl) 
Insulin 
(IU/ml) 
C-Peptide 
(ng/ml) 
Lactate 
(mg/dl) 
HDL- 
Cholesterol 
(mg/dl) 
LDL- 
Cholesterol 
(mg/dl) 
Total 
Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl) 
 
 
Fasted 
Lean 72.91.8 5.40.6 1.50.2 9.30.5 52.72.9 76.18.0 158.66.7# 36.53.8 
 
Overweight 69.33.5 7.71.7 2.30.5 8.50.6 45.73.4 100.64.6 197.014.3#
 
45.91.5 
Fed 
 
Lean 
 
104.85.1 39.56.4 9.11.0 10.10.7 48.93.7 68.38.3 145.810.3* 35.05.5 
 
Overweight 113.98.3 39.98.1 9.50.6 9.20.9 48.24.1 93.21.9 195.09.1* 46.76.2 
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(B)  
 
 
 
 
 
 
(C)  
 
 
 
 
 
 
 
 
 
Figure 6.1 - Biochemical parameters (glycemia (A), insulin (B) and C-Peptide (C)) profiles measured at specific 
time points during 100min after ingestion of the standardized test meal (0min) and before performing the RIST in 
the fed state (100min), in lean (n=7) and overweight (n=4) subjects. The right inserts correspond to the area 
under the curve (AUC) of glucose, insulin and C-peptide, respectively, calculated by the trapezoid rule for the 
100min after feeding the meal. Results are means±SEM. One-way ANOVA, followed by the Tukey-Kramer multiple-
comparison test. 
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As shown in Figure 6.1 and Table XIV, the incremental changes in glucose, insulin and C-
peptide plasma concentrations at different time points after ingestion of the standardized 
test meal had a similar increase in both lean and overweight subjects, and the 
corresponding AUCs were not statistically different when evaluated in the two groups (AUC 
Glucose - Lean vs Overweight: 3303419.6 vs 3039477.9mg/dl/100min; AUC Insulin - 
Lean vs Overweight: 2048629.6 vs 2708979.5IU/ml/100min; AUC C-Peptide - Lean vs 
Overweight: 388.5116.8 vs 550.834.9ng/ml/100min). In addition, the molar ratio of C-
peptide to insulin in response to the standardized test meal was not significantly different 
between the lean and overweight groups (0.2300.053 and 0.2290.070, respectively), 
suggesting that neither insulin secretion nor hepatic extraction was different between the 
two groups during the meal absorption. 
 
Table XIV - 24h fast basal values and specific time points following standardized test meal ingestion of glucose, 
insulin and C-peptide values, of both lean (n=7) and overweight subjects (n=4). Values are means±standard error. 
One-way ANOVA, followed by the Tukey-Kramer multiple-comparison test. 
 
     
Time after standardized test meal (min) 
 
 
   
Baseline          
24h Fast 
 
0 
 
20 
 
40 
 
60 
 
75 
 
85 
 
90 
 
95 
 
100 
Glucose 
Levels 
 
Lean 
 
72.91.8 
 
66.05.0 
 
93.55.7 
 
114.45.6 
 
123.44.8 
 
117.74.8 
 
112.46.1 
 
110.15.9 
 
110.05.6 
 
104.85.1 
 
(mg/dl)  
Overweight 
 
 
69.33.5 
 
67.01.0 
 
76.54.4 
 
100.82.8 
 
114.02.7 
 
115.03.4 
 
113.84.5 
 
113.86.1 
 
113.58.2 
 
113.98.3 
Insulin 
Levels 
 
Lean 
 
5.40.6 
 
9.22.0 
 
17.53.2 
 
36.13.5 
 
46.18.1 
 
50.07.0 
 
46.46.5 
 
39.28.3 
 
43.28.3 
 
39.56.4 
 
(IU/ml)  
Overweight 
 
 
7.71.7 
 
7.00.4 
 
31.312.9 
 
36.87.8 
 
41.810.9 
 
35.18.6 
 
35.49.6 
 
40.28.4 
 
36.710.2 
 
39.98.1 
C-Peptide 
Levels 
 
Lean 
 
1.50.2 
 
1.60.6 
 
2.70.6 
 
6.50.9 
 
8.91.1 
 
10.31.0 
 
10.71.5 
 
9.81.3 
 
9.31.4 
 
9.11.0 
 
(ng/ml)  
Overweight 
 
 
2.30.5 
 
1.90.5 
 
4.31.1 
 
7.50.6 
 
10.00.1 
 
9.51.7 
 
10.00.3 
 
11.00.5 
 
9.20.8 
 
9.50.6 
 
6.3.1.2. Comparison of the fasted and fed RIST dynamic profiles, in overweight 
and lean subjects 
 
On Figure 6.2, are represented the mean dynamic profiles of 24h-fast and fed insulin 
action for overweight subjects. In overweight subjects, the RIST dynamic profiles, both in 
the fasted and fed state, were slightly different in comparison with the ones obtained in lean 
healthy subjects (Chapter 5, Figure 5.3). Assuming that in the 24h-fasted state, HISS action 
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is absent, the mean dynamic curve for the HISS-dependent component25 can be calculated 
by subtracting each 24h-fast dynamic curve from the corresponding fed dynamic curve 
(Figure 6.3). Moreover, the comparison of the main characteristics of the dynamic curves for 
lean and overweight subjects (action peak magnitude, peak time, and action curve duration 
for 24h-fast and postprandial curves; and action peak magnitude, peak time, action curve 
onset and duration for HISS-dependent component curves) are shown on Table XV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 – Mean dynamic curves for the Rapid Insulin Sensitivity Test (RIST) performed on 24h-fast (simple line) 
and postprandial (bold line) states, in overweight subjects, n=4. The mean dynamic RIST curves were obtained by 
averaging glucose infusion rates at 0.1min intervals throughout the test. 
 
As stated before for the lean subjects, in the postprandial group all the dynamic 
parameters (action peak magnitude, peak time, and action curve duration) were higher in 
comparison to the 24h-fast group. 
Based on animal studies, the difference between the 2 curves from Figure 6.2, was 
plotted to show the dynamic action of the HISS-dependent component of insulin action, in 
overweight subjects (Figure 6.3 and Table XV). 
 
 
 
 
                                         
 
25 Based on animal studies, the HISS-dependent component can be calculated by subtracting each 24h-fast 
dynamic curve from the corresponding fed dynamic curve (Lautt et al., 2001). 
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Figure 6.3 – Mean dynamic profile curve for the HISS-dependent component of insulin action, calculated from the 
difference between the curves in Figure 6.2 in overweight subjects. HISS action began at 9.54.0min after the 
onset of insulin administration, n=4. 
 
The mean characteristics of the dynamic profiles of the RISTs obtained, in lean and 
overweight subjects, both in the fasted and in the fed states are summarized in Table XV. 
 
Table XV - Dynamic profile characteristics for the 24h-fast RIST, postprandial RIST and the HISS-dependent 
component of insulin action, for both lean (n=7) and overweight subjects (n=4). Values are means±SEM. 
#,§=p<0.01 between fasted state, fed state and HISS-dependent component. $=p<0.05 between fasted state, fed 
state and HISS-dependent component. Repeated measures ANOVA, followed by the Tukey-Kramer multiple-
comparison test, within the overweight group. 
 
 
 Lean Overweight 
 
Peak (mg glucose/kg/min) 8.0 ± 0.8 7.8 ± 1.4$ 
24h-Fast RIST Peak time (min) 16.1 ± 2.2 16.4 ± 4.6 
 Duration (min) 41.9 ± 2.9 34.0 ± 4.3#, § 
 Peak (mg glucose/kg/min) 13.3 ± 0.7 14.8 ± 2.6$ 
Postprandial RIST Peak time (min) 28.4 ± 3.0 26.3 ± 3.1 
 Duration (min) 90.5 ± 5.0 68.5 ± 11.4# 
 Onset (min) 6.3 ± 2.3 9.5 ± 4.0 
HISS-dependent component Peak (mg glucose/kg/min) 10.4 ± 0.8 11.5 ± 1.7 
 Peak time (min) 40.8 ± 4.7 27.5 ± 4.1 
 Duration (min) 90.4 ± 5.0 68.4 ± 11.4§ 
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As shown in Table XV there are no differences in the mean dynamic parameters (action 
peak magnitude, peak time, and action curve duration) for the 24h-fast and fed insulin 
action between the lean and overweight groups. 
 
6.3.1.3. Effect of fasting and feeding on insulin sensitivity, in lean and 
overweight subjects 
 
The area under each dynamic curve, from the results abovementioned (Figure 6.2 and 
Figure 5.1, Chapter 5) provides us the RIST index for each prandial state. 
In lean and overweight subjects, after the 24h fasting period, the RIST index was 
215.520.8 and 177.840.5mg glucose/kg bw, respectively. Thus, the insulin action per se 
was not different in lean and overweight fasted subjects. After feeding the standardized test 
meal, the RIST index increased to 681.260.9 and 388.8107.3mg glucose/kg bw (p<0.05), 
in lean and overweight subjects, respectively (Figure 6.4). The increase in insulin sensitivity 
in lean subjects was 232.146.3% while in overweight subjects was only 174.067.9%, 
corresponding to the percentage of potentiation of the insulin action induced by the meal. 
 
24h-Fast Lean Fed Lean 24h-Fast Overweight Fed Overweight
0
100
200
300
400
500
600
700
800
***
*
*
R
I
S
T
 I
n
d
e
x
(
m
g
 g
lu
c
o
s
e
/
k
g
 b
w
)
 
Figure 6.4 – Standardized test meal increases insulin sensitivity both in lean (n=7) and overweight (n=4) 
subjects. However, the increase in insulin sensitivity is much more marked in the lean subjects. Results are 
means±SEM. ***=p<0.001 and *=p<0.05. Paired t-test between the same groups of subjects and unpaired t-test 
between lean and overweight group. 
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The HISS-dependent component of total insulin action, calculated by subtracting the 24h-
fast RIST index from the corresponding fed RIST index, is lower in the overweight subjects 
than in the lean (465.757.8 vs 233.172.6mg glucose/kg bw, respectively, p<0.05, Figure 
6.5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 - The contribution of the HISS-dependent component of total insulin action is lower in overweight (n=4) 
than in lean (n=7) subjects. Results are means±SEM. *=p<0.05. Unpaired t-test. 
 
6.3.1.4. Plasma insulin and C-Peptide levels during the fasted and fed RIST, in 
lean and overweight subjects 
 
The evaluation of plasma insulin and C-peptide profiles during the RIST was done in 
fasted and fed state, in both lean (n=7) and overweight subjects (n=4). The fasted and fed 
insulinemia and C-peptide profiles in lean and overweight subjects were super-imposable 
and not significantly different at any time point (Figure 6.6 and Figure 6.7). 
Fasted basal insulinemia and C-peptide levels both in lean and overweight subjects were 
similar (5.40.6 and 7.71.7IU/ml, and 1.50.2 and 2.30.5ng/ml, respectively) and 1min 
after the insulin bolus injection of 50mU/kg the insulin levels spiked to similar concentration 
(487.344.0IU/ml, in the lean group and 478.088.3IU/ml, in the overweight group). At 
the end of the fasted RIST, approximately 42min for the lean group and 30min for the 
overweight group, plasma insulin levels returned to basal levels. The C-peptide levels 
remained stable and not statistically different from basal levels throughout the 24h-fast 
RIST, for both groups. The mean area under the curve (AUC) for insulin measured during 
the 24h-fast RIST in the lean and overweight subjects was similar (3633156.7 and 
4138406.7IU/ml, respectively) and the AUC for C-peptide was also not different between 
the lean and overweight group (15.84.2 and 10.81.7ng/ml, respectively) (Figure 6.6 (A) 
and Figure 6.7 (A)). In addition, the molar ratio of C-peptide to insulin during the 24h-fast 
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RIST was not significantly different between the lean and overweight groups (0.00440.0012 
and 0.00260.0002, respectively), suggesting that hepatic extraction of insulin was not 
different between the two groups, during the 24h-fast RIST. 
Both lean and overweight subjects were fed a standardized test meal and 100min after 
(the time required to achieve stable glycemia), the basal plasma insulin and C-peptide levels 
were similar in the two groups (39.56.4 and 39.98.1IU/ml, and 9.11.0 and 
9.50.6ng/ml, respectively). Immediately after the bolus of insulin (1min after starting the 
RIST), insulinemia reached a value of 501.630.2 (lean group) and 470.556.3IU/ml 
(overweight group).  
At the end of the fed RIST (70min), plasma insulin levels returned to basal plasma levels 
(lean subjects: 40.55.5 and overweight subjects: 33.93.1IU/ml). As noticed already in 
the 24h-fast RIST, the C-peptide levels remained stable and not statistically different from 
basal levels throughout the fed RIST, for both groups. The mean AUC for insulin measured 
during the postprandial RIST in the lean and overweight subjects was similar (5926919.3 
and 4265796.6IU/ml, respectively) and the AUC for C-peptide were also not different 
between the lean and overweight group (136.327.1 and 102.536.5ng/ml, respectively) 
(Figure 6.6 (B) and Figure 6.7 (B)). In addition, the molar ratio of C-peptide to insulin during 
the postprandial RIST was not significantly different between the lean and overweight 
groups (0.02480.0052 and 0.03720.0235, respectively), suggesting that hepatic 
extraction of insulin was not different between the two groups, during the fed RIST. The 
plasma insulin and C-peptide profiles obtained during the 24h-fast and fed RIST, in both 
lean and overweight subjects are represented in Figure 6.6 and Figure 6.7, respectively. 
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(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 - Plasma insulin profiles obtained during the 24h-fast (A) and fed RIST (B), in both lean (n=7) and 
overweight (n=4) subjects. The regular line represents the insulin level profile obtained for the lean 24h-fast and 
fed RIST and the bold line represents the insulin level profile obtained for the overweight 24h-fast and fed RIST. 
Statistically significant differences were not seen at any time point. Results are means±SEM. One-way ANOVA, 
followed by the Tukey-Kramer multiple-comparison test. Left insert: Insulin area under the curve (AUC) calculated 
by the trapezoid rule for 24h-fast RIST in both lean and overweight subjects. Right insert: Insulin area under the 
curve (AUC) calculated by the trapezoid rule for fed RIST in both lean and overweight subjects. Unpaired t-test. 
-100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80
100
200
300
400
500
600
700
Insulin Profile Fed Lean
Insulin Profile Fed Overweight
RISTStandardized
test meal
Time (min)
I
n
s
u
li
n
 L
e
v
e
ls
(
u
U
I
/
m
l)
-20 -10 0 10 20 30 40 50 60 70 80
100
200
300
400
500
600
700
Insulin Profile 24h-Fast Lean
Insulin Profile 24h-Fast Overweight
RIST
Time (min)
I
n
s
u
li
n
 L
e
v
e
ls
(u
U
I/
m
l)
 Lean Overweight 
0
1000
2000
3000
4000
5000
6000
7000
I
n
s
u
li
n
A
U
C
 R
I
S
T
(

I
U
/
m
l)
 Lean Overweight 
0
1000
2000
3000
4000
5000
6000
7000
I
n
s
u
li
n
A
U
C
 R
I
S
T
(

I
U
/
m
l)
Chapter 6  The HISS in overweight subjects 
  PhD Thesis, Rita S. Patarrão 
176 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 - Plasma C-peptide profiles obtained during the 24h-fast (A) and fed RIST (B), in both lean (n=7) and 
overweight (n=4) subjects. The regular line represents the C-peptide level profile obtained for the lean 24h-fast and 
fed RIST and the bold line represents the C-peptide level profile obtained for the overweight 24h-fast and fed RIST. 
Statistically significant differences were not seen at any time point. Results are means±SEM. One-way ANOVA, 
followed by the Tukey-Kramer multiple-comparison test. Left insert: C-peptide area under the curve (AUC) 
calculated by the trapezoid rule for 24h-fast RIST in both lean and overweight subjects. Right insert: C-peptide area 
under the curve (AUC) calculated by the trapezoid rule for fed RIST in both lean and overweight subjects. Unpaired 
t-test. 
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6.4. DISCUSSION 
 
The aim of the study described in this chapter was to characterize the meal-induced 
insulin sensitization (MIS) in overweight subjects, since it is well documented that adiposity 
is often associated with impaired glucose homeostasis,  metabolic abnormalities, insulin 
resistance, type 2 diabetes, lipid disorders and cardiovascular disease (Astrup et al., 2000; 
Kahn et al., 2006; LeRoith, 2007; Weyer et al., 1999b). 
 
The meal-induced insulin sensitization (MIS), in lean and overweight subjects 
 
When lean and overweight subjects were submitted to a 24h fasting period, when HISS is 
absent, the insulin action per se, is similar in both lean and overweight subjects (Figure 
6.4). However, after a meal, the increase in insulin sensitivity was observed in the two 
groups, but was much more evident in the lean subjects. The lower MIS observed in the 
overweight subjects is associated with an impairment of the HISS-dependent component, 
since the contribution of the HISS-dependent component of total insulin action is lower in 
overweight than in lean subjects (Figure 6.5). 
Our data are consistent with the hypothesis that insulin resistance observed in the fasted 
state is reversed by a meal, in both lean and overweight subjects. Furthermore, the MIS is 
much more pronounced in lean subjects (232.146.3%) in comparison to the overweight 
subjects (174.067.9%), suggesting that even mild overweight is already associated with a 
postprandial metabolic dysfunction. 
The results of a clinical study performed by Petersen and colleagues are consistent with 
the HISS hypothesis. They showed that, in lean insulin-resistant subjects, skeletal muscle 
insulin resistance predates hepatic insulin resistance (Petersen et al., 2007). The mechanism 
of the initiating skeletal muscle insulin resistance was not suggested, but is compatible with 
the postprandial (HISS-dependent insulin resistance) HDIR state. 
The question of the causal relationship between obesity and HDIR cannot be directly dealt 
within our study, but the theory that absence of MIS leads to adiposity suggests that mild 
adiposity may show significant HDIR. If adiposity causes HDIR, the impairment in HISS 
action would not be expected to be large in mildly overweight subjects. 
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The incremental changes in glucose, insulin and C-peptide after feeding the 
standardized test meal, in lean and overweight subjects 
 
The 24h-fast and fed basal values of glucose, insulin and C-peptide were not different 
between lean and overweight subjects (Table XIII). Since the overweight subjects recruited 
to this study were mildly overweight (BMI 27.70.4kg/m2), one would not expect severe 
differences within basal values. 
Following the ingestion of the meal, there was a rise in the glycemia, insulin and C-
peptide levels which was expected due to food absorption and assimilation. As shown in 
Figure 6.1 and Table XIV, the augment of glucose, insulin and C-peptide levels was identical 
in both lean and overweight subjects. The area under the curve (AUC) calculated during 
100min after the meal ingestion for glucose, insulin and C-peptide, as well as the molar ratio 
of C-peptide:insulin, were not statistically different when compared between the lean and 
overweight group (Figure 6.1, right insert). However, there was a trend toward an increase 
in the insulin and C-peptide AUCs which are in accordance with the results from Teff et al. 
(Teff et al., 1999b). The peripheral C-peptide:insulin molar ratio have been assumed to 
reflect changes in hepatic insulin extraction both in steady-state and non-steady state 
conditions (Bonora et al., 1983; Polonsky et al., 1984). The C-peptide:insulin molar ratio is 
dependent upon the interaction of many factors related to the secretion, metabolism, 
distribution and half-lives of the C-peptide and insulin26.  
Since the overweight subjects admitted in this study were mildly overweight and they 
were not hyperinsulinemic, one would not expect to observe major differences between the 
C-peptide:insulin molar ratio, suggesting the hepatic insulin extraction was not different 
between the lean and overweight group, after the meal ingestion.  
 
Insulin action and secretion, in lean and overweight subjects 
 
Besides the differences observed in basal levels of insulin and C-peptide, between fasted 
and fed states in both lean and overweight subjects, the insulin and C-peptide profiles 
during the RIST at both prandial states, had similar patterns. These profiles indicate that the 
differences observed in the postprandial insulin sensitivity between the two groups studied 
are not related to the insulin action per se nor endogenous insulin secretion. 
                                         
 
26 To assume that changes in the C-peptide:insulin molar ratio reflect changes in hepatic insulin extraction is a 
simplistic approach to a complex metabolic problem (Ahrén et al., 2003; Polonsky et al., 1984). 
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In this study, we showed that even with the low degree of insulin sensitivity at the fasted 
state in both lean and overweight subjects, the increase of the insulin sensitivity after a 
meal should not be due to the insulin action per se (Figure 6.4), since the insulin profiles 
were super-imposable and the AUC of insulin was not statistically different in the two groups 
studied (Figure 6.6). Assuming this similarity between the insulin profiles, the differences 
between the postprandial insulin sensitivity among lean and overweight subjects could not 
be due to insulin action per se, suggesting that HISS action has an additive insulin-like 
effect. These results also point out the advantage for the use of the RIST as a method to 
evaluate the degree of insulin resistance/insulin sensitivity in the postprandial state. 
Although in the recent past, evaluation of glycemic control has leaned heavily on 
assessments done in the fasted state, the importance of alterations in the postprandial 
periods has become increasingly recognized (Ceriello, 2005; Ceriello et al., 2008a; Ceriello 
et al., 2004; Hanefeld et al., 2002; Woerle et al., 2007). 
Postprandial glucose excursions are among the most important risk factors contributing to 
type 2 diabetes, micro and macrovascular complications (Del Prato, 2002; Meier et al., 
2009). Alterations in real-life glucose metabolism can only be fully understood if both fasted 
and fed states are considered. As frank diabetes develops, postmeal glucose excursions 
continue to worsen (Monnier et al., 2007). 
 
Based on evidence to date, the International Diabetes Federation guidelines recommends 
implementing a comprehensive management programme that targets both fasting and 
postmeal glucose, which should be initiated simultaneously at any HbA1c level to improve 
outcome in diabetes (Ceriello et al., 2008a). 
Some studies have also proposed that, loss of early insulin response to glucose and poor 
suppression of hepatic glucose output, are primarily responsible for postprandial 
hyperglycemia associated with impaired glucose tolerance (Mitrakou et al., 1992; Pratley et 
al., 2001). In contrast, under experimental conditions, defective insulin action was shown to 
contribute more to postprandial hyperglycemia than defective insulin secretion (Tripathy et 
al., 2000). 
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HISS and Prediabetes 
 
HISS action accounts for the increased response to insulin seen following a meal and the 
most straightforward method to quantitate MIS is to compare insulin sensitivity in the fasted 
state with the same determinations in the fed state. Most of the published studies evaluate 
insulin sensitivity in a fasted state, ignoring the fact that the first alterations of insulin 
sensitivity seem to occur in the postprandial state, in which the role of the HISS-dependent 
component of insulin action is crucial (Lautt, 2004). 
Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are intermediate 
states in glucose metabolism that exist between normal glucose tolerance and overt 
diabetes. Insulin resistance and impaired -cell function, the primary defects observed in 
type 2 diabetes, both can be detected in subjects with IGT and IFG. However, clinical studies 
suggest that the site of insulin resistance varies between the two disorders. While subjects 
with IGT have marked muscle insulin resistance with only mild hepatic insulin resistance, 
subjects with IFG have severe hepatic insulin resistance with normal or near-normal muscle 
insulin sensitivity. Both IFG and IGT are characterized by a reduction in early-phase insulin 
secretion, subjects with IGT also have impaired late-phase insulin secretion (Abdul-Ghani et 
al., 2006). 
The associated risk factors should benefit from efforts directed to early detection of 
abnormal MIS and to therapy directed toward the prevention or reversal of insulin resistance 
(Lautt et al., 2008). 
Within this study, we show that overweight subjects have a decrease in insulin action due 
to an impairment of MIS process, associated with a decrease in HISS action. A decrease in 
insulin sensitivity in the overweight subjects was only detected in the fed state, thus 
demonstrating an insulin resistance state seen already with mild adiposity. Within our 
results, these mild overweight subjects at the fasted state were considered healthy, but 
when insulin sensitivity was assessed in the fed state they revealed impaired insulin 
sensitivity. 
 
To summarize, the absence of HISS in the postprandial state might be the first metabolic 
defect that occurs in the prediabetic state. In this setting HISS dysfunction may contribute 
decisively to the progression of metabolic defects towards type 2 diabetes. 
Addressing the several possible aetiologies for prediabetes will provide clues for an earlier 
diagnosis, efficient treatment of these conditions and possibilities of slowing the 
deterioration towards type 2 diabetes. 
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7. THE RELEVANCE OF GLUCAGON ON HISS-DEPENDENT INSULIN 
SENSITIVITY 
 
7.1. INTRODUCTION AND AIMS 
 
We have recently proposed that the regulation of insulin action by the prandial status is 
dependent on hepatic glutathione (GSH) content, which is known to be strongly related to 
the nutritional status (Guarino et al., 2003; Tateishi et al., 1977). This hypothesis was 
highlighted by the observation that hepatic GSH depletion produced by administration of the 
-glutamylcysteine synthase inhibitor, L-buthionine-[S,R]-sulfoximine (BSO), produced 
insulin resistance in a degree similar to that observed after hepatic nitric oxide synthase 
(NOS) inhibition (Guarino et al., 2003). Therefore, both GSH depletion and NOS antagonism 
inhibit the insulin-sensitizing signal in the liver by blocking Hepatic Insulin Sensitizing 
Substance (HISS) action. Moreover, exogenous nitric oxide (NO) was not able to restore 
insulin action in BSO-treated rats in contrast to sham rats, which suggests that both GSH 
and NO are required in the liver to allow full peripheral insulin action (Guarino et al., 2003). 
Also, the reduced insulin sensitivity observed in the fasting state is only reversed after co-
administration of GSH and NO into the liver (Guarino et al., 2006). 
Considering that hepatic GSH is a crucial factor for HISS action, it becomes imperative to 
understand the mechanisms involved in the regulation of hepatic GSH levels. An important 
regulator of hepatic GSH levels is the cAMP pathway, since it has been shown that a rise in 
hepatic cAMP levels is associated with a decrease in hepatic GSH levels (Goss et al., 1994; 
Higashi et al., 1976; Lauterburg et al., 1981; Lu et al., 1990; Lu et al., 1991; Tateishi et al., 
1974). 
Glucagon is a pancreatic hormone, released in the fasted state in order to maintain an 
adequate level of blood glucose. According, to Lu and colleagues, glucagon‟s effects, 
mediated via cAMP, decrease hepatic GSH levels (which are reduced in the fasted state and 
raised in the postprandial state) due to an inhibition of the enzyme -glutamylcysteine 
synthase, which plays a key role in GSH synthesis (Lu et al., 1990; Lu et al., 1991). 
In healthy subjects, plasma glucagon levels increase with fasting and decrease in the 
immediate postprandial state (Ahrén, 2006; Butler et al., 1991), which is the inverse of GSH 
pattern (Leeuwenburgh et al., 1996; Vogt et al., 1993). However, in type 2 diabetes 
patients, plasma levels of glucagon are often abnormally high, even after ingestion of a meal 
and may contribute to impaired glucose tolerance and other metabolic changes, suggesting 
that the cAMP signaling pathway is upregulated in insulin-resistant individuals (Butler et al., 
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1991; Dunning et al., 2007; Meier et al., 2006). These observations lead us to speculate 
about a possible role of glucagon on hepatic GSH depletion, which can be related with 
postprandial insulin resistance and decreased insulin sensitivity in the fasted state. 
Glucagon has also been shown to be a hormone associated with hyperglycemia and 
hyperinsulinemia. This hyperinsulinemia is not able by itself to compensate for the observed 
hyperglycemia, leading to the question of which mechanism is thus responsible for this 
insulin resistance (Lechin et al., 2006). 
Therefore, the main objective of the present study was to test the hypothesis that 
glucagon modulates the hepatic GSH content, through the activation of the cAMP pathway, 
resulting in a state of HISS-dependent insulin resistance (HDIR). 
 
7.2. PROTOCOLS 
 
In this chapter, 9-weeks old male Sprague-Dawley (SD) rats (319.47.6g) were used in 
all experimental protocols. All animals were fasted for 8h, and then allowed ad libitum 
access to food for 2h to ensure postprandial state, as described in chapter 3, section 3.3.2. 
 
7.2.1. Hepatic effect of DBcAMP, a cAMP analogue, on insulin sensitivity 
 
The main goal of these experiments was to evaluate the hepatic effect of DBcAMP on 
insulin sensitivity.  
After a control RIST in the fed, DBcAMP was infused ipv at different doses ranging from 
0.01 to 1.0mg/kg, for 10min (t=-10min) at an infusion rate of 0.04ml/min. The second RIST 
was carried out after DBcAMP ipv infusion. During the experiment, blood samples were taken 
at specific time points, for insulin analysis. The detailed experimental protocol is described in 
chapter 3, Section 3.3.2.1. 
 
7.2.2. Hepatic effect of glucagon, on HISS-dependent insulin sensitivity 
 
The major objective of these experiments was to evaluate the hepatic effect of glucagon 
on HISS-dependent sensitivity. This protocol was divided into 2 different series. 
In the first series, after a control RIST, glucagon was infused ipv at different doses 
ranging from 0.5ng/kg to 20g/kg, for 10min (t=-10min) at an infusion rate of 0.04ml/min. 
The second RIST was carried out after glucagon infusion. The detailed experimental protocol 
is described in chapter 3, Section 3.3.2.2. 
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In the second series, after a control RIST, L-NMMA was infused ipv at a dose of 
0.73mg/kg for 10min at an infusion rate of 0.04ml/min. The second RIST was carried out 
after L-NMMA ipv infusion. Then, glucagon was infused ipv at 200ng/kg for 10min at an 
infusion rate of 0.04ml/min and a third RIST was carried out. The detailed experimental 
protocol is described in chapter 3, Section 3.3.2.2. 
 
7.3. RESULTS 
 
7.3.1. Hepatic effect of DBcAMP, a cAMP analogue, on insulin sensitivity  
 
7.3.1.1. Effect of DBcAMP on mean arterial pressure and arterial glycemia 
 
Preliminary experiments were performed to analyze the ipv DBcAMP infusion effect on 
arterial glycemia. Different doses of DBcAMP (0.01, 0.1 and 1mg/kg) were tested to achieve 
the dose that did not interfere with the glycemia during the assessment of the insulin 
sensitivity (Figure 7.1). The DBcAMP was infused during 10min; at minute 0, the glycemic 
profile was started.  
The values of mean arterial pressure were not significantly altered by the DBcAMP doses 
ipv infused (DBcAMP 0.01mg/kg: from 89.58.0 to 90.88.0mmHg; DBcAMP 0.01mg/kg: 
from 113.04.0 to 114.72.2mmHg; DBcAMP 1mg/kg: from 93.04.0 to 98.013.0mmHg). 
Basal glycemia levels, in the fed state, measured before DBcAMP ipv infusion (t=-10min), 
did not change after DBcAMP 0.01mg/kg infusion (t=0min) (from 119.35.8 to 
122.037.2mg/dl). The DBcAMP 0.1 and 1mg/kg doses increased glycemia levels (DBcAMP 
0.1mg/kg: from116.310.5 to 126.714.2mg/dl, p<0.05; DBcAMP 1mg/kg: from122.66.1 
to 187.825.3, p<0.05mg/dl). 
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Figure 7.1 - Glycemic profile at specific time points determined after DBcAMP 0.01, 0.1 and 1mg/kg ipv infusion. 
Results are means±SEM, n=10. 
 
From these results, the ipv DBcAMP 0.01mg/kg dose was the dose that not has an effect 
on the glycemia levels. Even though DBcAMP doses of 1 and 0.1mg/kg had an initial effect 
on glycemia, but by the time insulin sensitivity was assessed (post-DBcAMP RIST, 30min 
after DBcAMP infusion), the glucose levels were similar to controls. 
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7.3.1.2. Effect of DBcAMP on insulin sensitivity 
 
In this protocol, we evaluated ipv DBcAMP effect on insulin sensitivity and also if it was 
able to produce a similar degree of insulin resistance to that obtained with other 
pharmacological tools, previously used to evaluate the HISS-dependent insulin sensitivity. 
The results are summarized in Figure 7.2 and Figure 7.3. 
The control RIST index was 172.36.3mg glucose/kg bw and decreased to 125.78.3mg 
glucose/kg bw after ipv DBcAMP infusion (n=3, p<0.01), corresponding to a 27.22.1% 
inhibition of insulin sensitivity (Figure 7.2 and Figure 7.3). 
When the ipv DBcAMP administration was increased to 0.1mg/kg, the RIST index changed 
from 165.726.2 mg glucose/kg bw (control RIST index) to 77.07.5mg glucose/kg bw 
(post-DBcAMP 0.1mg/kg RIST index, n=2, p<0.05), corresponding to an insulin sensitivity 
inhibition of 51.612.2% (Figure 7.2 and Figure 7.3). 
With the higher ipv DBcAMP dose tested (1mg/kg), the control RIST index was 
173.224.0mg glucose/kg bw and decreased to 98.138.0mg glucose/kg bw after ipv 
DBcAMP infusion (n=3, p<0.05), corresponding to a 47.214.1% inhibition of insulin 
sensitivity (Figure 7.2 and Figure 7.3). 
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Figure 7.2 - Insulin sensitivity decreases after DBcAMP 0.01, 0.1 and 1mg/kg ipv infusion. Results are 
means±SEM. Paired t-test. **=p<0.01, *=p<0.05. 
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Figure 7.3 - Insulin sensitivity decreases after DBcAMP 0.01mg/kg infusion by 27.22.1%, after DBcAMP 0.1mg/kg 
infusion by 51.612.2% and after DBcAMP 1mg/kg infusion by 47.214.1%. Results are means±SEM. One-way 
ANOVA, followed by the Tukey-Kramer multiple-comparison test. *=p<0.05 vs DBcAMP 0.01mg/kg. 
 
 
From the results of the 3 different doses of DBcAMP infused, the doses of 1 and 0.1mg/kg 
were able to show a similar degree of insulin resistance to that obtained with other 
pharmacological tools (e.g., atropine, L-NMMA) that were previously used to evaluate the 
HISS-dependent insulin sensitivity. 
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7.3.1.3. Effect of DBcAMP on insulin levels 
 
In all the protocols, the different doses of DBcAMP did not affect insulin levels measured 
before the control RIST, after the DBcAMP infusion nor at the end of the DBcAMP RIST 
(Figure 7.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 – Effect of DBcAMP on plasma insulin levels. Insulin levels were not altered by the 3 doses of ipv 
DBcAMP infusion. Results are means±SEM. One-way ANOVA, followed by the Tukey-Kramer multiple-comparison 
test. 
 
7.3.2. Hepatic effect of glucagon, on HISS-dependent insulin sensitivity 
 
7.3.2.1. Effect of glucagon on arterial glycemia 
 
Preliminary experiments were performed to analyze the ipv glucagon infusion on arterial 
glycemia. In the fed state, different doses of glucagon (0.5, 1, 2.5, 5, 10, 200ng/kg, 2 and 
20g/kg) were infused to evaluate the glycemic profile after each dose infusion (Figure 7.5). 
The glucagon was infused during 10min; at minute 0, the glycemic profile was started. 
The values of mean arterial pressure were not significantly altered by the glucagon doses 
ipv infused (Table XVI). 
 
 
0
20
40
60
80
100
Before Control
RIST
End DBcAMP
0.01mg/kg RIST
After DBcAMP
0.01mg/kg
I
n
s
u
li
n
 l
e
v
e
ls
(

I
U
/
m
l)
0
20
40
60
80
100
Before Control
RIST
End DBcAMP
0.1mg/kg RIST
After DBcAMP
0.1mg/kg
I
n
s
u
li
n
 l
e
v
e
ls
(

I
U
/
m
l)
0
20
40
60
80
100
Before Control
RIST
End DBcAMP
1mg/kg RIST
After DBcAMP
1mg/kg
I
n
s
u
li
n
 l
e
v
e
ls
(

I
U
/
m
l)
Chapter 7                                                 The relevance of glucagon on HISS-dependent insulin sensitivity 
  PhD Thesis, Rita S. Patarrão 
 190 
Table XVI – Effect of ipv glucagon infusion on arterial pressure (n=14).  
 
Glucagon  
dose 
Arterial pressure before  
glucagon infusion  
(mmHg) 
Arterial pressure after  
glucagon infusion  
(mmHg) 
0.5ng/kg 69.0 85.0 
1ng/kg 103.37.8
 94.514.2 
2.5ng/kg 90.0 94.0 
5ng/kg 108.0 107.0 
10ng/kg 106.510.5
 117.53.5 
200ng/kg 118.39.0
 115.06.8 
2g/kg 111 96 
20g/kg 104 93 
 
 
Basal glycemia levels, in the fed state, before glucagon ipv infusion (t=-10min), did not 
change after glucagon 0.01mg/kg infusion (t=0min). The glucagon 200ng/kg, 2 and 20g/kg 
doses increased glycemia levels (Table XVII). 
 
 
Table XVII - Effect of ipv glucagon infusion on arterial glycemia (n=14).  
 
Glucagon  
dose 
Glycemia before 
glucagon infusion  
(mg/dl) 
Glycemia after  
glucagon infusion 
(mg/dl) 
0.5ng/kg 104.5 102.5 
1ng/kg 109.03.7
 111.34.1 
2.5ng/kg 113.1 115.5 
5ng/kg 102.5 104.5 
10ng/kg 113.40.9
 118.00.0 
200ng/kg 104.11.2
 116.33.6 
2g/kg 128.0 189.0 
20g/kg 104.0 176.5 
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Figure 7.5 – Glycemic profile at specific time points determined after glucagon 0.5, 1, 2.5, 5, 10, 200ng/kg, 2 and 
20g/kg ipv infusion. Results are means±SEM, n=14. 
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As shown in Figure 7.5, the higher ipv doses of glucagon tested (20 and 2g/kg) induced 
a significant increase in glucose levels after its infusion. However, by the time that insulin 
sensitivity was assessed (post-glucagon RIST, 30min after glucagon infusion), the glycemia 
was already returned to the pre-established baseline glycemia before glucagon infusion. 
 
7.3.2.2. Effect of glucagon on insulin sensitivity 
 
Given the results of the first glycemic profile experiments (Section 7.3.2.1.), the next 
step was to evaluate the ipv glucagon effect on insulin sensitivity and determined if it is able 
to produce a similar degree of insulin resistance to that obtained with other pharmacological 
tools (e.g., L-buthionine-[S,R]-sulfoximine, BSO), which were previously used to evaluate 
the HISS-dependent insulin sensitivity. 
As shown in Figure 7.6 and, Table XVIII all the different doses of glucagon tested that 
were previously ipv administered produced a decrease in insulin sensitivity in a dose-
dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 - Insulin sensitivity decreases after glucagon in a dose-dependent manner, for the ipv glucagon doses 
tested. Results are means±SEM, n=14. 
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Table XVIII - Percentage of inhibition of insulin sensitivity after ipv glucagon infusion (n=14).  
 
Glucagon dose  
(ng/kg) 
% inhibition of 
insulin sensitivity 
20000 67
 
2000 60
 
200 43
 
10 52
 
5 27
 
2.5 34 
1 22 
0.5 23 
 
 
7.3.2.3. Effect of glucagon on HISS-dependent insulin sensitivity 
 
Further studies were performed with a glucagon dose of 200ng/kg. This dose produced an 
hyperglycemia at the first minute after ipv infusion, but stabilized immediately at the basal 
levels. Simultaneously, it was able to decrease insulin sensitivity to the same level obtained 
with other pharmacological or surgical tools previously used to evaluate the HISS-dependent 
insulin sensitivity. The HISS pathway can be inhibited with several procedures such as, 
hepatic surgical denervation, blockade of hepatic muscarinic cholinergic receptors, hepatic 
NOS blockade, and depletion of hepatic glutathione levels. 
With the 200ng/kg ipv glucagon dose, the control RIST index was 173.05.3mg 
glucose/kg bw and decreased to 96.19.7mg glucose/kg bw after ipv glucagon 200ng/kg 
infusion (n=4, p<0.05), corresponding to a 42.66.5% inhibition of insulin sensitivity (Figure 
7.7). 
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Figure 7.7 - Insulin sensitivity decreases after glucagon 200ng/kg ipv infusion. Results are means±SEM, n=4. 
Paired t-test. *=p<0.05. 
 
To ascertain the role of glucagon on the HISS pathway, the pathway was inhibited with L-
NMMA (a NOS specific inhibitor), in order to decrease HISS-dependent insulin sensitivity, 
and after, glucagon was ipv infused.  
In this series of experiments, the control fed RIST index was 177.11.6mg glucose/kg bw 
and after ipv L-NMMA infusion the RIST index decreased to 81.08.3mg glucose/kg bw 
(n=5, p<0.001). Glucagon infusion did not alter the RIST index (80.45.9mg glucose/kg bw, 
n=5, Figure 7.8). Indeed, the percentages of inhibition of insulin sensitivity after 
administration of L-NMMA and glucagon were 54.24.9 and 54.63.5%, respectively. These 
results suggest that in HISS-impaired animals, glucagon does not produce an additional 
insulin resistance. 
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Figure 7.8 – Effect of L-NMMA and glucagon on insulin sensitivity. The insulin sensitivity decreased after ipv L-
NMMA 0.73mg/kg infusion and did not change after ipv glucagon 200ng/kg infusion. Results are means±SEM, n=5. 
Repeated measures ANOVA, followed by the Tukey-Kramer multiple-comparison test. ***=p<0.001 Control vs L-
NMMA 0.73mg/kg and Control vs Glucagon 200ng/kg. 
 
7.4. DISCUSSION 
 
The study in this chapter aimed to understand the highly regulated pathway involved in 
the glutathione (GSH) synthesis, controlled by 3‟,5‟-cyclic adenosine 5‟-monophosphate 
(cAMP) and/or glucagon action, and its repercussions on HISS-dependent insulin resistance 
(HDIR). Since it has been reported that glucagon, which increases intracellular cAMP 
concentration, decreases hepatic GSH content due to a decrease in enzymatic activity of -
glutamylcysteine synthase (Lu et al., 1991), and GSH is an important factor for HISS 
synthesis/release (Guarino et al., 2003; Guarino et al., 2006), it becomes important to 
understand the relationship between HISS action and glucagon. 
Our data show that both DBcAMP (N6,2‟-O-dibutyryladenosine 3‟,5‟-cyclic 
monophosphate), a cAMP analog, and glucagon produce a decrease of insulin sensitivity in a 
dose-dependent manner. 
The HDIR produced by N-monomethyl-L-arginine (L-NMMA) was not aggravated by 
glucagon, suggesting that glucagon, leads to reduced insulin sensitivity through a decrease 
of HISS action and not via some other indirect action. 
The two observations together are in support of our initial hypothesis that glucagon acts 
via cAMP pathway to decrease hepatic GSH levels, leading to an impairment of HISS 
synthesis/release resulting in an insulin resistance state responsible for the development of 
hyperglycemia and type 2 diabetes. 
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Hepatic cAMP and HISS-dependent insulin resistance 
 
The effect of glucose on insulin secretion can be amplified by signaling pathways involving 
inositol trisphosphate and diacylglycerol derived from activation of phospholipase C (Gilon et 
al., 2001; Howell et al., 1994) and by cAMP following activation of adenylate cyclase (Howell 
et al., 1994).  
Glucose itself has long been known to elevate the pancreatic islet -cell cAMP content 
(Grill et al., 1973). This cyclic nucleotide is generally accepted as an important amplifier of 
glucose-induced insulin release (Holz et al., 1992), particularly when its levels are increased 
by glucose itself (Harndähl et al., 2002). It has also been suggested that cAMP is a 
competence factor for normal islet -cell responsiveness to glucose (Huypens et al., 2000; 
Schuit, 1996). Numerous hormones that stimulate insulin secretion increase islet -cell 
cAMP, including glucagon (Huypens et al., 2000). 
Previous studies on rat -cells in vitro have suggested that insulin release is 
synergistically regulated by signaling molecules derived from glucose metabolism on the one 
hand and adenylate cyclase stimulation by glucagon or related peptides on the other (Schuit 
et al., 1985). In rodent -cells, regulation of the cAMP-dependent signaling pathway has 
been shown to depend on expression of specific receptors for glucagon (Unson et al., 1989). 
From our results, both ipv DBcAMP and glucagon infusion at different doses decreased 
insulin sensitivity (Figure 7.2Figure 7.2 and Figure 7.6). The insulin sensitivity results were not 
affected by the insulin levels, since insulinemias were not different before and after each 
RIST (Figure 7.4). Therefore, the main DBcAMP effect is not on insulin levels, but in its 
action instead. Indeed, it is proposed that increased cAMP level leads to a decrease of GSH 
and consequently to a state of insulin resistance.  
Based on our glucagon results, after blocking HISS-dependent insulin sensitivity with L-
NMMA, the subsequent ipv infusion of glucagon did not aggravate the insulin resistance in 
fed animals (Figure 7.8). These results showed that glucagon caused a state of HDIR. The 
glucagon infusion in the fed state may mimic the fasted state with respect to glucagon, 
hepatic cAMP and GSH levels, since glucagon is an hormone responsible for the regulation of 
GSH levels through the cAMP pathway (Lu et al., 1991). 
Intracellular cAMP levels depend on the balance between its formation through the 
activity of adenylate cyclase and its destruction by cAMP-degrading enzymes known as 
phosphodiesterases (PDEs). The activity of two of these cAMP-PDEs (PDE2A and PDE3B)27 in 
                                         
 
27 PDE2A is activated by cGMP, leading to cAMP hydrolysis. In contrast, PDE3B is inhibited by cGMP allowing cAMP 
intracellular accumulation (Houslay, 1995). 
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the liver is dependent on cGMP levels which are released through NO action28 (Beavo, 1995). 
Our group reported that hepatic NO/cGMP is essential for HISS action (Guarino et al., 2004), 
which strongly suggests that cGMP-dependent cAMP-PDEs may represent fine regulators of 
the HISS pathway, by controlling GSH levels through a cAMP/cGMP crosstalk (Conti, 2000; 
Houslay, 1995). 
In type 2 diabetes, the postprandial high glucagon levels, could compromise HISS 
secretion/release, due to a decrease of hepatic GSH levels. This impairment on HISS 
secretion/release will aggravate the insulin resistance state, leading to an increase of 
glucose excursions. This is in agreement with an imbalance of the insulin:glucagon molar 
ratio, since this ratio mainly affects hepatic glucose production (Unger, 1971). Because of 
the reduction of the insulin:glucagon molar ratio, basal endogenous glucose concentration 
will be higher causing fasting hyperglycemia, while the hepatic glucose output will not be 
efficiently suppressed after the ingestion of a meal, contributing to excessive postprandial 
glucose rise. The defect in insulin secretion is coupled with inappropriate secretion of 
glucagon. This results in significant changes in the portal insulin:glucagon molar ratio 
causing impaired regulation of glucose handling at the level of the liver (Del Prato et al., 
2004). 
 
Hyperglucagonemia and Diabetes 
 
When glucagon interacts with its receptor on liver cells, adenylate cyclase is activated and 
intracellular cAMP concentrations rise. The increase in cytosolic cAMP activates the all-
important PKA which, by phosphorylating certain key enzymes, induces the major hepatic 
actions of glucagon (stimulation of glycogenolysis, gluconeogenesis and, ketogenesis and 
inhibition of glycogen synthesis, glycolysis and lipogenesis) (Unger, 1971). Glycogenolysis is 
thereby increased and glycogenesis inhibited. Insulin opposes this action largely by reducing 
PKA activity (Gabbay et al., 1984). When insulin is not present, the unopposed action of 
glucagon greatly increases cAMP and PKA, and initiates the catabolic cascade (Unger, 1985). 
But, if glucagon is not present, cAMP and PKA are low and a major site of insulin action on 
hepatic fuel metabolism is eliminated. This explains why the excessive hepatic fuel 
production that characterizes the insulin-deficient state does not occur in the total absence 
of glucagon (Unger, 1985). 
                                         
 
28 Binding of NO to guanylate cyclase leads to generation of the second messenger cGMP (Beavo, 1995). 
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More than 30 years ago, Unger and Orci proposed the bihormonal hypothesis to explain 
the pathophysiology of diabetes (Unger et al., 1975). According to this hypothesis, this 
metabolic disease is the result of an insulin deficiency or resistance along with an absolute 
or relative excess of glucagon, which can cause a higher rate of hepatic glucose production 
than glucose utilization, favouring hyperglycemia. The rate of hepatic glucose output has 
been correlated with the hyperglycemia found in animal models of diabetes, as well as, in 
human diabetes, and the maintenance of this abnormality has also been associated with 
hyperglucagonemia (Dunning et al., 2007; Gastaldelli et al., 2000; Li et al., 2008).  
In type 2 diabetes, the impairment of insulin release and development of insulin 
resistance is often accompanied by absolute or relative increased levels of glucagon in the 
fasting and postprandial states (Butler et al., 1991; Larsson et al., 2000b). In this situation, 
insulin is not effective as a negative feedback for hepatic glucose output, while glucagon 
potentiates glucose mobilization from the liver, thus contributing to hyperglycemia.  
Another malfunction reported in diabetic patients is the lack of suppression of glucagon 
release in hyperglycemic conditions, which would contribute further to postprandial 
hyperglycemia, in type 2 diabetes (Dinneen et al., 1995; Henkel et al., 2005; Shah et al., 
2000). However, this irregular -cell behaviour does not occur when insulin levels are 
adequate, suggesting that abnormalities in glucagon release are relevant for hyperglycemia 
in the context of diabetes or impairment of insulin secretion or action (Shah et al., 1999). All 
these problems in the glucagon secretory response observed in diabetes have been 
attributed to several defects in -cell regulation including defective glucose sensing, loss of 
-cell function, insulin resistance or autonomic malfunction (Quesada et al., 2008). 
However, one could speculate about the involvement of glucagon on HISS pathway, and 
their implication on insulin sensitivity regulation. The sustained high levels of glucagon, 
usually seen in type 2 diabetes, could be due to a decrease in hepatic GSH levels that leads 
to a decrease in HISS secretion/action, culminating in a state of insulin resistance.  
 
Since insulin resistance anticipates diabetes onset by 15 years, all studies that contribute 
to its characterization and pharmacological control should be considered a priority. The 
studies in this chapter suggest new directions to understand the highly regulated pathway 
evolved in the GSH formation controlled by hormones that affect the cAMP pathway and its 
repercussions in insulin resistance. 
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8. GENERAL DISCUSSION 
 
The results presented in this PhD thesis regard both human and animal studies. The 
human experiments were designed to develop a new technique to evaluate insulin sensitivity 
in humans, both in the fasted and fed state, and also to characterize the role of a novel 
neurohumoral regulatory mechanism - the HISS hypothesis - that controls peripheral insulin 
sensitivity. Furthermore, the involvement of the cholinergic system in the HISS pathway was 
evaluated and observed to be inhibited by a cholinergic antagonist, in the fed state. 
The HISS pathway was likewise evaluated in lean and overweight subjects. This study is 
consistent with data from several other species, where the hepatic parasympathetic nerves 
also played a role in the HISS synthesis/release.  
Glucagon is a counter-regulatory hormone which levels are generally higher in type 2 
diabetic patients, particularly after a meal. The involvement of glucagon on HISS pathway 
and their implication on insulin sensitivity regulation was further observed. HISS-dependent 
insulin sensitivity can be affected by glucagon and this might be due to a decrease in the 
hepatic cAMP/GSH pathway. The constant hyperglucagonemia, usually seen in type 2 
diabetics, could be a result of a decrease in hepatic GSH levels, which is known to decrease 
HISS secretion/action, culminating in a state of insulin resistance. 
 
8.1. METHODOLOGICAL CONSIDERATIONS IN THE ASSESSMENT OF HUMAN 
WHOLE-BODY INSULIN SENSITIVITY 
 
The studies described in Chapter 4, suggest that the Rapid Insulin Sensitivity Test (RIST), 
is a valid technique to evaluate whole-body insulin sensitivity in vivo in humans, with the 
ability to be used in both fasted and fed state, with high sensitivity and reproducibility. The 
decision to develop the RIST in humans was based on the several advantages that this 
method presents regarding to other methods of insulin sensitivity assessment, as described 
below.  
In animals, the RIST, which is a modified euglycemic clamp, was already described as 
being a powerful research tool to assess the glucose utilization action of an insulin bolus in 
fasted and fed states, both evaluated in the same day. 
The RIST has been only described in laboratory animals, such as rats (Lautt et al., 
1998a), cats (Xie et al., 1996c) and mice (Latour et al., 2002a). In animals, it offers 
advantages over other forms of insulin sensitivity testing for a number of reasons. As many 
as four consecutive RIST‟s can be carried out in the same anaesthetized animal on the same 
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day. Moreover, glucose, insulin, glucagon and catecholamine levels remain unchanged 
between tests (Afonso et al., 2007b; Xie et al., 1995a). The RIST is extremely sensitive and 
can be shown to generate very clear dose-response relationships to insulin and muscarinic 
receptor antagonism. This insulin sensitivity test, showed that insulin sensitivity is highest in 
the immediately postprandial state and lowest in the fasted state, when insulin action is not 
useful or desirable (Lautt et al., 2001). The RIST index (parameter to evaluate insulin 
sensitivity) is physiologically relevant; it does not only need to be carried out in the fasted 
state, and reveals that insulin sensitivity is normally extremely low in the conditions required 
for other tests. 
Several other studies have been tried to evaluate postprandial insulin action, like the oral 
glucose tolerance test (OGTT) and the meal tolerance test (MTT). Regarding to the OGTT, it 
was shown by Sadri et al. that glucose per se was not able to activate the HISS pathway, 
and therefore does not induce a maximal insulin action (Sadri et al., 2006). Thus, the OGTT 
is only sensitive to changes related to the loss of insulin action per se (independent of 
HISS). Moreover, the MTT has been found to be a more potent stimulator of insulin action 
than glucose alone (Berthiaume et al., 2002), it is able to better mimic the conditions of 
lifestyle nutritional conditions, it is more capable to discriminate among non-diabetic, 
prediabetic and type 2 diabetic subjects than the OGTT, and it is a more consistent and 
reproducible method than the OGTT (Wolever et al., 1998). So, the MTT is much more 
physiological and accurate method to evaluate postprandial insulin action than the OGTT. 
 
The RIST was specifically designed to avoid the counter-regulatory responses to 
hypoglycemia that follows an insulin bolus, as administered in an insulin tolerance test (ITT) 
and also to prevent the non-physiological approach of the maintained continuous 
hyperinsulinemia throughout the hyperinsulinemic euglycemic clamp (HIEC), since these 
were the most commonly used tests to evaluate insulin sensitivity. 
The RIST allows us to quantify HISS-dependent and HISS-independent insulin action in a 
series of studies that suggest that this novel pathway is of major physiological, pathological, 
and therapeutic importance.  
While the ITT is equally able to detect HISS action, the ensuing hypoglycemia requires a 
longer time to reach baseline, has the danger of unpleasant effects from the hypoglycemia, 
and has the complication of interference by counter-regulatory mechanisms to restore 
euglycemia. This latter complication prevents full dynamic estimation of HISS action over 
the entire duration of the test (Reid et al., 2002). 
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In contrast with the RIST and ITT, the HIEC is only able to detect HISS action over the 
first few minutes of insulin infusion, but by the end of the test, HISS action cannot be 
detected and post-HIEC tests, using either the RIST or ITT in rats, show that the HIEC 
produces blockade of HISS action (Reid et al., 2002)29. So, HIEC may introduce some 
artifacts in the measurement of postprandial insulin sensitivity, which result from the 
prolonged continuous infusion of insulin (Lautt, 2003a).  
Therefore, for any study attempting to evaluate HISS action, the chosen method must 
first show HISS action detection under the specific and appropriate test conditions. 
 
In summary, the RIST is a new insulin sensitivity test that has decreased time duration; 
is able to be performed not only in the fasted state, but also in the postprandial state, on the 
same day with the same volunteer; it is reproducible, that is, can be performed more than 
one RIST per day without significant differences; permits pharmacological manipulation, so 
one can infuse more than one drug and evaluate the drugs‟ effect on insulin sensitivity, 
allowing us to design paired experiments; and the RIST does not cause discomfort, because 
the RIST is an euglycemic test and does not trigger any counter-regulatory hormonal 
response. 
 
The traditional focus on insulin sensitivity and blood levels of markers of risk determined 
in the fasted state, is inconsistent with the large volume of recent data that indicates that 
the metabolic defect, in the prediabetic and diabetic condition, relates more strongly to 
postprandial deficiency than to the fasting state. 
Growing awareness of the importance of postprandial plasma glucose (PPG) levels in the 
overall control of glycemia has led to the suggestion that PPG monitoring be integrated into 
routine diabetes care, particularly because patients‟ diabetes may not be adequately 
controlled if monitoring is based on glycosylated hemoglobin (HbA1C) and fasting plasma 
glucose (FPG) data alone. Given the strong correlation between PPG levels and glycemic 
status and the emergence of cardiovascular complications in patients with type 2 diabetes, it 
is reasonable to suggest that PPG levels be tracked along with the conventionally monitored 
FPG and HbA1C parameters (Bastyr et al., 2000). Inclusion of PPG measurement in a patient 
home monitoring plan, will provide comprehensive information on the total glycemic status 
of the patient that may be used as a basis for altering the treatment regimen, to better 
control postprandial excursions (Fonseca, 2003). 
                                         
 
29 The blockade of HISS action by HIEC may happen due to the alterations produced by the constant infusion of 
insulin, which physiologically has a pulsatile behaviour, and it is known that changes in insulin secretion pattern 
leads to glucose intolerance (Zarkovic et al., 1999) 
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More recently, emphasis has been put on the years that precede the development of type 
2 diabetes, characterized by a progressive decline in both insulin action, and defects in the 
early phase of insulin secretion. As impaired glucose tolerance is worldwide acknowledged as 
a prediabetic stage, it becomes clear that loss of postprandial glucose control occurs before 
deterioration of the fasting glucose concentration (Monnier et al., 2007).  
 
Based on all these assumptions and since insulin action varies with the prandial state, it 
become essential to evaluate whole-body insulin sensitivity in the fed state. Therefore, we 
developed the RIST methodology in humans due to the perceived limitations of other the 
methods of assessing insulin action. The RIST was found to be a useful, reliable, and 
reproducible tool, both in the fasted and fed state. 
 
8.2. MEAL-INDUCED INSULIN SENSITIZATION IN HUMANS AND ITS 
PARASYMPATHETIC REGULATION 
 
The “HISS hypothesis”, first proposed in 1997, appears to explain a range of metabolic 
responses both in health and disease and, represents a paradigm shift from the classic 
understanding of what is insulin resistance. The most pioneering aspect of this new 
mechanism is the finding that 50-60% of the hypoglycemic action of insulin is the 
responsible for an humoral factor, secreted by the liver, which acts on skeletal muscle and in 
the postprandial state. 
It is well known that, in response to a meal, the glucose disposal response to insulin more 
than doubles. However, insulin sensitivity determinations made in the fasted state only 
represent the direct action on insulin, and disregards the HISS-dependent component of 
insulin action. The evaluation of the insulin sensitivity only in the fasted state leads to a late 
detection and an underestimation of the insulin resistance condition. 
The results presented and discussed in Chapters 5 and 6 showed that the meal-induced 
insulin sensitization (MIS) process occurs and, HISS secretion/action is able to be blocked 
through the cholinergic pathway.  
MIS is a readily identified phenomenon that has been only recently quantified in animals 
(Sadri et al., 2006). MIS is illustrated by the dramatic increase in the glucose disposal 
response to insulin immediately following a meal. The phenomenon of MIS is derived from 
the observation that the dynamic response to insulin-stimulated glucose disposal determined 
after a 24h fast, is at least doubled when tested after administration of a mixed meal. The 
process of MIS is a result of HISS action. 
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The MIS process was evaluated both in lean (Chapter 5) and overweight (Chapter 6) 
subjects. It was shown that in the fasted state the insulin sensitivity, evaluated using the 
RIST, was the same in both groups; however, the postprandial state insulin sensitivity was 
lower in the overweight than in the lean subjects, suggesting that in the overweight subjects 
HISS secretion/action is decreased, which is responsible for the impaired insulin sensitivity. 
These results strongly suggest the importance of assessing the sensitivity in the postprandial 
state. 
Several studies have shown that, by considering only the fasting glucose levels, a large 
proportion of subjects with impaired glucose tolerance (IGT) are overlooked (de Vegt et al., 
1998; Larsson et al., 1998). There is considerable controversy regarding the relative 
importance of insulin resistance and abnormal insulin secretion in the pathogenesis of IGT 
(Dinneen, 1997). Some studies have proposed that loss of early insulin response to glucose 
and poor suppression of hepatic glucose output, are primarily responsible for postprandial 
hyperglycemia associated with IGT (Mitrakou et al., 1992). In contrast, under experimental 
conditions, defective insulin action was shown to contribute more to postprandial 
hyperglycemia than defective insulin secretion (Basu et al., 1996). 
The pattern of insulin secretion differs between IGT and impaired fasting glucose (IFG). 
People with isolated IFG have a decrease in first-phase (0–10min) insulin secretory response 
to iv glucose and a reduced early phase (first 30min) insulin response to oral glucose. 
However, the late-phase (60–120min) plasma insulin response during the OGTT is normal in 
isolated IFG. Isolated IGT also has a defect in early-phase insulin secretion in response to an 
oral glucose load, and in addition has a severe deficit in late phase insulin secretion. The 
combination of hepatic insulin resistance and defective insulin secretion in isolated IFG, 
results in excessive fasting hepatic glucose production accounting for fasting hyperglycemia. 
The impairment in early insulin response in combination with hepatic insulin resistance 
results in the excessive early rise of plasma glucose, in the first hour of the OGTT. However, 
the preservation of late insulin secretion combined with normal muscle insulin sensitivity 
allows glucose levels to return to the preload value in isolated IFG. In contrast, in isolated 
IGT the defective late insulin secretion, combined with muscle and hepatic insulin resistance, 
results in prolonged hyperglycemia after a glucose load (Nathan et al., 2007). 
 
The strong association between diabetes and obesity suggests that the first priority is the 
maintenance of healthy weight and obesity prevention. All individuals who are overweight or 
obese, regardless of their blood glucose value, should be intensively counselled to lose 
weight and to exercise (Nathan et al., 2007). 
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The association of obesity, insulin resistance, and the onset of type 2 diabetes is well 
documented. However, the mechanisms underlying such relationship remain unclear, and 
can vary according to the way obesity is induced (Cornier et al., 2006; Kahn et al., 2006). 
Obesity is not only a problem of too much fat, per se, but also a much more far-reaching 
dysregulation of metabolism that affects adipose tissue and other organs, such as the liver, 
muscle, and pancreas (Hansen et al., 2006). To further blur the relationship between obesity 
and insulin resistance, most of the published studies evaluate insulin sensitivity in a fasted 
state, ignoring the fact that the first alterations of insulin sensitivity seem to occur in the 
postprandial state, in which the role of the HISS-dependent component of insulin action is 
crucial. 
From the results presented in Chapter 6, one could consider that overweight subjects 
have a decreased in insulin action due to an impairment of HISS release/action. This 
decrease in insulin action was only noticed in the fed state, the state where HISS is present.  
 
Another main conclusion from these human studies is consistent with the hypothesis that 
iv atropine administration suppresses HISS (Chapter 5), in a dose-dependent manner, once 
it has been allowed to develop. The partial blockade of HISS by atropine is consistent with 
the hypothesis that a hepatic parasympathetic “feeding signal” is necessary in order for 
insulin to cause the release of HISS from the liver. 
From the human studies, we observed that even in the fed state, the whole-body insulin 
sensitivity evaluation after atropine infusion was decreased and the plasma insulin profiles 
during the control fed and atropine fed RIST were superimposable. Taken these results 
together, we can postulate that some factor other than insulin per se is responsible for the 
difference in the dynamic insulin action seen (Figure 8.1). 
Atropine has previously been demonstrated in numerous publications to result in 
impairment of the HISS-dependent response with the post-atropine RIST index in fed 
animals being similar to that in fasted animals. However, in humans the HISS-independent 
component of insulin action obtained after iv infusion of atropine was not completely 
abolished, since the RIST index after atropine 0.5 and 0.75mg infusion was not the same as 
the one obtained after a 24h-fast RIST; these doses of atropine used were the highest 
therapeutic doses ethically permissible and that had minor side effects. Based on animal 
atropine results, we estimate that an atropine dose of 4mg in humans should produce a full 
block of HISS release. 
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Atropine does not impact on the HISS-independent component of insulin action (Lautt et 
al., 2001). Similar dependence on the hepatic parasympathetic signal was demonstrated in 
animals where surgical denervation was carried out prior to administration of the meal. 
These data confirm that, in humans, the hepatic parasympathetic signal is essential for 
HISS-mediated MIS and that absence of the signal can prevent MIS from occurring and 
eliminate it once it has occurred. 
 
 
 
Figure 8.1 - Atropine infusion results in a HISS-dependent decreased insulin sensitivity due to blockade 
of the muscarinic receptors. After a meal, insulin sensitivity increases in the skeletal muscle. On the other hand, 
in the postprandial state, after atropine infusion, we partially block the muscarinic receptors and subsequently 
decrease the release of HISS, leading to a state of insulin resistance at the skeletal muscle. 
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According to the HISS hypothesis, loss of MIS occurs as a result of lack of HISS release, 
thereby resulting in postprandial hyperglycemia and compensatory hyperinsulinemia. One 
could speculate that the elimination of HISS action on skeletal muscle, results in 
postprandial hyperinsulinemia maintaining glycemic control in the prediabetic state, by 
increased glucose uptake in insulin-sensitive tissues, primarily liver and adipose tissue. 
 
In the scope of understanding pathophysiology it is clear that fasting glucose represents a 
different pathophysiological process from the 2h-glucose, and that however diabetes is 
defined in the future, there will always be a value in studying these different processes 
alongside measures of insulin resistance and -cell function in order to understand disease 
mechanisms. The progression from prediabetes to type 2 diabetes occurs over many years 
and strong evidence exists to support intervention to delay the progression from prediabetes 
to diabetes (Aroda et al., 2008).  
With the increasing recognition that the prediabetic state represents mainly a 
postprandial defect and the ability of the HISS hypothesis to account for selective skeletal 
muscle insulin resistance observed in impaired glucose tolerant subjects, obesity, metabolic 
syndrome and full blown diabetes, one can suggest that the HISS hypothesis and the MIS 
phenomenon may represent the “missing link” between lifestyle issues and insulin resistance 
in prediabetes, diabetes and obesity. In the fasted state, overweight subjects showed the 
same degree of insulin resistance as lean subjects; however, in the fed state, the insulin 
sensitivity in the overweight subjects was lower than lean subjects. In summary, if 
overweight subjects were only evaluated in the fasted state, they were normal subjects in 
terms of insulin resistance, but from postprandial insulin sensitivity results, they were insulin 
resistant subjects (Figure 8.2). 
According to our hypothesis, an impairment of HISS would be the first event in the 
development of insulin resistance; progression to obesity and to frank diabetes, would only 
be detectable in the fed state. 
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Figure 8.2 – Overweight subjects have impaired insulin sensitivity due to a compromise of HISS-
dependent component. Fasting is a state of insulin resistance and HISS release is inhibited, both in lean and 
overweight subjects. However, in lean subjects, one can reverse this HISS inhibition with a provision of a meal, 
which will increase insulin sensitivity, at the skeletal muscle. On the other hand, in overweight subjects, even after 
a meal, a decrease of HISS release is observed, leading to a decrease of insulin sensitivity. This decrease in insulin 
sensitivity, in overweight subjects, could be important in the detection postprandial insulin resistance.  
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8.3. THE RELEVANCE OF GLUCAGON ON HISS-DEPENDENT INSULIN 
SENSITIVITY 
 
Glucagon is a pancreatic hormone, which is released in the fasted state in order to 
maintain glucose levels in a steady-state. After a meal, in healthy subjects glucagon levels 
decrease and increase with the duration of fasting, which have the inverse pattern of the 
hepatic GSH content (Tateishi et al., 1974). In the fasted state, type 2 diabetic patients 
have continuously higher levels of glucagon than healthy subjects which do not change even 
after a meal (Butler et al., 1991). In addition, in the fasted state, glucagon through 
adenylate cyclase activation promotes an increase of the cAMP levels. Studies performed by 
Lu and colleagues, showed that high levels of cAMP leads to a decrease of the hepatic GSH 
synthesis, due to a alteration in the -glutamilcysteine synthase enzyme, one of the key 
enzymes involved in GSH synthesis (Lu et al., 1991). Since the GSH molecule is a crucial 
molecule to HISS synthesis and release, it becomes imperative to understand the highly 
regulated pathway involved in the GSH formation controlled by either hormones or enzymes 
that affect the cAMP pathway, and its repercussions in HISS-dependent insulin resistance. 
The results presented in chapter 7 indicated that ipv administration of DBcAMP (N6,2‟-O-
dibutyryladenosine 3‟,5‟-cyclic monophosphate), a cAMP analog, and glucagon produce a 
decrease of insulin sensitivity. Moreover, ipv administration of glucagon cause a decrease in 
insulin sensitivity and, after inhibition of the HISS pathway, with a specific inhibitor of NOS, 
L-NMMA, glucagon infusion did not alter insulin sensitivity, suggesting that glucagon inhibits 
HISS-dependent insulin sensitivity (Figure 8.3). 
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Figure 8.3 - DBcAMP and glucagon produces a decrease of insulin sensitivity. The cAMP analog and 
glucagon promote an increase in hepatic cAMP levels that are related to the decrease of hepatic GSH synthesis, 
leading to an impairment of HISS synthesis/release and resulting in an insulin resistance state responsible for the 
development of hyperglycemia and type 2 diabetes. DBcAMP: N6,2‟-O-dibutyryladenosine 3‟,5‟-cyclic 
monophosphate; cAMP: 3‟,5‟-cyclic adenosine 5‟-monophosphate; NO, nitric oxide; GSH, gluthatione 
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Glucagon should be an important parameter to consider in relation to glucose intolerance 
in prediabetic subjects, and may be a novel risk factor for diabetes development. 
As mention earlier, glucose regulates pancreatic hormone secretion, that is, insulin and 
glucagon in an opposite manner and it is the molar ratio between insulin and glucagon, that 
determines in a qualitative and quantitative, the amount of glucose that circulates across the 
liver. Although glucose triggers insulin secretion through its metabolism by -cells, the 
regulation of glucagon secretion is more complex and depends on several control 
mechanisms (Gerich et al., 1976).  
Pancreatic -cells have an intrinsic capacity to monitor glucose levels, but are also under 
the control of insulin secretion by the -cells, which inhibits glucagon secretion. There is 
ample evidence that the -cell secretory activity is strongly regulated by both, the 
sympathetic and parasympathetic nervous systems, implying that glucose and hypoglycemia 
detecting cells, control the activity of the autonomic nervous system (Lechin et al., 2006; 
Teff, 2008).  
 
Therefore, based on our hypothesis, an autonomic nervous dysfunction observed in 
impaired glucose tolerance states, leads to an abnormal hyperglucagonemia, leading to an 
impairment of HISS secretion/release. 
Eventhough, one can observed an hyperinsulinemia in a prediabetic state, the shut down 
of HISS secretion/release by the increased glucagon levels, results in a postprandial insulin 
resistant state (Figure 8.4). 
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Figure 8.4 – The hyperglucagonemia hypothesis. In the fed state, at an early stage, the autonomic nervous 
dysfunction, results in increased levels of glucagon, leading to a decrease of HISS-dependent insulin sensitivity, at 
the skeletal muscle. On the other hand, the increase of postprandial glucose excursions results in obesity. 
Afterwards, hepatic insulin resistance state will be present, due to an abnormal postptandial increase of the 
endogenous glucose production. The transition from prediabetes to overt diabetes seems to result from the sum of 
deficiencies in HISS secretion/action, which was caused by high levels of glucagon, of insulin action per se (HISS-
independent) and, later of pancreatic insulin secretion. 
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8.4. FUTURE DIRECTIONS 
 
In light of the present PhD thesis and as is the prerogative of any research project, the 
observations associated with the development of the work itself raise new questions which 
future work may respond. 
Although the studies presented in this dissertation provided further knowledge about the 
HISS hypothesis in lean and overweight subjects, additional work is required to clarify not 
only the mechanisms involved in the regulation of HISS secretion/action, but also its 
relevance in human insulin resistance syndromes, like hypertension, obesity and type 2 
diabetes. Considering what is known about the HISS mechanism, in terms of physiology and 
pathophysiology, it will be very important to understand the mechanism behind human 
insulin resistance diseases. 
 
In the future, it will be essential to perform the nutritional characterization of the 
physiological stimulus that activates the mechanism of insulin action sensitization after a 
meal. In this regard, preliminary experiments performed by our group in collaboration with 
the Lautt‟s group, confirmed that a liquid mixed-meal is capable of triggering the MIS, rather 
than carbohydrates (glucose and sucrose). However, it is still not known either which 
nutrients or the exact nature of the feeding signal that are involved in this MIS. Whether 
these nutrients act upon absorption or stimulate a neural reflex is not yet known and it 
constitutes one of the future objectives. In this future studies, the recognition together with 
the disclosure of the trigger of the MIS mechanism in humans will be the first steps for 
better understand its impact on both, prediabetic and diabetic states. 
 
Another important perspective of this thesis was the role of glucagon on the HISS 
pathway, and its relationship with the hepatic GSH levels, which are crucial to HISS release. 
More studies need to be developed in order to bring insight into the mechanisms that lead to 
HISS-dependent insulin resistance and type 2 diabetes, through the hepatic cAMP pathway. 
It is reasonable to assume that antagonists of glucagon will suppress the actions of 
endogenous circulating glucagon, and will provide evidence that glucagon is a contributing 
factor to diabetes mellitus. Most of the effects of glucagon are mediated by its interaction 
with specific receptors in the liver to increase the intracellular cAMP level. Due to the 
relationship between glucagon and cAMP levels, hepatic GSH and HISS-dependent insulin 
sensitivity, it will be relevant to study the effect of the administration of a glucagon receptor 
antagonist on HISS-dependent mechanism.  
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Our group reported that hepatic NO/cGMP is also essential for HISS action which strongly 
suggests that cGMP-dependent cAMP-PDEs may represent fine regulators of the HISS 
pathway, by controlling GSH levels through a cAMP/cGMP cross-talk. 
Furthermore, we expect that pharmacological blockade of the cAMP pathway in the liver 
will enhance hepatic GSH levels, and HISS-dependent insulin sensitivity in animal models of 
insulin resistance, an approach that can be used to improve insulin sensitivity in humans. 
 
Since insulin resistance can anticipate diabetes onset by 15 years, all studies that 
contribute to its characterization and pharmacological control should be considered a 
priority. The understanding of the regulation of the cAMP pathway from the early-stage of 
insulin resistance to frank diabetes can provide a solid platform for the development of new 
forms of therapy foreseeing the prevention and control of the epidemic of diabetes. 
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APPENDIX 
 
INSTITUTO PORTUGUÊS DE ONCOLOGIA FRANCISCO GENTIL 
 
RESEARCH STUDY: “THE RELEVANCE OF THE HEPATIC INSULIN SENSITIZING 
SUBSTANCE (HISS) ON DISEASES ASSOCIATED WITH INSULIN RESISTANCE” 
 
SUBJECTS STUDY INFORMATION 
 
You are invited to participate in a research study conducted by an international research 
team consisting of scientists, physicians, and pharmacists from Canada and Portugal. The 
study involves the testing of a new method to assess the ability of insulin to act in the body.   
Insulin is normally released from the body in response to glucose (sugar) that appears in 
the blood following a meal. Most types of diabetes are caused by a decreased ability of 
insulin to stimulate the removal of glucose from the blood and storage for later use. These 
individuals are said to be insulin resistant. Current methods used to assess insulin resistance 
are of limited value. The researchers of this project developed a new method to evaluate 
insulin sensitivity called by Rapid Insulin Sensitivity Test (RIST). The RIST that will be tested 
in participants of this study has been fully validated in animal studies and is shown to be an 
excellent test that can clearly identify insulin resistance and that can also be used to 
determine the type of therapy that should be used to restore insulin sensitivity to normal 
levels.   
These studies will be carried out in several phases. If you are a healthy you could 
participate in phase 1a, 1b or 1c, or if you want in two phases in or all of them. The phase 
1a is to determine the dose of most accurate dose of to perform the RIST. The phase 1b 
want to check if the RIST is influenced by ingestion of food, and in this case, the volunteers 
will perform an initial RIST; after the volunteer fed 16 cookies and drink 0.5l of mineral 
water, and a second RIST will take place 100min after the meal. In the phase 1c, the RIST 
will be performed before and after intravenous administration of atropine (0.5mg), in order 
to block the parasympathetic nervous system.  
The test will involve administration of a small dose of insulin through one catheter and 
administration of glucose through the other catheter in order to maintain your blood glucose 
level absolutely constant. The fasted RIST has duration of approximately 20-50min and the 
fed RIST will take around 45-90min. In phases 1a and 1b, the test will be carried out in fast 
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and the last meal was the breakfast (ham and cheese sandwich, orange juice, croissant with 
cheese or ham) on the day before the test, which should occur between 10:00 and 
10:15am. In stage 1c, the RIST‟s will be done after the standardized test meal. The test will 
begin at 10am. 
The rapid insulin sensitivity test (RIST) consists of placement of an intravenous catheter 
into each arm. One catheter will be used for blood sampling and the other will be used for 
the administration of insulin and glucose (sugar). The arm from which blood will be sampled 
will be warmed throughout the test. The entire blood volume removed during the testing will 
be less than half of that which is normally taken for a routine blood donation. Samples will 
be taken from the blood throughout the test period to determine the blood glucose level. 
The blood removed by this method will be stored and made available to measure a variety of 
substances. You should experience no discomfort since your blood glucose level will not be 
allowed to fluctuate during the test. The dose of atropine administered is not usually 
associated with any symptoms, but may cause a slight decrease in heart rate, dryness of 
mouth and some decrease in sweating. An electrocardiogram will be performed before the 
study and your heart rate will be monitored during the test. 
It is important that you read and understand the following general principles which apply 
to all participants in our studies: 
1. Your participation is entirely voluntary; 
2. There is no immediate personal benefit by participating in this study; 
3. Withdrawal from the study may be done at any time without jeopardy or prejudice; 
4. The information derived from this study will become part of several scientific 
publications and presentations but your identity will remain completely confidential; 
5. If you request, you will be provided with full scientific details of the completed studies. 
You are free to inquire the researchers about any aspect of the study;  
6. Allows the researchers to perform the determination, in the blood that will be sampled 
during the test, for all substances that will be considered necessary to performed an 
accurate project; 
7. This study does not involve any cost from the financial point of view; 
7. The study was analyzed and approved by the Ethics Committee of the IPO, Lisboa, 
Portugal. 
Thank you very much. 
 
The project researchers. 
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INSTITUTO PORTUGUÊS DE ONCOLOGIA FRANCISCO GENTIL 
 
RESEARCH STUDY: “THE RELEVANCE OF THE HEPATIC INSULIN SENSITIZING 
SUBSTANCE (HISS) ON DISEASES ASSOCIATED WITH INSULIN RESISTANCE” 
 
SUBJECT CONSENT FORM 
 
I,______________________________________________________, born in 
_____________, at ___/____/____, agree to take part in phase ___ of the study “The 
relevance of the Hepatic Insulin Sensitizing Substance (HISS) on diseases associated with 
insulin resistance” 
 
I understand that my participation in this study is voluntary and the doctor gave me all 
the information about the study participation, from who I received a written information 
sheet. I declare that I have read and understood this page and I can clarify any doubts with 
the researcher. More declare that I give the authorization to the researchers to use the 
blood that was collected during this study in subsequent research projects, if authorized by 
the Ethics Committee of the Francisco Gentil Portuguese Institute of Oncology. 
 
Signature (Volunteer)_____________________________    Date____________ 
 
Signature (Investigator) ____________________________  Date____________ 
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INSTITUTO PORTUGUÊS DE ONCOLOGIA FRANCISCO GENTIL 
 
ESTUDO: “IMPORTÂNCIA DA SUBSTÂNCIA HEPÁTICA SENSIBILIZADORA DA 
ACÇÃO DA INSULINA EM DOENÇAS ASSOCIADAS A INSULINO-RESISTÊNCIA” 
 
FOLHA DE INFORMAÇÃO AO VOLUNTÁRIO 
 
É convidado a participar num estudo de investigação conduzido por uma equipa 
internacional que envolve cientistas Canadianos e Portugueses e que tem como objectivo o 
desenvolvimento nos humanos de um novo teste de sensibilidade à insulina. 
A insulina é normalmente libertada em resposta a um aumento de glucose (açúcar) no 
sangue que ocorre após as refeições. Na maioria das situações de diabetes mellitus existe 
uma diminuição da capacidade da insulina em remover a glucose do sangue para a 
armazenar nos tecidos do organismo. Os indivíduos em que a insulina não é capaz de 
remover a glucose do sangue de forma eficiente são denominados resistentes à insulina. Os 
métodos actualmente usados para a avaliação da resistência à insulina têm várias 
limitações. Os investigadores deste projecto desenvolveram um novo método de avaliação 
da resistência à insulina, designado por teste rápido de sensibilidade à insulina (RIST), que 
tem demonstrado ser mais reprodutível que outros métodos em vigor e que já foi testado 
em diferentes espécies animais.  
Este estudo decorrerá em fases distintas. Se for um voluntário normal poderá participar 
na fase 1a, 1b ou 1c, ou caso o deseje em duas fases ou em todas elas. A fase 1a tem como 
objectivo determinar a dose de insulina mais adequada para o RIST. A fase 1b pretende 
verificar se o RIST é influenciado pela ingestão de alimentos, e neste caso, os voluntários 
farão um RIST inicial que será seguido da ingestão de 16 bolachas integrais e de 0.5l de 
água mineral, sendo um segundo RIST efectuado 100min após esta refeição. Na fase 1c o 
RIST será realizado antes e após a administração de atropina (0.5mg) por via endovenosa, 
de modo a bloquear o sistema nervoso parassimpático.  
O RIST consiste na administração de uma dose de insulina seguida de uma perfusão de 
glucose de forma a manter as concentrações de glucose no sangue em valores estáveis. O 
RIST em jejum tem a duração aproximadamente entre 20-50min e o RIST pós-prandial tem 
a duração aproximadamente entre 45-90min. Nas fases 1a e 1b, o teste será realizado em 
jejum sendo a última refeição o pequeno-almoço (tosta mista, sumo de laranja, croissant 
com queijo ou fiambre) do dia anterior ao do teste, que deverá ocorrer entre as 10h00m e 
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as 10h15m. Na fase 1c, os RIST‟S serão realizados após a refeição standard. O teste terá 
início às 10h da manhã.  
Para realizar este teste é necessário colocar um catéter intravenoso em cada braço. Um 
dos catéteres será utilizado para retirar sangue para a avaliação da glicémia (concentração 
de glucose no sangue) e o outro para a administração de glucose e insulina. O braço usado 
para avaliação da glicémia no sangue será mantido aquecido durante todo o procedimento. 
A quantidade de sangue retirada durante o teste será menos de metade da quantidade 
normalmente retirada quando se faz uma doação de sangue. O sangue retirado será 
armazenado e posteriormente utilizado para a determinação de várias substâncias. Não 
deverá sentir qualquer tipo de desconforto durante o teste dado que não haverá flutuações 
nos níveis de glicémia. A dose de atropina administrada não está geralmente associada a 
qualquer sintoma, embora possa provocar uma ligeira diminuição da frequência cardíaca, 
alguma secura de boca e diminuição da sudação. Fará um electrocardiograma prévio ao 
estudo e a sua frequência cardíaca será monitorizada durante o teste. 
É importante que leia e compreenda os seguintes princípios gerais que se aplicam a todos 
os participantes neste estudo: 
1. A sua participação no estudo é totalmente voluntária; 
2. Não existe beneficio pessoal imediato ao participar neste estudo; 
3. Em qualquer altura pode desistir de participar no estudo, sem ter de dar explicações e 
sem que a qualidade dos cuidados médicos seja afectada; 
4. A informação obtida com este estudo poderá originar algumas publicações científicas, 
mas a sua identidade será sempre mantida confidencial; 
5. Se assim o desejar, ser-lhe-á fornecido detalhe científico sobre o estudo em questão. 
Será livre de fazer perguntas aos investigadores sobre o projecto; 
6. Autoriza os investigadores a realizar a determinação, no sangue que lhe vai ser 
retirado durante o teste, de todas as substâncias que forem consideradas necessárias para 
uma eficaz realização do projecto; 
7. Este estudo não lhe acarreta qualquer custo do ponto de vista financeiro; 
8. O estudo foi analisado e aprovado pela Comissão de Ética do IPO. 
Muito obrigado. 
 
Os investigadores do projecto. 
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INSTITUTO PORTUGUÊS ONCOLOGIA FRANCISCO GENTIL 
 
ESTUDO: “IMPORTÂNCIA DA SUBSTÂNCIA HEPÁTICA SENSIBILIZADORA DA 
ACÇÃO DA INSULINA EM DOENÇAS ASSOCIADAS A INSULINO-RESISTÊNCIA” 
 
CONSENTIMENTO INFORMADO DO VOLUNTÁRIO 
 
Eu,______________________________________________________, natural de 
_______________, em ___/____/____, concordo em participar na fase ___ do estudo 
“IMPORTÂNCIA DA SUBSTÂNCIA HEPÁTICA SENSIBILIZADORA DA ACÇÃO DA INSULINA EM 
DOENÇAS ASSOCIADAS A INSULINO-RESISTÊNCIA”. 
 
Estou ciente de que a minha participação neste estudo é voluntária, tendo sido informado 
pelo meu médico sobre o estudo em que participo, do qual recebi uma folha informativa 
escrita. Declaro que li e compreendi esta folha e que pude esclarecer todas as dúvidas com o 
investigador. Mais declaro que autorizo os investigadores a utilizar o sangue que me foi 
retirado durante o estudo em ulteriores projectos de investigação, distintos do que agora me 
é proposto, desde que autorizados pela Comissão de Ética do Instituto Português de 
Oncologia. 
 
Assinatura (Voluntário)______________________________ Data____________ 
 
Assinatura (Investigador)____________________________ Data____________ 
 
